<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
   xmlns:ao="http://www.w3.org/ns/oa#"
   xmlns:dailymed="http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/"
   xmlns:dct="http://purl.org/dc/terms/"
   xmlns:domeo="http://www.w3.org/ns/domeo#"
   xmlns:foafx="http://xmlns.com/foaf/0.1/"
   xmlns:ncit="http://purl.bioontology.org/ontology/NCIT#"
   xmlns:pav="http://purl.org/pav/"
   xmlns:permissions="http://vocab.deri.ie/cpo#"
   xmlns:poc="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#"
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
   xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
   xmlns:sio="http://semanticscience.org/resource/"
>
  <rdf:Description rdf:about="urn:domeoclient:uuid:760EB474-EF58-4374-B2D9-EC1C2A117479">
    <pav:createdOn>2014-05-30 20:46:22 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:750B313C-5E26-4DEF-8171-E44FEF807165"/>
    <pav:lastSavedOn>2014-05-30 20:55:24 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:F431C560-0771-4D18-B86C-CE95DA1A0EA9"/>
    <pav:previousVersion>urn:domeoserver:annotationset:1C00F548-9B08-4884-8F8A-EA2359A411BC</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:712D0B93-947C-4E60-94CD-CA048223D543"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:1E8A1D02-1448-4CEA-9E12-30A25E2BFA66"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AB8114CE-610C-4124-9C3E-2295E1567A55</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:5D0AE06F-D83C-4974-A73E-AB2A9BD6E21E"/>
    <pav:lineageUri>urn:domeoserver:annotationset:23D022D1-EA80-4401-9CAD-1D389D3CBFA6</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:007C39EF-F7FF-4A41-B4B6-98F069755344"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9AE33C26-FA00-40A8-A8A6-F8E0A93D6460"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:7F85F574-EDDD-4436-9FDD-C3FEC9657727"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:A466DCB0-3CE4-4C4E-BA7B-AC46DC8AFAAF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5DD668F6-2293-44D1-9324-A9BE0FD2BCD2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:34E63D34-1418-44B0-97CD-7CB4FAAB9700">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B1DC5CBA-947F-4ACA-AB8B-EF1CE2F7E6FA">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:B2F978C2-CA3C-4875-AA6D-C42D9A4FFE85"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:235C0D89-15E5-49F6-B714-A7A25AFA9D41"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6113881B-0446-46DB-8402-89CDC3C770E1"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:710AA502-4DC7-453E-835B-7C94AA6D6FC2"/>
    <pav:lineageUri>urn:domeoserver:annotation:1DB8A56F-4EE8-4183-8618-7F968C91F934</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:9C4C7207-57B0-4DBD-B736-06E6D6721873"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AB8114CE-610C-4124-9C3E-2295E1567A55</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:createdOn>2014-05-30 21:02:42 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:3FD2EA01-F336-4A53-A416-9D778C301842"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:9327D741-315C-4EA1-8C35-BC475642722A"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-05-30 21:04:28 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B21EC6B5-C2EE-4874-A4F2-AF1A3F4EFEC2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9FC61583-D771-4783-B2EC-AF97FFC879A4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2B3B1B0F-EB68-49FD-A395-B1EE8DE84DB0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5DD668F6-2293-44D1-9324-A9BE0FD2BCD2">
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <rdfs:label>Prodrug</rdfs:label>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to Prodrug</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:84A930F5-FD5F-4824-AACB-620C690DC46D">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>breast cancer, </poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8420E1EA-C07C-4C94-A02D-FAC9986FAECD">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:E823DCB5-68E6-44D4-90AF-E073AC268320">
    <ao:item rdf:resource="urn:domeoclient:uuid:D217AC15-238E-462D-B127-1282765E996E"/>
    <pav:lastSavedOn>2014-06-11 23:20:00 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:1BC31CD3-4807-42D6-98DC-9E688603602F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3525E0B9-9E13-4D14-A0C0-6E86A5C5A4B0"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:0415E508-97A8-4C52-A926-62A939770177"/>
    <permissions:permissions rdf:nodeID="Naef51cb4210c458588c5b872e1a0636f"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304628d4c0014629cdc71a0000"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:697EBEC0-D67B-49F2-8728-B421A0C8254F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9E2A8002-D6F7-4867-956C-4B34CF836ADE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1A713645-4012-4097-9711-D7E513A81EA1"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:3B159BCE-6B30-4AF9-95B2-C0A773F4AE82"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:B4323A5D-56AC-4392-85FA-23F6FB53396D"/>
    <pav:lineageUri>urn:domeoserver:annotationset:59590A65-90C8-4E95-A16E-96DB23D9D119</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:3B1A09B1-2BA5-40EE-B074-6B52E7DE2542</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:0C058F94-94D1-4AEE-BF18-3B8E067C9F8A"/>
    <pav:createdOn>2014-06-11 22:43:53 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0633CD7E-C8F7-4156-BD95-B928101B271C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:43653153-B11C-40E9-8080-04E3E9C301ED"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:CFA29740-CED7-4D5F-8A5F-BDE8F47DE421"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F3091362-0406-40EA-8DCC-799617CD755D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9BE604B7-EBBE-4B0E-9A59-AC3F7715C1A0">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-08-11 09:14:11 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:BB195C09-0F47-4105-9F73-99BBDA5078FD"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8917A0C6-4EB0-4018-922E-B216A9A1DB0C</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:A3F48D31-5539-4F30-A2B9-C37E55FB8811"/>
    <pav:previousVersion>urn:domeoserver:annotationset:287C4CBC-902E-47BD-88F8-C2E62505CF69</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:9B8317DC-DBC5-4662-8517-859AC64AF1BB"/>
    <pav:lineageUri>urn:domeoserver:annotationset:5EBB77FD-51B8-46AE-8874-51C32A57C8E9</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:E3609C9E-AE63-4C95-A952-DC3DA4BDA90B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D327E6E7-D871-4646-8BBA-E3BD6539060E"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:6575B7DA-A97D-4781-81EC-941DBAFAE3DA"/>
    <pav:lastSavedOn>2014-08-11 09:16:06 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:D59588BF-E727-4435-AF5A-27902B64F28F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6AA59FBE-7293-46F0-BAD8-E6280C2AE5D6">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E464726E-DEBC-48DC-8C6D-12E7E85B1734">
    <rdfs:label>poor-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E4EB772E-E861-4676-80ED-5F865DE3C74E">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-05-30 21:38:11 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E4EB772E-E861-4676-80ED-5F865DE3C74E"/>
    <ao:prefix>The safety and effectiveness and the pharmacokinetics of codeine sulfate in pediatric patients below the age of 18 have not been established. FDA has not required pediatric studies in ages birth to one month because there is evidence strongly suggesting that codeine would be ineffective in this pediatric group since the metabolic pathways to metabolize codeine are not mature. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Respiratory depression and death have occurred in children with obstructive sleep apnea who received codeine in the post-operative period following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6 or high morphine concentrations). These children may be particularly sensitive to the respiratory depressant effects of codeine that has been rapidly metabolized to morphine. Codeine is contraindicated for post-operative pain management in all pediatric patients undergoing tonsillectomy and/or adenoidectomy [see Contraindications (4)].</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8807ADF7-6B92-467F-9259-A54B7471185B">
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdfs:label>Variant Frequency</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E83BA42D-B9C5-478C-93C4-8B6245CC41FD">
    <rdfs:label>Clinical Trial</rdfs:label>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dct:description>Referred to clinical trial</dct:description>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B79E5FF8-397A-4E53-9107-6884F2354A54">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ESR1, PGR</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0CA59420-1D9E-44F2-AE9F-252EA8FFE1B6">
    <ao:prefix>ions, and comorbidities) are generally accounted for along with genotype in the ranges expressed in the Table. VKORC11639 G(rs9923231) variant is used in this table. Other co-inherited VKORC1 variants may also be important determinants of warfarin dose. </ao:prefix>
    <domeo:uuid>0CA59420-1D9E-44F2-AE9F-252EA8FFE1B6</domeo:uuid>
    <pav:createdOn>2014-06-11 23:20:00 -0400</pav:createdOn>
    <ao:suffix>g</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:exact>Patients with CYP2C9 *1/*3, *2/*2, *2/*3 and *3/*3 may require more prolonged time (&gt;2 to 4 weeks) to achieve maximum INR effect for a given dosage regimen.*1/*1*1/*2*1/*3*2/*2*2/*3*3/*3GG5 to 7 mg5 to 7 mg3 to 4 mg3 to 4 mg3 to 4 mg0.5 to 2 mgAG5 to 7 mg3 to 4 mg3 to 4 mg3 to 4 mg0.5 to 2 mg0.5 to 2 mgAA3 to 4 mg3 to 4 mg0.5 to 2 mg0.5 to 2 mg0.5 to 2 mg0.5 to 2 m</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0CA59420-1D9E-44F2-AE9F-252EA8FFE1B6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B4FC53D9-B7AC-4F94-8AE1-348C6FF7D27D">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7FDE3645-8332-4712-93E0-1B6161EDC307">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7AFF7907-9685-4787-9538-5C33837A6047">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:338C70DE-6F55-45D8-B4AE-13D96803529F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:1A9267A8-5284-4711-BCFA-4B1FC22D6C5C">
    <pav:lineageUri>urn:domeoserver:annotationset:FAE19553-957D-45CE-8E2F-EDE4651240ED</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:074A4900-EE8E-4439-B149-5E948C112AFC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:61993713-5415-4CAA-A0C5-31296A96C352"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1C454AE0-AF11-4379-AA8E-A38C7734DCFB"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">16</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <pav:previousVersion>urn:domeoserver:annotationset:BC135CDB-B78D-4CA8-8678-1569A434A60C</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:F2EE233D-7466-4053-ABF4-1FBEF5907FC1"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D064E953-E6EE-4178-9C53-4A4327444278"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E86BAABD-588E-4E10-9EED-3177D2DF01EB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:04DDDCD4-8E85-474C-A1FF-3F0CD8E3238C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:21AF41BB-0A1D-4D6E-9BEB-7C6537782D4D"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdOn>2014-06-01 19:55:50 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:6DED6328-BB8E-4963-99FF-9232EF2ECF37"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7FE349C7-0D9E-4D58-A274-CAF51B5515AE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AF1E00CB-65B3-4FA7-8983-A7F0F462E481"/>
    <pav:lastSavedOn>2014-06-01 20:47:01 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:7EFA0404-5716-4EF8-832A-9950F139B157"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <permissions:permissions rdf:nodeID="Nb21997a420a34d389c270510273769ab"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304628d4c0014629cdc71a0000"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E4484BF6-2A71-453E-8379-1C7D4B47A7A7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:071EF91C-F1B0-4F3B-92DE-4CF6E10605F6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EF5688AD-11CB-4ADB-B3B0-D972E39E6E50">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C26D08C1-000D-4C41-920A-0962FE68BD68">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:CD417AEB-F1C9-4975-B082-898B774DDB0C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">27</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:236F5979-1FBA-4772-8B92-B6FE2A4EA75C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7E3F7435-2585-4B8A-884B-21F0A2AD3755"/>
    <pav:createdOn>2014-05-30 21:24:45 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AB8114CE-610C-4124-9C3E-2295E1567A55</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:FA6CF576-BA2B-4674-A310-C4159468BEED"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:23D022D1-EA80-4401-9CAD-1D389D3CBFA6</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:9F618CDC-6E54-41F8-9378-1C8EDE82CED5"/>
    <pav:lastSavedOn>2014-05-30 22:04:01 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:4FE2FB6E-6B8E-49B8-A407-14D1A81AF659"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:D1EF8E78-149A-454F-80FB-6CDADFF863C5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1E54F0B2-CA54-41AC-A744-71A1F6618816"/>
    <pav:previousVersion>urn:domeoserver:annotationset:8EE8A11C-69C8-4A10-87FD-55C6274CF5A0</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6E4A8813-711F-430E-9983-79C3342D4206">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-05-30 22:03:19 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6E4A8813-711F-430E-9983-79C3342D4206"/>
    <ao:exact>    Advise patients that nursing mothers taking codeine can have higher morphine levels in their breast milk if they are ultra-rapid metabolizers. These higher levels of morphine in breast milk may lead to life-threatening or fatal side effects in nursing babies. Advise nursing mothers to watch for signs of morphine toxicity in their infants which includes increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness.</ao:exact>
    <ao:prefix>•</ao:prefix>
    <ao:suffix> Instruct nursing mothers to talk to the baby’s doctor immediately if they notice these signs and, if they cannot reach the doctor right away, to take the baby to an emergency room or call 911 (or local emergency services)</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3D147974-AF2F-452E-B19D-C76CDB084E1D">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:11FE431F-D534-4FB5-8FD3-886028880C51">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(66106-6) PHARMACOGENOMICS</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>(66106-6) PHARMACOGENOMICS</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AE7F9525-1179-43D7-B3E0-3F4D44CFF1F5">
    <ao:body rdf:resource="urn:linkedspls:uuid:1AD73171-F5E6-4C0B-A456-2F41B101FB2E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:485C9112-4FEE-4EAA-8973-98D0688DAE42"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:89F7CFDB-3891-4DCB-A87B-BD3C0387A574"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AB8114CE-610C-4124-9C3E-2295E1567A55</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:658947BF-6474-4863-9B00-AF08AC87C241"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E4EB772E-E861-4676-80ED-5F865DE3C74E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7D879C25-F119-46DE-BB77-1D9B1C62A661"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-05-30 21:38:11 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:891377B7-86F4-4748-8B29-F52B454F56F8"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:255C0BC6-A709-4BB6-8DB0-EAD522DDB51A"/>
    <pav:lastSavedOn>2014-05-30 21:38:12 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:F458BC55-5BDC-4147-B188-2A7D48CDE9E7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6DFDAA16-44D3-43E0-8A12-F4471F995081"/>
    <pav:lineageUri>urn:domeoserver:annotation:B353A3B9-91D2-44DA-B2EE-AA1008B042E3</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:207BCCE4-7FBE-4EE8-841D-A4A6ABDFABDC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D4806A08-8AB4-4C29-B5A0-19F95D95456A">
    <ao:body rdf:resource="urn:linkedspls:uuid:AE800E3E-F603-40B7-8D9F-760C016723B2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:77C74F0C-9D35-436F-BDE7-215BA8B93567"/>
    <pav:createdOn>2014-05-31 14:52:21 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:F6127F6B-C3CB-4328-AE9D-64A04E8BDEEC"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:F7AD1DA6-748F-47CC-966D-BE4E50126C67"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0AC0314D-9D17-4DFF-BCA9-CB04D6F3F88C"/>
    <pav:lineageUri>urn:domeoserver:annotation:9FE0C18E-D071-41C4-8F99-B7FF3045014F</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:A84EA4DD-61D0-433D-98C0-AEDF2E9BD642"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-06-09 15:47:30 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:0F79766A-29DC-4606-9626-088C67DBD507"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:DECC9F11-B952-4822-B8CD-4014DFC45407</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:7CC2D857-BE71-4354-A78A-5295F374E728"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1E8A1D02-1448-4CEA-9E12-30A25E2BFA66">
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7FE349C7-0D9E-4D58-A274-CAF51B5515AE">
    <ao:body rdf:resource="urn:linkedspls:uuid:F0B1660B-2C74-47B7-A5C7-9C2449E35886"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:81770CFC-5B23-4D34-B89B-EA666A357006"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:05CE04BA-9DB6-41CA-BC81-3E4FDB6EC2C0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:11758337-A0BC-4C04-BDD6-B5573FC44DFB"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:B27FFF87-B3D3-4C30-A4A5-BDB56AC4984D"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1A9267A8-5284-4711-BCFA-4B1FC22D6C5C</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:FAE19553-957D-45CE-8E2F-EDE4651240ED</pav:lineageUri>
    <pav:lastSavedOn>2014-06-01 20:17:38 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:E551EA94-1404-489C-BDD5-14D13FDCB84A"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:8F2BD2B5-4CB5-4F8A-A2CF-8FD0876E535A</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:A217F02D-01C1-4AA2-AABD-B86B9BCD15B4"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-06-01 20:17:22 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:F3404877-ED90-4B73-80AC-39D302D28B84"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:98D69A5B-C1CF-4A98-AE3B-7B606CC1A3F4">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:98D69A5B-C1CF-4A98-AE3B-7B606CC1A3F4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact> In a small substudy (N = 81) of the NSABP P-1 trial, there appeared to be no benefit to screening women for Factor V Leiden and Prothrombin mutations G20210A as a means to identify those who may not be appropriate candidates for tamoxifen therapy.</ao:exact>
    <domeo:uuid>98D69A5B-C1CF-4A98-AE3B-7B606CC1A3F4</domeo:uuid>
    <ao:prefix>ministered with chemotherapy, there may be a further increase in the incidence of thromboembolic effects. For treatment of breast cancer, the risks and benefits of tamoxifen should be carefully considered in women with a history of thromboembolic events.</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-06-01 20:44:26 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:65A3E5C7-33A3-442B-A6F5-07D168A16AD0">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:65A3E5C7-33A3-442B-A6F5-07D168A16AD0"/>
    <ao:prefix> </ao:prefix>
    <domeo:uuid>65A3E5C7-33A3-442B-A6F5-07D168A16AD0</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOMPIRAMINE-4074b555-7635-41a9-809d-fae3b3610059.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the activity of this isozyme and make normal meta</ao:suffix>
    <ao:exact>Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-08-11 10:06:24 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:095B0883-346F-4B42-A3F9-355366683D05">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>(34067-9) INDICATIONS AND USAGE</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34067-9) INDICATIONS AND USAGE</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C5690880-0EE9-46B4-81EA-4D3F8209FFC2">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0415E508-97A8-4C52-A926-62A939770177">
    <ao:body rdf:resource="urn:linkedspls:uuid:658E09B7-8541-44FD-BE5F-3166BE415A0E"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:DA8E62CA-7575-4B2B-831C-6AED2AEB4954"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:575FF64B-A150-4E5F-BFC4-C07E27E45946"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:A8AD1C73-797E-4880-98AC-3E9A39F3A6ED"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A91EF184-DE3B-4CDE-995D-15015C878693"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:createdOn>2014-06-11 22:59:56 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:7C0DCB1D-4EA0-4D69-A1AD-66C615677CE4"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:9E39FCEE-4DFF-4CF1-9F19-486CDBD27E32"/>
    <pav:lineageUri>urn:domeoserver:annotation:C94AA33D-91DE-4ED0-B443-A39E489CC79D</pav:lineageUri>
    <pav:lastSavedOn>2014-06-11 23:03:21 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E823DCB5-68E6-44D4-90AF-E073AC268320</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:78C3F62C-A766-4362-AAB1-91C4818C1AC8">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:78C3F62C-A766-4362-AAB1-91C4818C1AC8"/>
    <ao:exact>    Advise patients that some people have a genetic variation that results in codeine changing into morphine more rapidly and completely than other people. Most people are unaware of whether they are an ultra-rapid codeine metabolizer or not. These higher-than-normal levels of morphine in the blood may lead to life-threatening or fatal respiratory depression or signs of overdose such as extreme sleepiness, confusion, or shallow breathing</ao:exact>
    <ao:suffix>. Children with this genetic variation who were prescribed codeine after tonsillectomy and/or adenoidectomy for obstructive sleep apnea may be at greatest risk based on reports of several deaths in this population due to respiratory depression</ao:suffix>
    <ao:prefix>•</ao:prefix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-05-30 21:58:56 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:DECC9F11-B952-4822-B8CD-4014DFC45407">
    <pav:createdOn>2014-05-31 14:35:51 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <permissions:permissions rdf:nodeID="N1618a8982cc042c993d462ab8b021d9a"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:C4B9C2C0-AC5D-4314-8B3F-C425ACE48FAA"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304628d4c0014629cdc71a0000"/>
    <pav:lineageUri>urn:domeoserver:annotationset:FA00EA59-A1F3-4077-9ADE-15EBC5C257E2</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:45C4377C-5302-4A10-A5B3-1FC32B4890E9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4CCBADD5-D553-4927-97A1-5E9C0E0373DB"/>
    <pav:lastSavedOn>2014-06-09 15:47:30 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:BBC7B698-9706-4746-9721-2E24BDE09EAB</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:annotatesResource>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:D4806A08-8AB4-4C29-B5A0-19F95D95456A"/>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:37CB8974-A3E5-4033-B63B-2E5149F4770A">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EF9794C3-352E-4126-BD14-1B210084ED33">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdfs:label>Codeine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F75B92E6-2073-46BC-AEB9-CA1CB371AB24">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Metabolism Increase</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:130EB555-04BD-4630-9645-B1D58D9C3656">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-08-11 08:54:29 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:C248DA70-0F7D-45F9-8DFE-C3873FCB6963"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D4DE924D-6DB5-40ED-A5EF-5DD5E8735F07"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B0A9489B-4D94-43A5-8E80-0165EF8C34B3</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:670BDB34-0CF5-4C6B-A1EA-763CF9446F45"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:EF5688AD-11CB-4ADB-B3B0-D972E39E6E50"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:899D476C-F5E4-4D2D-9CB4-0E92FDBF03BE"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:81CA2F07-4B3D-46EF-8AB1-9B8D8DA26D3D"/>
    <pav:createdOn>2014-08-11 08:54:27 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:0AF3E985-4E57-42CD-892A-EF3C03D77886"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C329A109-0A50-4C94-88A2-996BEB7A06F5"/>
    <pav:lineageUri>urn:domeoserver:annotation:8B9551A8-713F-4BD5-A69A-0CA22908A146</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A09FB5EC-B7A0-4198-8AB7-A4A4CB06C3A8">
    <ao:body rdf:resource="urn:linkedspls:uuid:A2882C4E-428B-43C1-9CF6-DFFCAF05D1DB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1553C2FB-88A9-4ADB-B08E-C0E3C9F74918"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:0D365496-AE4A-487E-BBD5-1A444096DB46"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8CBB02C2-085F-4ADA-9BD7-FA840705DD6D</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:34BCFD81-E525-4D87-801E-8BF68CF4067E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:42F4C828-0CF6-4F9B-A5C4-0138E8F9AE2F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:B3013ABA-CAF8-454F-A591-9577FAB9211D</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:A450E726-0EB5-4B8F-99D6-3DC0A90EC6C7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D2A2444C-4BA9-4190-BF52-CEBFB9BBA949"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-08-11 09:41:13 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-08-11 09:44:19 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:34458739-6469-4197-83EC-E6C8EB6BC493">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ultra-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7EFA0404-5716-4EF8-832A-9950F139B157">
    <pav:createdOn>2014-06-01 20:44:09 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7B3568DD-1DE6-413F-B09A-6DBA416AADD9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:67DE162A-DA85-4146-836D-0F1035653732"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:70FD5292-2B34-4C99-BB2E-B0E7E40EE8CD"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">13</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1A9267A8-5284-4711-BCFA-4B1FC22D6C5C</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:98D69A5B-C1CF-4A98-AE3B-7B606CC1A3F4"/>
    <pav:lineageUri>urn:domeoserver:annotationset:FAE19553-957D-45CE-8E2F-EDE4651240ED</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:2FB9922F-5AFF-4C22-88E7-263E440CEBEE</pav:previousVersion>
    <pav:lastSavedOn>2014-06-01 20:44:33 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:62C5FDED-B1F7-439B-A88C-C50E2B735FBB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2EDEDB72-1596-4773-905C-25A19A2EFCBB">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8CAD0D52-C5C4-46D7-98C8-FB954DA7A0A1">
    <rdfs:label>Variant Frequency</rdfs:label>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:04DDDCD4-8E85-474C-A1FF-3F0CD8E3238C">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:F958F428-C8AC-4342-BA1F-00448919C596"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C626ECB3-EE49-492C-8C12-0F8DD52C22EB"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1A9267A8-5284-4711-BCFA-4B1FC22D6C5C</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:9FE3DB68-2973-46A7-A5BC-A0B694ADE712</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:0C7D8BCC-11E3-42F3-8CFC-F3702CB17CD0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:84A930F5-FD5F-4824-AACB-620C690DC46D"/>
    <pav:lastSavedOn>2014-06-01 20:46:49 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:82AD605C-D9BE-4FD4-82FA-8D791B59A15D"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:A2F50048-A931-4DEF-A83C-25F87CE8F002"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:createdOn>2014-06-01 20:16:17 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:FAE19553-957D-45CE-8E2F-EDE4651240ED</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:AE322383-4638-47D3-A12E-DCB5BDAFE0EB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B91E7C5C-388E-4BC6-B871-0E3637976FE5"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:101B85D6-7313-4E3E-BEC7-5A2A07DC97E1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C19A3897-6FD8-453C-BFBB-A90D6DD2296F">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:23663</dailymed:HGNCGeneSymbol>
    <rdfs:label>VKORC1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FC927ED3-A2A7-49AB-87AC-B0A167F6CA9E">
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-06-01 20:00:41 -0400</pav:createdOn>
    <ao:suffix>Among 29,441 patients with ER positive or unknown breast cancer, 58% were entered into trials comparing tamoxifen to no adjuvant therapy and 42% were entered into trials comparing tamoxifen in combination with chemotherapy vs. the same chemotherapy alone</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FC927ED3-A2A7-49AB-87AC-B0A167F6CA9E"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:exact>The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) conducted worldwide overviews of systemic adjuvant therapy for early breast cancer in 1985, 1990, and again in 1995. In 1998, 10 year outcome data were reported for 36,689 women in 55 randomized trials of adjuvant tamoxifen using doses of 20 to 40 mg/day for 1 to 5+ years. Twenty-five percent of patients received one year or less of trial treatment, 52% received 2 years, and 23% received about 5 years. Forty-eight percent of tumors were estrogen receptor (ER) positive (&gt; 10 fmol/mg), 21% were ER poor (&lt; 10 fmol/l), and 31% were ER unknown. </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AF34AEA4-B827-4D72-90A3-5CFA8902A66C">
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:61993713-5415-4CAA-A0C5-31296A96C352">
    <ao:body rdf:resource="urn:linkedspls:uuid:98E4E343-CF29-4C67-966C-BDB013B7AF46"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1A9267A8-5284-4711-BCFA-4B1FC22D6C5C</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:5BE86617-EF9E-48F2-9D21-149A3734C784"/>
    <pav:lastSavedOn>2014-06-01 20:01:43 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:858DBF32-AD18-4CD9-A58A-3F4F5D647BE1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E205ECA7-1611-4418-9C6E-D07A3C966002"/>
    <pav:lineageUri>urn:domeoserver:annotationset:FAE19553-957D-45CE-8E2F-EDE4651240ED</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:AA9B1851-EFBB-4B93-A177-A60A01DF2AB6"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-06-01 20:01:42 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:DA214073-2362-48DC-9D34-A21E64C023DD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F1557B24-E3F8-43AB-BBFF-CAFBF8278531"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:4A881955-7882-48B0-82B3-290FABDED458"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:82D57F69-146C-49DE-8423-547A6134FCBF">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F3091362-0406-40EA-8DCC-799617CD755D">
    <ao:body rdf:resource="urn:linkedspls:uuid:F252085F-2ADD-4E6C-BEE1-E41BC65F23F3"/>
    <pav:previousVersion>urn:domeoserver:annotationset:B1692B62-223D-4770-8153-B59F6A0FD965</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1949E7D1-321A-4393-95AF-90925788C494"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:FBDFC45D-EF70-4091-878E-0FD07632F3E1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:25F3EB1C-22D6-48CC-9715-E3CD0818E8FA"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:C55D8F3D-2A90-46A8-BD71-FBBA80DB6590"/>
    <pav:lastSavedOn>2014-06-11 23:16:49 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:1B92794A-5D16-44FF-9839-347A36320F8A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7B417F76-E2BF-4AE6-934A-BBCA251C5264"/>
    <pav:lineageUri>urn:domeoserver:annotationset:59590A65-90C8-4E95-A16E-96DB23D9D119</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:6A30D2D0-C7F2-4DCF-9E4F-3B73BBEE44D3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B2F1336A-CE5A-440D-B811-8A04ECAD66FB"/>
    <pav:createdOn>2014-06-11 23:16:49 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E823DCB5-68E6-44D4-90AF-E073AC268320</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:221F7C86-009D-4635-88A4-D4D29EE3F743">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A83D3BE1-F713-4A8A-AF83-80E88F3E09D5">
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdfs:label>Prodrug</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <dct:description>Referred to Prodrug</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:074A4900-EE8E-4439-B149-5E948C112AFC">
    <pav:lastSavedOn>2014-06-01 20:01:43 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-06-01 20:00:41 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:3EE1F896-7F97-4ACD-83FA-900C07C5EB3B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A84F12D8-CFCB-4C2E-93F3-B9E05CF8B7B2"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:3D147974-AF2F-452E-B19D-C76CDB084E1D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:FAE19553-957D-45CE-8E2F-EDE4651240ED</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:FC927ED3-A2A7-49AB-87AC-B0A167F6CA9E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2A95B900-ADEB-4BD8-86A1-6E0E334E1F25"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:334439E9-9AF3-48C7-A414-21D98ECD9456"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:9A72C8FC-2539-4E0A-907E-33D2FB07D903"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1A9267A8-5284-4711-BCFA-4B1FC22D6C5C</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:8ED2287A-DCC6-4329-90B4-09269229842A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2EDEDB72-1596-4773-905C-25A19A2EFCBB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BA3D4FC3-D4A8-45EF-B295-6256DA05F50F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>breast cancer</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0690D778-4E31-4414-AF0D-C52BDEDBBCA1">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00049</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Rasburicase</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0EDF569A-4478-4086-8B88-B6987E68A913">
    <ao:suffix>.6,7</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0EDF569A-4478-4086-8B88-B6987E68A913"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact> In 201 Caucasian patients treated with stable warfarin doses, genetic variations in the VKORC1 gene were associated with lower warfarin doses. In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gene alone; about 40% of the variance in warfarin dose could be attributed to variations in VKORC1 and CYP2C9 genes combined.5 About 55% of the variability in warfarin dose could be explained by the combination of VKORC1 and CYP2C9 genotypes, age, height, body weight, interacting drugs, and indication for warfarin therapy in Caucasian patients.5 Similar observations have been reported in Asian patients</ao:exact>
    <ao:prefix>.</ao:prefix>
    <pav:createdOn>2014-06-11 23:01:22 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F53530C7-F9B4-45F0-BA66-9CF8BBD31A54">
    <pav:createdOn>2014-08-11 09:18:27 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:2D3C53BE-F0C3-4C6A-9B15-0425B99E8CBA"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:E3EAE727-22B5-409D-8F3D-BEB2E7D4613B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CC627C3D-857E-4804-9D92-84F409E58486"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6311CEA1-933E-4F82-9A78-141447F539CE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:992566F3-FFA4-42DC-9DB4-595F92F623C2"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8917A0C6-4EB0-4018-922E-B216A9A1DB0C</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:86D504AD-BBC8-443A-A553-79235C02F793"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:B395F536-46D9-4B82-BD99-22E9D07B4A22</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:F1552F75-D639-4451-9E82-568A07E36CA9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:4D3FD3EB-8A3B-4840-BA6B-AC7762FB73EF"/>
    <pav:lastSavedOn>2014-08-11 09:19:30 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:8420E1EA-C07C-4C94-A02D-FAC9986FAECD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D70F7EB6-3197-4B39-9ECE-D27D645B1AD2"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:631DABFD-76E2-40E6-AFB1-A8F8EF76BE0A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C653116F-7526-437C-8DF3-490943F87724"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D544FA4B-2E59-4E71-8C09-112D2ADAE5ED"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0F79766A-29DC-4606-9626-088C67DBD507">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <domeo:uuid>0F79766A-29DC-4606-9626-088C67DBD507</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0F79766A-29DC-4606-9626-088C67DBD507"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> These interventions lead to decreased tumor mass or delayed progression of tumor growth in some women.</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-06-09 15:47:28 -0400</pav:createdOn>
    <ao:exact>The growth of some cancers of the breast is stimulated or maintained by estrogens. Treatment of breast cancer thought to be hormonally responsive (i.e., estrogen and/or progesterone receptor positive or receptor unknown) has included a variety of efforts to decrease estrogen levels (ovariectomy, adrenalectomy, hypophysectomy) or inhibit estrogen effects (antiestrogens and progestational agents).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:81CA2F07-4B3D-46EF-8AB1-9B8D8DA26D3D">
    <ao:suffix>Table 13: SVR Rates by IL28B G</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:81CA2F07-4B3D-46EF-8AB1-9B8D8DA26D3D"/>
    <ao:exact>A retrospective genome-wide association analysis1,2 of 1671 subjects (1604 subjects from Study 4 [see Clinical Studies (14.1)] and 67 subjects from another clinical trial) was performed to identify human genetic contributions to anti-HCV treatment response in previously untreated HCV genotype 1 subjects. A single nucleotide polymorphism near the gene encoding interferon-lambda-3 (IL28B rs12979860) was associated with variable SVR rates. The rs12979860 genotype was categorized as CC, CT and TT. In the pooled analysis of Caucasian, African-American, and Hispanic subjects from these trials (n=1587), SVR rates by rs12979860 genotype were as follows: CC 66% vs. CT 30% vs. TT 22%. The genotype frequencies differed depending on racial/ethnic background, but the relationship of SVR to IL28B genotype was consistent across various racial/ethnic groups (see Table 13). Other variants near the IL28B gene (e.g., rs8099917 and rs8103142) have been identified; however, they have not been shown to independently influence SVR rates during treatment with pegylated interferon alpha therapies combined with ribavirin.1</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-08-11 08:54:27 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/PEGINTERFERON_ALFA-2B-0a8f3137-0e3a-4a60-a872-cb7d761b30e1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>81CA2F07-4B3D-46EF-8AB1-9B8D8DA26D3D</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:05D6F5CE-CCB5-41CA-91C7-5CED687A51CE">
    <ao:body rdf:resource="urn:linkedspls:uuid:4CAED7E0-8FF2-4BA9-9B67-950D17E07D7C"/>
    <pav:createdOn>2014-08-11 11:34:07 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:34E63D34-1418-44B0-97CD-7CB4FAAB9700"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:ED718500-30EB-4DC5-93BE-1577F3828D52"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3B6B17D2-B6A8-442E-9E28-66ADC7447594"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:0C5FB150-013E-495E-9A90-192BFAC6CBF5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D83DA952-EF7A-4B56-8361-8ACDF5A03A79"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7B0DAF9E-E2E6-4143-A5E9-998F48DEDF2E"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:E39C36F3-9EAD-4FA7-8D2C-54B909CEEBAD</pav:lineageUri>
    <pav:lastSavedOn>2014-08-11 11:34:12 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:01E6A884-4CF2-46AE-9EF0-6FAD18DB4E77"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:A9E8823F-1264-471E-92FE-9A5C76144578"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:23D232D6-9A25-47F3-8DA1-D7CE366FB4BF</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:7F85C5F2-AB6F-4E72-9822-94E1F4700750"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:7769A299-9EDC-46D5-9A8E-2DC99C2B622F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:993DD603-0A5B-4FCF-B104-9D37985E9AF3">
    <ao:item rdf:resource="urn:domeoclient:uuid:FA61827A-7535-4493-9D28-FC5B538B3030"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2C8A9047-AC0C-4C44-989D-8F17FBD8C401"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:47DCA083-21ED-43F8-84D4-80617779F31A</pav:previousVersion>
    <pav:createdOn>2014-08-11 09:49:23 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304628d4c0014629cdc71a0000"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:29A5AD9F-02AC-4AE7-9AE3-9B2312712BC5</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IMIPRAMINE-1827a5aa-733a-49d9-89d9-48ea0367b230.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="N7bed07458efb4267935763d51762fccd"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2014-08-11 09:55:18 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:216B87B1-6061-4265-94E4-F0655317673A">
    <ao:exact>Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:216B87B1-6061-4265-94E4-F0655317673A"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-06-09 15:35:27 -0400</pav:createdOn>
    <domeo:uuid>216B87B1-6061-4265-94E4-F0655317673A</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:B0A9489B-4D94-43A5-8E80-0165EF8C34B3">
    <permissions:permissions rdf:nodeID="N6916bd533ab64524831cea121fe6811b"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:previousVersion>urn:domeoclient:uuid:B1DBF7A3-DB5A-4D64-9CF5-3E5B6E91BA9C</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304628d4c0014629cdc71a0000"/>
    <pav:lastSavedOn>2014-08-11 08:54:28 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:130EB555-04BD-4630-9645-B1D58D9C3656"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/PEGINTERFERON_ALFA-2B-0a8f3137-0e3a-4a60-a872-cb7d761b30e1.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2014-08-11 08:48:13 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:C84C004A-0078-4D91-8BCC-9FCC8074E687</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9F618CDC-6E54-41F8-9378-1C8EDE82CED5">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>doesn't fit very well</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B94B4D30-9482-4AE7-A3DB-756CB93EF0AE">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9A342490-BA59-4518-ADBB-92AB5B53FBE0">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:43653153-B11C-40E9-8080-04E3E9C301ED">
    <pav:lineageUri>urn:domeoserver:annotation:050FB636-1BEA-4B6A-A604-3D3F53EF5567</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:D2DBCEA4-A79C-418A-8450-AED0D1F3D2E8"/>
    <pav:createdOn>2014-06-11 23:12:34 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:C5BF20C2-063A-4763-9C18-A72E5D283501"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A0BE39E4-856F-4C5F-A4B6-14F1AFB1A118"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E823DCB5-68E6-44D4-90AF-E073AC268320</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:921DD4DE-1801-4A8F-88EC-01393ACEAEB4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D8726ED9-ECDB-4232-81F1-F3FA746E767C"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:B81A2078-50C0-4910-A12C-3046FE1A92AB"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:58A545C3-0C67-41DA-9D8A-8C3A046798A4"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:648DC081-1A41-4B91-A341-82121D34ED7B"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-06-11 23:12:35 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A80EF5E9-B3C7-488C-953D-86523C030390">
    <ao:body rdf:resource="urn:linkedspls:uuid:EA18C77F-C132-4E66-A85C-2936D0CE2688"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:81310DBB-B705-40ED-B397-0EE4A46B8875</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:2E934232-9AF8-479B-884A-AC8CDD2390BA"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:437C6B85-1383-49D7-997E-1836FFFF051C"/>
    <pav:lastSavedOn>2014-08-11 10:06:24 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-08-11 10:05:17 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:3C31A0A4-BC10-4EE2-B299-34551320C59C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:22CAE21C-241A-45AF-B24A-F734D3ADD3D3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D470A236-07D2-4FEB-B41C-8C309D957A6A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3A1A2DB1-B595-412A-A19B-1DD1EC83B05C"/>
    <pav:lineageUri>urn:domeoserver:annotation:2E622C5B-035C-4837-8CEB-F4729043D14D</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:C5690880-0EE9-46B4-81EA-4D3F8209FFC2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:15EDD256-2022-4CB1-8006-E9050FAC7991">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>42232-9 PRECAUTIONS SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42232-9 PRECAUTIONS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9C64FD15-405B-4B8A-941B-8CA88780E202">
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8BA4D7E3-AA90-4C5B-9E4B-51B8981B3592">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F7AD1DA6-748F-47CC-966D-BE4E50126C67">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Letrozole</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E5335936-B45E-45FB-88B1-5412D6A59C96">
    <sio:SIO_000111>(34068-7) DOSAGE AND ADMINISTRATION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34068-7) DOSAGE AND ADMINISTRATION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:45C4377C-5302-4A10-A5B3-1FC32B4890E9">
    <ao:body rdf:resource="urn:linkedspls:uuid:7C5595A3-7B04-4765-B27C-AF9D94170E06"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:216B87B1-6061-4265-94E4-F0655317673A"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-06-09 15:35:28 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:2C5BD56A-E020-4675-BB40-DD0A1B5891F7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-05-31 14:40:09 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:476ACFAB-3FD0-4A82-885F-482B97DF26D1"/>
    <pav:previousVersion>urn:domeoserver:annotationset:C800C645-670A-4B2A-A7FF-4C23CC505D41</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:BFF14F39-B888-4590-94C7-29C8F2DEFDAC"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:DECC9F11-B952-4822-B8CD-4014DFC45407</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:21B5271B-CDE6-4B0C-AA09-3A37D5F78FE2"/>
    <pav:lineageUri>urn:domeoserver:annotationset:FA00EA59-A1F3-4077-9ADE-15EBC5C257E2</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:D28BD509-7995-462B-B1D6-7EF14705EEEF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2A95B900-ADEB-4BD8-86A1-6E0E334E1F25">
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdfs:label>Clinical Trial</rdfs:label>
    <dct:description>Referred to clinical trial</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1A713645-4012-4097-9711-D7E513A81EA1">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:CF36AEF0-A63A-46BA-822E-60118413C424"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E823DCB5-68E6-44D4-90AF-E073AC268320</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:59590A65-90C8-4E95-A16E-96DB23D9D119</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:A01BBC9E-77E3-477B-8355-90E231DA0A25</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:875E64F8-05B0-4653-B39F-3C01D331DE3F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:50FA1816-5081-4E2F-A153-69B3F1DCA5AC"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:9F8455FE-40B6-499D-8AA6-6FCE4F1ED600"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:232C456A-AD10-4715-A3DA-32F723E5BEFE"/>
    <pav:lastSavedOn>2014-06-11 23:08:53 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-06-11 23:08:28 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:10D511DE-9049-477C-804F-816B19E1AC32"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9E2A8002-D6F7-4867-956C-4B34CF836ADE">
    <ao:body rdf:resource="urn:linkedspls:uuid:BD5A9C23-7261-4124-8C7A-EE9A70F2B47B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1643699C-B62C-4A36-8D7A-4D109304FDD6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C2E7571D-EE81-4466-A0FC-4F946020B57C"/>
    <pav:lineageUri>urn:domeoserver:annotation:86A23C2F-19F7-4C5A-9A4E-DB3C357F7DF4</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:51803E64-2743-47F4-922F-8182279DDD24"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E63ED68A-406B-4C87-A640-801F945CD796"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E823DCB5-68E6-44D4-90AF-E073AC268320</domeo:belongsToSet>
    <pav:lastSavedOn>2014-06-11 23:03:21 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-06-11 22:58:54 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:42DD5054-7518-4436-8BF5-3C9712B8C6B2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A6338818-C41B-4AD9-A254-4C19EC45EC7B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6F649B39-A8EA-43CF-8743-84185775E0F2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:11FE431F-D534-4FB5-8FD3-886028880C51"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E8417695-A485-406D-9874-2FCD4E30F0C5"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:9DDECF86-419A-42F5-901E-662CA3B37338"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0C71A1DE-B3BE-4E3F-940A-55107C9E2FD1">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D064E953-E6EE-4178-9C53-4A4327444278">
    <ao:body rdf:resource="urn:linkedspls:uuid:182DFCE4-0DF9-4262-8B5D-5549152326E5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9CDFD245-0D94-4BAB-8C5B-DA64F5B60CA8"/>
    <pav:lastSavedOn>2014-06-01 20:46:49 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:00912755-73D6-4B51-90B0-80DF9BE1274F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9A342490-BA59-4518-ADBB-92AB5B53FBE0"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:C836722F-7BEC-415A-8929-4F586A537BCB"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1A9267A8-5284-4711-BCFA-4B1FC22D6C5C</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2B0185C8-59AA-4FE3-B38D-775C36A6FCA6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:227A5D0C-7BA3-439E-BEE7-3B9D8C97D212"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:DD43C8BC-2C95-438D-B8EE-7A8590B1ADDE"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:FAE19553-957D-45CE-8E2F-EDE4651240ED</pav:lineageUri>
    <pav:createdOn>2014-06-01 20:25:35 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B4FB2FD7-E678-4286-BD4E-AD1AAE5CBC1E"/>
    <pav:previousVersion>urn:domeoserver:annotationset:9FE3DB68-2973-46A7-A5BC-A0B694ADE712</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0C5FB150-013E-495E-9A90-192BFAC6CBF5">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F8158949-9BC4-4394-AC59-0A2ED6B83ADB">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0633CD7E-C8F7-4156-BD95-B928101B271C">
    <domeo:belongsToSet>urn:domeoserver:annotationset:E823DCB5-68E6-44D4-90AF-E073AC268320</domeo:belongsToSet>
    <pav:createdOn>2014-06-11 22:45:18 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:1F7D5BB1-2314-460E-BDF3-441604623507</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:ED5E969D-E897-4E6E-A5BC-5DCBEA735062"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:125D4098-DFEB-4C27-878C-BA3274477BB7"/>
    <pav:lastSavedOn>2014-06-11 22:54:16 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:59590A65-90C8-4E95-A16E-96DB23D9D119</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:567489D0-D90D-4084-81AD-F4F95290D857"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B4FC53D9-B7AC-4F94-8AE1-348C6FF7D27D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:46C7ACCC-401F-4C49-AA5C-1FD2B825E099"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C202EFD3-1731-4A08-BDA1-687FB9F032DC"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:96B326D1-79D6-4078-8D78-E4D420F7661F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7F85F574-EDDD-4436-9FDD-C3FEC9657727">
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7F85F574-EDDD-4436-9FDD-C3FEC9657727"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:exact>Respiratory depression and death have occurred in children who received codeine in the post-operative period following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6 [CYP2D6] or high morphine concentrations). </ao:exact>
    <ao:suffix>Deaths have also occurred in nursing infants who were exposed to high levels of morphine in breast milk because their mothers were ultra-rapid metabolizers of codeine </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-05-30 20:55:23 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4CCBADD5-D553-4927-97A1-5E9C0E0373DB">
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:FA09E146-1527-4DD9-A474-62CC009AA182"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FE255348-0CA7-46D9-8A07-AEE9528AC9E7"/>
    <pav:lastSavedOn>2014-06-09 15:36:12 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:FA00EA59-A1F3-4077-9ADE-15EBC5C257E2</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:DECC9F11-B952-4822-B8CD-4014DFC45407</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:F5D43909-3F68-4792-8D1B-0A1E7607829C"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-05-31 14:46:37 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:095B0883-346F-4B42-A3F9-355366683D05"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EB2A64A0-F97F-4CBA-BA78-FBB8C09A8EAA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C7710F78-E171-4D17-BA7B-BA89034BE79F"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:B79E5FF8-397A-4E53-9107-6884F2354A54"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E88ECE97-0020-499D-BA2C-3FB2A9F6B89A"/>
    <pav:previousVersion>urn:domeoserver:annotationset:6C6F5067-209F-4909-B081-65F44E7E0E99</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B4323A5D-56AC-4392-85FA-23F6FB53396D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B37CEB82-FBDE-4810-AAB7-410EE82AB578"/>
    <pav:lastSavedOn>2014-06-11 23:03:21 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:34FFFD8F-0932-4522-9B73-7489CDB20686"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E823DCB5-68E6-44D4-90AF-E073AC268320</domeo:belongsToSet>
    <pav:createdOn>2014-06-11 23:01:22 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:0EDF569A-4478-4086-8B88-B6987E68A913"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:7D46C748-6F55-4EF9-AF2C-7C911242A72F"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:95035BEF-49E8-456F-BF8C-6D80EE2D0277"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4A0EC5B8-4233-41D6-9282-20CC0F57567E"/>
    <pav:lineageUri>urn:domeoserver:annotation:1CDECFCB-D296-4169-9EE0-A0FE0B9DACD7</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:A9AD9EFC-A746-47AD-BC2D-A953146DE48D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:88A0E7E7-706E-4FD4-9B9F-B8EB161DF234"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EB7F1BA4-B05F-4434-9BB2-FB4E73BCDBD9">
    <rdfs:label>gene-haplotype-negative</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-negative</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7CC2D857-BE71-4354-A78A-5295F374E728">
    <poc:Comment>not sure if i should include this annotation bc its not specifically about letrozone. </poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DD6818B5-BF5E-4BB3-89C3-ACC2249D6D83">
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:18BBF23F-3C36-4AB2-9878-873E7698F865">
    <pav:createdOn>2014-06-01 20:46:48 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>on, axillary dissection, and breast radiation). After 5 years of treatment, there was a significant improvement in disease-free survival in women receiving tamoxifen. This benefit was apparent both in women under age 50 and in women at or beyond age 50. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:18BBF23F-3C36-4AB2-9878-873E7698F865"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>18BBF23F-3C36-4AB2-9878-873E7698F865</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>One additional randomized study (NATO) demonstrated improved disease-free survival for tamoxifen compared to no adjuvant therapy following total mastectomy and axillary dissection in postmenopausal women with axillary node-negative breast cancer. In this study, the benefits of tamoxifen appeared to be independent of estrogen receptor status.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9B6AA731-4D11-46AE-AEEB-A7355AA00D5F">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-level-low</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-level-low</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C5BF20C2-063A-4763-9C18-A72E5D283501">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34068-7) DOSAGE AND ADMINISTRATION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(34068-7) DOSAGE AND ADMINISTRATION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:87A30941-784A-48C2-85EC-6E8408176B32">
    <ao:exact>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so-called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IMIPRAMINE-1827a5aa-733a-49d9-89d9-48ea0367b230.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:87A30941-784A-48C2-85EC-6E8408176B32"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).</ao:suffix>
    <ao:prefix> </ao:prefix>
    <pav:createdOn>2014-08-11 09:53:33 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4F172E35-1434-4C38-B1C1-518434AE5B59">
    <ao:context rdf:resource="urn:domeoclient:uuid:F90ACC5B-6D0A-405E-B915-A14C66CD9386"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FBCA9007-0EA3-4DF5-89D0-58E2A94E087B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0690D778-4E31-4414-AF0D-C52BDEDBBCA1"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8917A0C6-4EB0-4018-922E-B216A9A1DB0C</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:BF5138D5-018B-4DE6-8FEB-2BFBE2837B77"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0100375E-6C66-4D5A-BA68-DA8813CEE98F"/>
    <pav:createdOn>2014-08-11 09:10:44 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:39A13F2B-CD5B-422D-AB05-623607D20F9A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:618476AA-4D11-476A-8AEA-306370717435"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1CEDDA85-963C-4A54-8397-2E6850BA4EA8"/>
    <pav:lineageUri>urn:domeoserver:annotationset:5EBB77FD-51B8-46AE-8874-51C32A57C8E9</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:F7C58D05-6A18-4BC2-A3FF-57CF5791EFF0</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:8A8D925D-835B-4D44-B7A7-B8F6C7960539"/>
    <pav:lastSavedOn>2014-08-11 09:12:14 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0EB0E245-2D2C-4498-ACF7-D0506797B006"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:22151E28-B4F0-4EAD-AEA1-AC7B24276C0D">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:EFB058D5-D26B-4202-86A7-539B60FA08CE"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:A71D4530-E5CB-4468-AE44-2D8198AEFA3E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7FDE3645-8332-4712-93E0-1B6161EDC307"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DE8F307F-8E67-439D-95BF-FA8E4BA2DC86"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0C8955C0-E620-4E69-BA2A-398A81C5E1D8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DDDCA2AB-140F-4AC8-8A93-9A491387DA6C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:createdOn>2014-08-11 10:44:07 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:40B4D8AC-8544-4AC8-B121-1C057F907B17</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-08-11 10:44:08 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:612C854A-ABD0-498F-B420-5EEBFCBC78B0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4E0ADC3B-B8FA-435D-AD38-A81840D33A5A"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:23D232D6-9A25-47F3-8DA1-D7CE366FB4BF</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EFB058D5-D26B-4202-86A7-539B60FA08CE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>*28</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:49AE4751-F95D-4FD4-91E4-56608E2453F0">
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <rdfs:label>Recommended</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:99B48402-7F9C-491D-AA16-4F6070F05428">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ESR1</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1E54F0B2-CA54-41AC-A744-71A1F6618816">
    <rdfs:label>Not Important</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-important</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is not associated any clinically relevant pharmacokinetic with respect to the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AA9B1851-EFBB-4B93-A177-A60A01DF2AB6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D970767A-45AD-49F4-BE28-26ED292A3E62">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42232-9 PRECAUTIONS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>42232-9 PRECAUTIONS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3338E6D3-C4DA-4CB9-9E36-7B052E30D34B">
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5FB54727-E732-44AA-AF8C-16375388C122">
    <ao:body rdf:resource="urn:linkedspls:uuid:20F57989-7BB0-43C0-A137-3F40F71DF17A"/>
    <pav:createdOn>2014-08-11 09:31:52 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:7B28BBA4-58C5-4DE8-A6D0-57CA21C3BB71"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BFEB65CB-2814-4AD8-A783-8BE84FC3019F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5577F2EC-D99F-4443-9541-C267391FCB4F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoclient:uuid:B93ABF38-7B62-436A-98EB-148CE1F69464</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:4504339D-9515-45C4-BBEC-A51E70B6B08C"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8CBB02C2-085F-4ADA-9BD7-FA840705DD6D</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:92D11857-AC3C-4F10-830F-4DC679E72BB6</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:E340B5EF-6C23-48E8-B6FC-2BC88A334DDD"/>
    <pav:lastSavedOn>2014-08-11 09:31:54 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:D781577C-73DF-48C4-9F44-9C43DC0474F1"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:9819ABA2-582F-4DAC-8C77-A1B2945346D2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DB79FC8E-9B12-4E9B-89F4-23F28BFC72A0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FBCA9007-0EA3-4DF5-89D0-58E2A94E087B">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:80CFC228-C5AD-4697-B4BC-A0BEB597B99B">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB08820</dailymed:pharmgxDrug>
    <rdfs:label>Ivacaftor</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2C8A9047-AC0C-4C44-989D-8F17FBD8C401">
    <ao:body rdf:resource="urn:linkedspls:uuid:4A1B0DE6-1E89-48B2-AD14-460A3AAE91B4"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:8F1A0E06-9096-4D0A-8CC0-41A7835D1F9A"/>
    <pav:lastSavedOn>2014-08-11 09:53:43 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:7E6F32AA-05C0-41A0-892C-BC1440B56A52</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:CB47B861-6AFD-49F1-A341-3200E25FD70F"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:87A30941-784A-48C2-85EC-6E8408176B32"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:28D78CA7-B125-4E41-ADD8-84C01BDC8716"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0C749FEB-4CF0-4A48-81AD-1EC629725AA2"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:993DD603-0A5B-4FCF-B104-9D37985E9AF3</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:6C29BC4E-4436-4E07-B8CA-79B0959178F9"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:8CAD0D52-C5C4-46D7-98C8-FB954DA7A0A1"/>
    <pav:createdOn>2014-08-11 09:50:26 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E0117D95-059E-48FC-A208-FDBF96D17A48">
    <rdfs:label>VKORC1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:23663</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FA61827A-7535-4493-9D28-FC5B538B3030">
    <ao:body rdf:resource="urn:linkedspls:uuid:A1FCB28F-22A4-4A1E-8688-A0EFE963260B"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:72477FCD-9596-4DC3-AC10-288164FE5812"/>
    <pav:lastSavedOn>2014-08-11 09:55:19 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:BA476DCB-2C26-4971-9305-A432013E7B4A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:33A0F277-AAA6-489D-BE2B-6AA41F5A91CB"/>
    <pav:createdOn>2014-08-11 09:55:18 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:8D480615-10DE-4B2F-8A84-433E5FFF50CE"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:9E0CF3F8-5667-40B1-ADC1-1789D3231C8E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:993DD603-0A5B-4FCF-B104-9D37985E9AF3</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:B3496ACB-63DA-47BD-B5B2-8D358C48A6B9</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:5B4975CD-8602-4FBA-8F3A-481CF5348CE2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5FD85CCC-B925-4A8A-8E81-107133289231"/>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DBF911A3-DA19-4C9A-9E86-9CD741EC7C67">
    <dct:description>A required monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#required</poc:MonitoringRecommendation>
    <rdfs:label>Required</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CA5F2011-211B-4BB3-A00A-864828B8FB28">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D4A21C62-3976-4345-96EE-2B53E77FA491">
    <rdfs:label>ESR1</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0DE492CC-375E-4575-AEA5-007BE44AAF67">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>cystic fibrosis</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E799D960-1B67-4513-8772-168D22143816">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>G6PD</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4057</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E329FA1D-EAA0-4508-9A60-233980C1CA0D">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(66106-6) PHARMACOGENOMICS</poc:productLabelSection>
    <sio:SIO_000111>(66106-6) PHARMACOGENOMICS</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:39A13F2B-CD5B-422D-AB05-623607D20F9A">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34066-1 BOXED WARNING SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34066-1 BOXED WARNING SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9C4C7207-57B0-4DBD-B736-06E6D6721873">
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdfs:label>Prodrug</rdfs:label>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to Prodrug</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:56C4A1D8-6C50-47B7-A739-52ED0271119D">
    <ao:body rdf:resource="urn:linkedspls:uuid:5A4B6334-D8F8-47CB-A7EE-87EB926A3273"/>
    <pav:lastSavedOn>2014-08-11 09:12:14 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:B106C82C-2445-4565-8B23-119EBE1AAFAB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F753B571-DFFF-4AF6-A8BB-5435EA5A9721"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:createdOn>2014-08-11 09:07:48 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8917A0C6-4EB0-4018-922E-B216A9A1DB0C</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:345C8298-3DC9-43D5-A7FD-B4A816C710F9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EFDE0DDE-C4EB-4672-9316-AAD90F075F4F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AD336335-5550-4CE1-A924-F414BCBBD4CE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:80CD5B75-A3FD-4D1E-A268-8198FEBBF6B0"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:F7C58D05-6A18-4BC2-A3FF-57CF5791EFF0</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:089E1BAF-C3A9-4ECC-A064-E87C51504FAA"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:B8AFC44F-5BF6-49A7-B333-80B112548B34"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5AC1006F-C104-46C9-9EB8-77A43580FE51"/>
    <pav:lineageUri>urn:domeoserver:annotationset:5EBB77FD-51B8-46AE-8874-51C32A57C8E9</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FBDFC45D-EF70-4091-878E-0FD07632F3E1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-11 23:16:49 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>The patient's CYP2C9 and VKORC1 genotype information, when available, can assist in selection of the starting dose</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>FBDFC45D-EF70-4091-878E-0FD07632F3E1</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FBDFC45D-EF70-4091-878E-0FD07632F3E1"/>
    <ao:suffix>. Table 5 describes the range of stable maintenance doses observed in multiple patients having different combinations of CYP2C9 and VKORC1 gene variants. Consider these ranges in choosing the initial dose.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BD5A9C23-7261-4124-8C7A-EE9A70F2B47B">
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A1E72881-9857-48B6-BADF-BFCA7D7E7D11">
    <sio:SIO_000111>42229-5 SPL UNCLASSIFIED SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42229-5 SPL UNCLASSIFIED SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:62C5FDED-B1F7-439B-A88C-C50E2B735FBB">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34071-1) WARNINGS</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>(34071-1) WARNINGS</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:42F4C828-0CF6-4F9B-A5C4-0138E8F9AE2F">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34090-1 CLINICAL PHARMACOLOGY SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34090-1 CLINICAL PHARMACOLOGY SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:765924DC-1F41-4886-95B6-2751263F960E">
    <ao:body rdf:resource="urn:linkedspls:uuid:9ABDBB8F-5A5E-44F8-91C2-5F5FC91A7445"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:066884BC-8DA8-42FA-A803-39C4B6330130</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:C7ABDA17-708E-4752-94A9-A7F8F6866040"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:6A134217-69F9-48C3-A4D9-F3B264FFB552"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-05-30 21:54:51 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:DA0BBCD9-AE30-4547-8826-864EB07FD2F5"/>
    <pav:lineageUri>urn:domeoserver:annotationset:23D022D1-EA80-4401-9CAD-1D389D3CBFA6</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:213F21FB-4220-480F-B77B-34166DE42650"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">23</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AB8114CE-610C-4124-9C3E-2295E1567A55</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:107C00DB-57D0-4D17-9EA4-E6FF35655A39"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:78C3F62C-A766-4362-AAB1-91C4818C1AC8"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:F75B92E6-2073-46BC-AEB9-CA1CB371AB24"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9F6D48E0-E480-41A0-8123-BD1B114C23B0"/>
    <pav:lastSavedOn>2014-05-30 21:59:36 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B5AA1B9C-4219-4D7B-A32D-27A3B23EB958"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:13CAA60E-F118-4C0A-AF10-407EC050BE3C">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-level-low</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>biomarker-level-low</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:18205CDD-8772-4061-8721-0A5E34C33200">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4057</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>G6PD</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:13CDA93B-1A06-435B-8673-F230C0DAF54E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>When administered in combination with other agents, or as a single-agent, a reduction in the starting dose by at least one level of CAMPTOSAR should be considered for patients known to be homozygous for the UGT1A1*28 allele [see Dosage and Administration (2.1 and 2.2) and Warnings and Precautions (5.3)]. However, the precise dose reduction in this patient population is not known, and subsequent dose modifications should be considered based on individual patient tolerance to treatment (see Tables 1–4).</ao:exact>
    <pav:createdOn>2014-08-11 10:38:32 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:13CDA93B-1A06-435B-8673-F230C0DAF54E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IRINOTECAN-e518dfc6-7e93-4fee-a66c-51e1ab71c056.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F7215BEA-75B5-430F-A678-EE60062C02FF">
    <rdfs:label>Irinotecan</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00762</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:20F57989-7BB0-43C0-A137-3F40F71DF17A">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5D8BED39-A132-4BB4-A712-DA7693E3199D">
    <ao:body rdf:resource="urn:linkedspls:uuid:2902BD91-BA54-41F1-AD03-1637EE6A183C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:51F340EB-0793-4DE5-A16D-3D879F5D710B"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:78CD071A-8A83-43E3-BFA8-20599AB468CD"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:60F900F0-AEC5-4C65-9922-275EC5D3B65A"/>
    <pav:lastSavedOn>2014-06-02 13:36:04 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-05-30 20:37:28 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:38BDCE31-FFC7-4D65-B0A0-A8173E83A9E7"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:23D022D1-EA80-4401-9CAD-1D389D3CBFA6</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:91B1C664-2F5D-4DA9-9910-31F8CC497DCA"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">30</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:8884A95A-78BA-4744-9667-E8D7174B552F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B4BC87FA-A814-4D8D-9825-F2076A3E2DD6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4CB55AB2-FFA0-484C-BEDF-42E3A8579A59"/>
    <pav:previousVersion>urn:domeoserver:annotationset:F2EF7816-4A75-43FA-94A8-F2682304F70F</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AB8114CE-610C-4124-9C3E-2295E1567A55</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:2A09FE24-D61B-4A4E-9C17-D82FE20B4AF1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4574D005-AAB3-4DDC-AD6D-94FCA9CB49A8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AF1E00CB-65B3-4FA7-8983-A7F0F462E481">
    <ao:body rdf:resource="urn:linkedspls:uuid:C8B76DF6-F630-4603-9A11-340E0CE5AADC"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1A9267A8-5284-4711-BCFA-4B1FC22D6C5C</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:9D7DA31C-DADD-4663-AD3E-246C6FFB0855"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E1F634FA-0B50-4678-B039-7AC9BD9E20B3"/>
    <pav:previousVersion>urn:domeoserver:annotationset:70E66F87-5CA0-4DB4-8229-E65C782A31CF</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:758344AB-8D2C-4F3C-9A8E-EA2B0EE3E323"/>
    <pav:lastSavedOn>2014-06-01 20:47:01 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:397832A6-9A69-42AA-8A17-D177DA89F0FE"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:4998874B-1A5E-4B67-B6C7-648AD7C1D990"/>
    <pav:lineageUri>urn:domeoserver:annotationset:FAE19553-957D-45CE-8E2F-EDE4651240ED</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:600CF376-91F6-49B3-AACF-A44E7BA0F614"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:B899C256-E92F-4A91-8422-32334B954484"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:633B5B68-6257-4DC5-BE7F-E205BAC802C2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-06-01 20:31:56 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0F5B0035-B040-4413-89A7-0D6C98096DDF">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E86BAABD-588E-4E10-9EED-3177D2DF01EB">
    <ao:body rdf:resource="urn:linkedspls:uuid:434D95B3-1543-4A9E-AFA3-65A24E8E401D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FBBB479A-855A-4B80-A8C8-ADF728E459D4"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:B2E9D831-40A3-42D2-B855-D69568385012"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:F8158949-9BC4-4394-AC59-0A2ED6B83ADB"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:C39646A7-8258-45CA-82AB-826462109036"/>
    <pav:createdOn>2014-06-01 20:06:05 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:DA46D445-577C-4454-BEAA-8EE2C7D79FCE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6FDFE80C-09DD-4F16-B16F-3F70B8370AAC"/>
    <pav:previousVersion>urn:domeoserver:annotationset:CEFA1DA5-D555-4EEA-A6A1-6AC677C0C52B</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:FAE19553-957D-45CE-8E2F-EDE4651240ED</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1A9267A8-5284-4711-BCFA-4B1FC22D6C5C</domeo:belongsToSet>
    <pav:lastSavedOn>2014-06-01 20:08:37 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:E444892B-98F2-4385-99DE-D83E88BAEF9B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:439A84D7-5D2F-4067-8AFC-0D0F43057F20">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(43685-7) WARNINGS AND PRECAUTIONS</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>(43685-7) WARNINGS AND PRECAUTIONS</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F5D43909-3F68-4792-8D1B-0A1E7607829C">
    <rdfs:label>Letrozole</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:11758337-A0BC-4C04-BDD6-B5573FC44DFB">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ESR1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:61A9C8B3-9E23-454A-8577-8ED786B424DA">
    <ao:exact>The variant alleles CYP2C9*2 and CYP2C9*3 result in decreased in vitro CYP2C9 enzymatic 7-hydroxylation of S-warfarin. The frequencies of these alleles in Caucasians are approximately 11% and 7% for CYP2C9*2 and CYP2C9*3, respectively1. Patients with one or more of these variant CYP2C9 alleles have decreased S-warfarin clearance</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> (Table 1).2</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:61A9C8B3-9E23-454A-8577-8ED786B424DA"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <pav:createdOn>2014-06-11 22:54:05 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>The S-enantiomer of warfarin is mainly metabolized to 7-hydroxywarfarin by CYP2C9, a polymorphic enzyme. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D1EF8E78-149A-454F-80FB-6CDADFF863C5">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> However, some women are ultra-rapid metabolizers of codeine. These women achieve higher-than-expected serum levels of codeine’s active metabolite, morphine, leading to higher-than-expected levels of morphine in breast milk and potentially dangerously hi</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:prefix>Codeine is secreted into human milk. </ao:prefix>
    <pav:createdOn>2014-05-30 22:04:02 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D1EF8E78-149A-454F-80FB-6CDADFF863C5"/>
    <ao:exact>In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent.</ao:exact>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4D5479E5-8240-48AE-8BF8-49F3E6BE2419">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>F508</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4E0C4F09-6B85-4E68-9712-4B0E61E32B7E">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:42DD5054-7518-4436-8BF5-3C9712B8C6B2">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:42DD5054-7518-4436-8BF5-3C9712B8C6B2"/>
    <ao:exact>In an observational study, the risk of achieving INR &gt;3 during the first 3 weeks of warfarin therapy was determined in 219 Swedish patients retrospectively grouped by CYP2C9 genotype. The relative risk of over anticoagulation as measured by INR &gt;3 during the first 2 weeks of therapy was approximately doubled for those patients classified as *2 or *3 compared to patients who were homozygous for the *1 allele</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-06-11 22:58:54 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>.4</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E5417C1F-0AC1-440C-9AF7-3EA4CBBE6A0D">
    <ao:body rdf:resource="urn:linkedspls:uuid:A848E299-3D2C-4584-96EC-6D1F0EDC0E2D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:B957FC56-3803-4393-BE2E-7CA67A1D53EA</pav:lineageUri>
    <pav:createdOn>2014-08-11 09:19:07 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:F5C52947-B8B8-4CFB-A586-A3CC341EB1B1"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:E799D960-1B67-4513-8772-168D22143816"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:13CAA60E-F118-4C0A-AF10-407EC050BE3C"/>
    <pav:lastSavedOn>2014-08-11 09:19:30 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8917A0C6-4EB0-4018-922E-B216A9A1DB0C</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:65E214AD-E447-487C-805C-46E6304AA30D"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:B1F3EB09-6D39-4C92-8835-6F2C1B38EA5A"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:000CBFF7-A536-481F-B29E-C34569C8BFFA"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4C24D90F-5EB2-4628-8C61-BE8894CD184E">
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB08820</dailymed:pharmgxDrug>
    <rdfs:label>Ivacaftor</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B98A97A3-27F6-4BE3-8E93-CC3FA17B06E2">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>cystic fibrosis</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:64DDD100-240D-4C42-92AF-E6FBF90BA0CE">
    <ao:exact>Tamoxifen citrate tablets are indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation.\n\nThe estrogen- and progesterone-receptor values may help to predict whether adjuvant tamoxifen citrate tablet therapy is likely to be beneficial.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:64DDD100-240D-4C42-92AF-E6FBF90BA0CE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Tamoxifen citrate tablets are indicated for the treatment of node-positive breast cancer in postmenopausal women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In some tamoxifen adjuvant studies, most of the benefit to date has been in the subgroup with four or more positive axillary nodes. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-06-01 20:37:53 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A1FCB28F-22A4-4A1E-8688-A0EFE963260B">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00458</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Imipramine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B2F1336A-CE5A-440D-B811-8A04ECAD66FB">
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <rdfs:label>Recommended</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:421F42CA-FAD6-48F9-B6B6-5187F7F5ADA6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>UGT1A1</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12530</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E4484BF6-2A71-453E-8379-1C7D4B47A7A7">
    <pav:lineageUri>urn:domeoserver:annotation:E07750FC-5A9E-4526-AD4C-2115C28CBFEB</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:32B08FD0-4B17-4E4B-90ED-664575C528E9"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:D7EBE39C-C926-4CF7-94D0-5D5134BD7E4F"/>
    <pav:createdOn>2014-06-01 20:11:28 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1A9267A8-5284-4711-BCFA-4B1FC22D6C5C</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:D30F34EA-099B-466C-96D3-277E2BC3D633"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:00655BEA-9C8D-4E9D-9918-EA549CDA1000"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:338C70DE-6F55-45D8-B4AE-13D96803529F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EDF04A7B-AD1A-4009-BC06-B0871EB93435"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CC513CF2-EB46-4314-B584-C5E6E349887C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:BA0A2CCB-A66A-4E3E-B2CD-C0585FD48A08"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C97D3E3E-0F53-4385-830E-230D80B7C71B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:01B98F2F-E13E-4140-81AB-058B2903744E"/>
    <pav:lastSavedOn>2014-06-01 20:11:37 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:9C64FD15-405B-4B8A-941B-8CA88780E202"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:03CEFBFC-E1A2-448D-A350-9AC0CDCC4C9C">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Codeine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5202BAC1-A366-40F2-B6A6-29F1283FB203">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>*28</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1C93816A-0721-43F3-8EF6-40E27BDC3CF6">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-08-11 09:09:18 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting Elitek therapy (4, 5.2).</ao:exact>
    <ao:prefix>. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/RASBURICASE-0ae10bc4-6b65-402f-9db5-2d7753054922.html</ao:hasSource>
    <domeo:uuid>1C93816A-0721-43F3-8EF6-40E27BDC3CF6</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1C93816A-0721-43F3-8EF6-40E27BDC3CF6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A71D4530-E5CB-4468-AE44-2D8198AEFA3E">
    <ao:prefix>) in combination with bolus 5-FU/LV, the incidence of grade 4 neutropenia in patients homozygous for the UGT1A1*28 allele was 18.2%, and in patients heterozygous for this allele the incidence was 11.1%.  Grade 4 neutropenia was observed in 6.8% of patients homozygous for the wild-type allele. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>When administered in combination with other agents or as a single-agent, a reduction in the starting dose by at least one level of CAMPTOSAR should be considered for patients known to be homozygous for the UGT1A1*28 allele. However, the precise dose reduction in this patient population is not known and subsequent dose modifications should be considered based on individual patient tolerance to treatment [see Dosage and Administration (2)].</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A71D4530-E5CB-4468-AE44-2D8198AEFA3E"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-08-11 10:44:07 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IRINOTECAN-e518dfc6-7e93-4fee-a66c-51e1ab71c056.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1C454AE0-AF11-4379-AA8E-A38C7734DCFB">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">14</pav:versionNumber>
    <pav:createdOn>2014-06-01 20:06:56 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1A9267A8-5284-4711-BCFA-4B1FC22D6C5C</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:B157947C-E68B-493C-9CCA-A69FFAAE539A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EFC96F15-EB0C-4B97-9204-E6395785E4B1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CD5198BF-D7AD-4002-8129-AAD38CE56DBE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9F39B172-380F-45DA-9FEB-5F209CDD16E0"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-06-01 20:45:36 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:FAE19553-957D-45CE-8E2F-EDE4651240ED</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:1537B5B1-327F-4D78-B32A-7D38E4760E41"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7CFC1D14-598A-4CC4-BD02-4E9E347AE3EB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E64CBD14-4A0C-4364-BBE8-4E573E3E7B3A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F7D23FAD-3D78-4F2B-B321-7C84D21CD2AB"/>
    <pav:previousVersion>urn:domeoserver:annotationset:6217F9CF-14EB-4960-A33B-E2B62B85AF88</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BB70B9F9-F9D1-4B52-9E5E-765B3B969ED3">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:21B5271B-CDE6-4B0C-AA09-3A37D5F78FE2">
    <poc:MedicalCondition>postmenopausal, early breast cancer</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:60BE726A-6CBA-4702-8177-1F8E90B3002B">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:prefix>Advise patients that some people have a genetic variation that results in codeine changing into morphine more rapidly and completely than other people. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Most people are unaware of whether they are an ultra-rapid codeine metabolizer or not. These higher-than-normal levels of morphine in the blood may lead to life-threatening or fatal respiratory depression or signs of overdose such as extreme sleepiness, confusion, or shallow breathing. Children with this genetic variation who were prescribed codeine after tonsillectomy and/or adenoidectomy for obstructive sleep apnea may be at greatest risk based on reports of several deaths in this population due to respiratory depression. Codeine is contraindicated in children who undergo tonsillectomy and/or adenoidectomy. Advise caregivers of children receiving codeine for other reasons to monitor for signs of respiratory depression.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:60BE726A-6CBA-4702-8177-1F8E90B3002B"/>
    <pav:createdOn>2014-05-30 21:58:39 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:42BAA89A-99B1-458E-8ED2-25A3BE50DAD4">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:23D232D6-9A25-47F3-8DA1-D7CE366FB4BF">
    <ao:item rdf:resource="urn:domeoclient:uuid:5D31B77B-2A58-4049-BE94-312637AC6B8B"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304628d4c0014629cdc71a0000"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:68E1E368-791B-4268-9B73-7FD092675258</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IRINOTECAN-e518dfc6-7e93-4fee-a66c-51e1ab71c056.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:22151E28-B4F0-4EAD-AEA1-AC7B24276C0D"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:156006C3-2DEB-4094-8ADA-E3E97A326E9D"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdOn>2014-08-11 10:29:00 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:F93A42FB-85AB-454A-876A-5F61EDEB190B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:932B560B-6084-4C46-9D8A-3F1C39C7C095"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:05D6F5CE-CCB5-41CA-91C7-5CED687A51CE"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:E9F7EB74-4FBD-43C4-BF4C-75366355E766"/>
    <pav:lineageUri>urn:domeoserver:annotationset:DA691DE3-F7C0-4EE6-A746-38D540E1AA19</pav:lineageUri>
    <pav:lastSavedOn>2014-08-11 11:34:11 -0400</pav:lastSavedOn>
    <permissions:permissions rdf:nodeID="N1f86d1fdb27a4fc289037390a651da41"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:314BCEF4-0FF7-4FF6-98A4-1870933D139B">
    <domeo:belongsToSet>urn:domeoserver:annotationset:AB8114CE-610C-4124-9C3E-2295E1567A55</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:F0A7C2E6-17FB-4164-841D-D3FCD1ABD689</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:3AC25B98-BE61-42EA-B711-7AF4AA730C0B"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:37CB8974-A3E5-4033-B63B-2E5149F4770A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:439A84D7-5D2F-4067-8AFC-0D0F43057F20"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1B5D6A9A-E3B1-40BB-A570-F2A637C887EE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:448BDC25-26B6-4F32-B3A5-CB0A9AB8BCEC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BAF3BB27-DF50-4BA9-B74F-2C86F2DB2297"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0CCFAF6C-8269-4F99-B1E1-9F12C9D356CD"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:createdOn>2014-05-30 20:26:08 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-05-30 20:28:00 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:AEEF2B8A-832D-4932-B3BD-F237AB38B922"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:41B4380D-E9E8-448C-815D-2175DFF7E34D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:1AD7E9BF-E7B7-4AD9-93C2-348373810B26"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6916bd533ab64524831cea121fe6811b">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2D3C53BE-F0C3-4C6A-9B15-0425B99E8CBA">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>G6PD</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4057</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BFEB65CB-2814-4AD8-A783-8BE84FC3019F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB08820</dailymed:pharmgxDrug>
    <rdfs:label>Ivacaftor</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7A8CA5B7-DBD1-4651-AE34-3CAE5A10D2D0">
    <pav:createdOn>2014-05-30 20:55:37 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7A8CA5B7-DBD1-4651-AE34-3CAE5A10D2D0"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Respiratory depression and death have occurred in children who received codeine in the post-operative period following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6 [CYP2D6] or high morphine concentrations). </ao:prefix>
    <ao:exact>Deaths have also occurred in nursing infants who were exposed to high levels of morphine in breast milk because their mothers were ultra-rapid metabolizers of codeine [see Use in Specific Populations (8.4)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A2882C4E-428B-43C1-9CF6-DFFCAF05D1DB">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7E3F7435-2585-4B8A-884B-21F0A2AD3755">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7D879C25-F119-46DE-BB77-1D9B1C62A661">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:422FF05E-3360-43EB-A942-F9397CA2BDA6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5D0AE06F-D83C-4974-A73E-AB2A9BD6E21E">
    <poc:MedicalCondition>respiratory depression, death, adenoidectomy, tonsillectomy, post-operative</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:701FFC73-E68A-488A-95DE-F31620897352">
    <ao:body rdf:resource="urn:linkedspls:uuid:69D56571-D51E-4E60-B89E-8AC18205728D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8BA4D7E3-AA90-4C5B-9E4B-51B8981B3592"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0809D41C-DDCF-4224-8C9A-99FAC41A6E5D"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:6EA21C8B-CAA9-44A6-A96E-785D93994656"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:E49A8CE3-66CF-4BE6-A6FC-6D706B0D31F5</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:A7EFD62D-B87A-45FB-A018-C5588824815C"/>
    <pav:createdOn>2014-08-11 09:59:31 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:13801219-5A2A-4077-946C-7C8800233016"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:7F751CAA-3765-4CEA-B3AB-F50FCA926D77</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:15EDD256-2022-4CB1-8006-E9050FAC7991"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2BF08D4D-676B-4B26-B46B-1E72556B734F"/>
    <pav:lastSavedOn>2014-08-11 10:01:51 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:F5CA6799-DCEC-466B-9EB1-D53E0F3A71BE"/>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B2F978C2-CA3C-4875-AA6D-C42D9A4FFE85">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(43685-7) WARNINGS AND PRECAUTIONS</poc:productLabelSection>
    <sio:SIO_000111>(43685-7) WARNINGS AND PRECAUTIONS</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7C0DCB1D-4EA0-4D69-A1AD-66C615677CE4">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>gene-SNP-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-SNP-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:227A5D0C-7BA3-439E-BEE7-3B9D8C97D212">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>total mastectomy and axillary dissection, segmental resection, breast radiation, breast cancer</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:96DD0695-5250-4676-A6D2-ADA9A5665EDC">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(68498-5) PATIENT MEDICATION INFORMATION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(68498-5) PATIENT MEDICATION INFORMATION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:58A545C3-0C67-41DA-9D8A-8C3A046798A4">
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-06-11 23:12:34 -0400</pav:createdOn>
    <ao:exact>The dose of warfarin sodium tablets must be individualized by monitoring the PT/INR. Not all factors causing warfarin dose variability are known. The maintenance dose needed to achieve a target PT/INR is influenced by:\n\n●\n         Clinical factors including age, race, body weight, sex, concomitant medications, and comorbidities and \n\n●\n         Genetic factors (CYP2C9 and VKORC1 genotypes). </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:prefix>An INR of greater than 4.0 appears to provide no additional therapeutic benefit in most patients and is associated with a higher risk of bleeding. Initial Dosage </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:58A545C3-0C67-41DA-9D8A-8C3A046798A4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F2EE233D-7466-4053-ABF4-1FBEF5907FC1">
    <ao:body rdf:resource="urn:linkedspls:uuid:39FEA412-819C-4C0D-86FA-8CC5A530161E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A839E5B1-73AB-48CF-9F1A-6A743BEE8446"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7256C964-CB91-4D53-857B-541FF202FEFE"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:A135C925-B8C7-4840-A1E5-2B3F5D238CA8"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:BD3CA01F-BBC4-4CBC-9AEE-72C34636957E"/>
    <pav:lastSavedOn>2014-06-01 20:45:36 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:D4A21C62-3976-4345-96EE-2B53E77FA491"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1A9267A8-5284-4711-BCFA-4B1FC22D6C5C</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:F1E77C2F-A625-4BF7-93F0-9ECDCBA34773"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">14</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:33CDA666-671E-4706-87B3-05E0EB5FC02E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-06-01 20:08:33 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:6217F9CF-14EB-4960-A33B-E2B62B85AF88</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:A4889A7B-C631-4691-8F08-9B1598CB39F3"/>
    <pav:lineageUri>urn:domeoserver:annotationset:FAE19553-957D-45CE-8E2F-EDE4651240ED</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C5743B39-3807-4708-AAD0-38ED73FF71F3">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AMITRIPTYLINE-e454fe56-0896-4d40-862c-95ef0fc0bc82.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7% to 10% of Caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).\n\n</ao:exact>
    <pav:createdOn>2014-08-11 08:27:35 -0400</pav:createdOn>
    <ao:suffix>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C5743B39-3807-4708-AAD0-38ED73FF71F3"/>
    <domeo:uuid>C5743B39-3807-4708-AAD0-38ED73FF71F3</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:658E09B7-8541-44FD-BE5F-3166BE415A0E">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:397832A6-9A69-42AA-8A17-D177DA89F0FE">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F5C52947-B8B8-4CFB-A586-A3CC341EB1B1">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Recommend</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0C7D8BCC-11E3-42F3-8CFC-F3702CB17CD0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In the Hubay study, patients with a positive (more than 3 fmol) estrogen receptor were more likely to benefit. In the NSABP B-09 study in women age 50 to 59 years, only women with both estrogen- and progesterone-receptor levels 10 fmol or greater clearly benefited, while there was a nonstatistically significant trend toward adverse effect in women with both estrogen- and progesterone-receptor levels less than 10 fmol. In women aged 60 to 70 years, there was a trend toward a beneficial effect of tamoxifen without any clear relationship to estrogen- or progesterone-receptor status.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-06-01 20:46:09 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0C7D8BCC-11E3-42F3-8CFC-F3702CB17CD0"/>
    <domeo:uuid>0C7D8BCC-11E3-42F3-8CFC-F3702CB17CD0</domeo:uuid>
    <ao:prefix>o adjuvant cytotoxic chemotherapy. In the Hubay study, tamoxifen was added to "low-dose" CMF (cyclophosphamide, methotrexate and fluorouracil). In the NSABP B-09 study, tamoxifen was added to melphalan [L-phenylalanine mustard (P)] and fluorouracil (F). </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:253B53A7-DCE5-4C46-A701-839D86872338">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2014-08-11 08:28:52 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:D5E03124-9770-4F4A-B0F6-8BC0B95821D0"/>
    <pav:createdOn>2014-08-11 08:25:20 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <permissions:permissions rdf:nodeID="N7fa45c1e6381458eafa1dac3a353bceb"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304628d4c0014629cdc71a0000"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AMITRIPTYLINE-e454fe56-0896-4d40-862c-95ef0fc0bc82.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:lineageUri>urn:domeoserver:annotationset:33893F78-D18B-4E0C-8122-B8E844EDAD2A</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4B3630AE-2F0E-405C-AB3A-305B64A525B4">
    <rdfs:label>Tamoxifen</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:01B98F2F-E13E-4140-81AB-058B2903744E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ESR1</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A2F50048-A931-4DEF-A83C-25F87CE8F002">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdfs:label>ER_receptor</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1949E7D1-321A-4393-95AF-90925788C494">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdfs:label>Influences Drug Response</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E2E802A3-D5AF-4770-B15B-809809AD101B">
    <pav:lastSavedOn>2014-08-11 09:44:19 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:5ECCC512-6425-4B02-A6BC-789EDFB17A9C"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:7FA245FC-343C-46A5-A8B0-66AA73754F3C"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8CBB02C2-085F-4ADA-9BD7-FA840705DD6D</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:ABC3D8F9-AAFA-47F2-8209-24344F8D1099"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:D1DCE20B-C7F3-462D-A0A2-8BD9EB0F1A58"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E835F65E-751D-40B2-B2FC-B4ED11EAD9BF"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:5E6952F5-F167-424A-A398-06547BB8D349"/>
    <pav:createdOn>2014-08-11 09:37:50 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:67327FCB-D35F-4028-87F7-FCAA70114D05"/>
    <pav:lineageUri>urn:domeoserver:annotation:D5845B36-80BA-4185-8F9A-4153BC544CE8</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:E582725A-F7B5-4491-97DA-2FC0690054E9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:143816BE-4598-4182-B7E2-841B4BD1D3C0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D59588BF-E727-4435-AF5A-27902B64F28F">
    <rdfs:label>Do not start</rdfs:label>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-start</poc:DrugSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is not associated with any drug selection recommendation.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0177F263-51E4-4295-AD8B-8E97BBE69DF4">
    <pav:previousVersion>urn:domeoserver:annotationset:F7C58D05-6A18-4BC2-A3FF-57CF5791EFF0</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:CC45D2E0-DCCB-4F21-9A42-877802AE1E4D"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:4A877B68-D6A4-4B4E-A6DC-6D9FFC98F744"/>
    <pav:lineageUri>urn:domeoserver:annotationset:5EBB77FD-51B8-46AE-8874-51C32A57C8E9</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:B9E417AB-68D7-405F-8085-8A3676799FB2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:50AC0747-86DA-40B2-8A81-E912BEA6B2E8"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdOn>2014-08-11 09:11:46 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:18205CDD-8772-4061-8721-0A5E34C33200"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9B6AA731-4D11-46AE-AEEB-A7355AA00D5F"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8917A0C6-4EB0-4018-922E-B216A9A1DB0C</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:A96B7152-56EB-40F5-8549-B9B13CC0F722"/>
    <pav:lastSavedOn>2014-08-11 09:12:14 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:244AF803-63BF-4AD6-B0EB-82FB70703A6F">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34090-1 CLINICAL PHARMACOLOGY SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34090-1 CLINICAL PHARMACOLOGY SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CFCABD5D-4BFF-4849-B3E2-E980FC0FA54A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C8531EAF-6F1D-474A-B122-9915A99F4714">
    <ao:prefix>Individuals who are homozygous for the UGT1A1*28 allele (UGT1A1 7/7 genotype) are at increased risk for neutropenia following initiation of CAMPTOSAR treatment. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C8531EAF-6F1D-474A-B122-9915A99F4714"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In a study of 66 patients who received single-agent CAMPTOSAR (350 mg/m2 once-every-3-weeks), the incidence of grade 4 neutropenia in patients homozygous for the UGT1A1*28 allele was 50%, and in patients heterozygous for this allele (UGT1A1 6/7 genotype) the incidence was 12.5%. No grade 4 neutropenia was observed in patients homozygous for the wild-type allele (UGT1A1 6/6 genotype).</ao:exact>
    <pav:createdOn>2014-08-11 10:42:07 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IRINOTECAN-e518dfc6-7e93-4fee-a66c-51e1ab71c056.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FE255348-0CA7-46D9-8A07-AEE9528AC9E7">
    <rdfs:label>biomarker-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F431C560-0771-4D18-B86C-CE95DA1A0EA9">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(43685-7) WARNINGS AND PRECAUTIONS</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>(43685-7) WARNINGS AND PRECAUTIONS</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D470A236-07D2-4FEB-B41C-8C309D957A6A">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Clomipramine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01242</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3700ACB4-2452-471C-AEFC-F6FDA9B069DA">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42229-5 SPL UNCLASSIFIED SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>42229-5 SPL UNCLASSIFIED SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BB195C09-0F47-4105-9F73-99BBDA5078FD">
    <rdfs:label>G6PD</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4057</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1442B962-ACFC-4270-880D-17CA73493CAA">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34068-7 DOSAGE AND ADMINISTRATION SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34068-7 DOSAGE AND ADMINISTRATION SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:28BFC3D2-4FCE-45FB-AAED-50961B6B3546">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:670BDB34-0CF5-4C6B-A1EA-763CF9446F45">
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FBBB479A-855A-4B80-A8C8-ADF728E459D4">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FAA5D452-A6B4-4DA0-AF68-2DFB1DB9CF37">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:3BC8D1CC-8AF3-4D34-956F-9B816B7D1679"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:lastSavedOn>2014-08-11 09:31:01 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:3745D0DE-8525-456F-A7A7-27B9A58FB224"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8CBB02C2-085F-4ADA-9BD7-FA840705DD6D</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:2FA2182A-FCE8-44BD-B87E-E4EC718D2246"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:700515BA-CB28-4B9B-A2DF-EAB6732AF85D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:14C29279-2575-4E13-9D89-1CA9E8B51410"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CFCAFF12-40D6-475A-8EB8-DEBB506AFD60"/>
    <pav:createdOn>2014-08-11 09:27:30 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:CFCABD5D-4BFF-4849-B3E2-E980FC0FA54A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:92D11857-AC3C-4F10-830F-4DC679E72BB6</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:69FCED5B-802D-492B-881C-3F9235BAA2F5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B0E30E75-A51D-4AE1-9F4D-8ABDDB1BE17D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:29451F08-7CF7-4042-9F81-C3DF0DB3B24D"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C7ABDA17-708E-4752-94A9-A7F8F6866040">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ultra-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:858873E0-5564-4039-9659-DFE0191571E0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8CBB02C2-085F-4ADA-9BD7-FA840705DD6D</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:AE643F72-0639-490A-AC1E-ED2480A9FBFB"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:3A1C64BF-E219-4A28-8082-120EA42928B1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4D5479E5-8240-48AE-8BF8-49F3E6BE2419"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:3B7230BE-C691-4047-80E8-10D1C90920CB"/>
    <pav:lineageUri>urn:domeoserver:annotation:F3FA492C-2BCD-4E76-911E-2CDF3F9D9D3B</pav:lineageUri>
    <pav:createdOn>2014-08-11 09:44:18 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:55D8D3AE-CB65-4FF2-98EE-324FBE75B67C"/>
    <pav:lastSavedOn>2014-08-11 09:44:19 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:D2BA7E62-55F9-4F03-AE45-4A038C6303D9"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:4A346667-A2AD-4844-A4D0-1DB34D3C364F"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:D36812F9-ED9C-48FF-B48A-E7431CB631BD"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:21AF41BB-0A1D-4D6E-9BEB-7C6537782D4D">
    <pav:lineageUri>urn:domeoserver:annotationset:FAE19553-957D-45CE-8E2F-EDE4651240ED</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1A9267A8-5284-4711-BCFA-4B1FC22D6C5C</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:18BBF23F-3C36-4AB2-9878-873E7698F865"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8F4E203D-604E-43E0-B731-E7F3F4924417"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2ABD4105-D202-43EA-B659-FF4F8F9CEB16"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A13C2109-BF6C-421F-9281-7F7FF9A5D781"/>
    <pav:lastSavedOn>2014-06-01 20:46:49 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-06-01 20:27:10 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:C2ABDA4C-3DC7-4244-8EBE-DA6794F48AB3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:99B48402-7F9C-491D-AA16-4F6070F05428"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:E59CEE6C-28A3-49F4-BFD4-B063AAB97FAD"/>
    <pav:previousVersion>urn:domeoserver:annotationset:9FE3DB68-2973-46A7-A5BC-A0B694ADE712</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:313EEDAB-77F3-4A80-A1A0-4BC7AB232A13"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5ECCC512-6425-4B02-A6BC-789EDFB17A9C">
    <rdfs:label>Ivacaftor</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB08820</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:person:uuid:080e14304628d4c0014629cdc71a0000">
    <foafx:name>mikediduch</foafx:name>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <foafx:title></foafx:title>
    <foafx:email>mdiduch23@gmail.com</foafx:email>
    <foafx:firstname>Michael </foafx:firstname>
    <foafx:picture>http://www.hcklab.org/images/me/paolo%20ciccarese-boston.jpg</foafx:picture>
    <foafx:middlename></foafx:middlename>
    <rdfs:label>mikediduch</rdfs:label>
    <foafx:lastname>Diduch </foafx:lastname>
    <foafx:homepage></foafx:homepage>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BBC10EFA-53E6-4C34-9B2E-34B215CFD530">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>no gene symbol provide but is required. is patient medication info the same as patient counseling? </poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:98E4E343-CF29-4C67-966C-BDB013B7AF46">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A2DFC83C-6A39-4071-900F-8235B89FCAD2">
    <rdfs:label>CFTR</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:1884</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5D31B77B-2A58-4049-BE94-312637AC6B8B">
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:421F42CA-FAD6-48F9-B6B6-5187F7F5ADA6"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:2572BDB2-3424-437E-A3AF-AFB6B2EF494B"/>
    <pav:lastSavedOn>2014-08-11 10:31:04 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:DE455B1F-320B-4EC5-A467-62E687447CCF"/>
    <pav:createdOn>2014-08-11 10:30:46 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:83EA85D0-5404-4AFF-99EF-671BD16F1942"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:23D232D6-9A25-47F3-8DA1-D7CE366FB4BF</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:83DDBC6F-DE82-4789-B72A-999CC8B94B10</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:2D4017E4-9310-4CC2-B770-976481F72DDB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4573ADD2-C87F-40CE-AB64-6B4B2DC21EE2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:39014587-DC25-4E0A-88C6-1533483C98E7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F851EC8F-462C-4B22-BD30-4E182DF6A476"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3700ACB4-2452-471C-AEFC-F6FDA9B069DA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8ED2287A-DCC6-4329-90B4-09269229842A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ER_receptor</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:454625FE-AA6E-403D-BDEF-45E4AAF0F9FE">
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:createdOn>2014-05-30 21:31:44 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:3F877F22-06C0-46C2-81DA-9539EF470EA2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:28BFC3D2-4FCE-45FB-AAED-50961B6B3546"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">26</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:E78C1263-515D-48F8-92BF-994FF6A4961D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8F633A1E-F893-4514-B632-12D8BAB8F1B2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:92B5AF9E-5429-4D66-9291-831F8D2829CB"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:492B7290-FA1D-4695-971A-D05DF24768C3</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:23D022D1-EA80-4401-9CAD-1D389D3CBFA6</pav:lineageUri>
    <pav:lastSavedOn>2014-05-30 22:03:44 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:8BDD7B0F-3154-4442-959F-025AEC13F806"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0EAFF42F-A32F-40BB-8BE2-3F3CA61DA578"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FC3C56C7-F768-4370-B469-75408C898599"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E7DD7830-B387-493A-A27D-3EE25F45CCC2"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:110C086B-6C5F-467B-8F39-9E447CF281CA"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AB8114CE-610C-4124-9C3E-2295E1567A55</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E63ED68A-406B-4C87-A640-801F945CD796">
    <ncit:Alleles>*2,*3,*1</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3BC8D1CC-8AF3-4D34-956F-9B816B7D1679">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use. (1) </ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IVACAFTOR-0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25.html</ao:hasSource>
    <domeo:uuid>3BC8D1CC-8AF3-4D34-956F-9B816B7D1679</domeo:uuid>
    <pav:createdOn>2014-08-11 09:29:19 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3BC8D1CC-8AF3-4D34-956F-9B816B7D1679"/>
    <ao:suffix>Limitations of Use: Not effect</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:96B326D1-79D6-4078-8D78-E4D420F7661F">
    <poc:MedicalCondition>clotting</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:80CD5B75-A3FD-4D1E-A268-8198FEBBF6B0">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>hemolysis</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7B3568DD-1DE6-413F-B09A-6DBA416AADD9">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B0E30E75-A51D-4AE1-9F4D-8ABDDB1BE17D">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7B0DAF9E-E2E6-4143-A5E9-998F48DEDF2E">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AF4D1134-F274-4751-A992-420E45473EB2">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CC45D2E0-DCCB-4F21-9A42-877802AE1E4D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CC45D2E0-DCCB-4F21-9A42-877802AE1E4D"/>
    <pav:createdOn>2014-08-11 09:11:46 -0400</pav:createdOn>
    <domeo:uuid>CC45D2E0-DCCB-4F21-9A42-877802AE1E4D</domeo:uuid>
    <ao:exact> Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting Elitek [see Contraindications (4), Warnings and Precautions (5.2)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Do not administer Elitek to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Immediately and permanently discontinue Elitek in patients developing hemolysis. </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/RASBURICASE-0ae10bc4-6b65-402f-9db5-2d7753054922.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EAA16FB0-6E50-445E-BF34-DA761109B6BE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <rdfs:label>Recommended</rdfs:label>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:697EBEC0-D67B-49F2-8728-B421A0C8254F">
    <ao:body rdf:resource="urn:linkedspls:uuid:75C67174-1C9D-4BFB-BDD8-D1A117FBDE7C"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:2124832A-A4E1-40D2-B6C7-E760197CFD52"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E4B7AEB5-3AC4-4B5D-9402-12D9A17FD11E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4176C587-0C84-43AE-A494-C8F9A9A7236F"/>
    <pav:createdOn>2014-06-11 22:57:11 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-06-11 23:03:21 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:91E09E80-9836-4378-8EB6-A4753C404BED"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:EDACF861-0712-42A8-A67C-62DEBC7398B0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D7A83E36-F4FB-45BB-B52E-6131237A4E04"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:B323F5BD-8FB7-47F3-AC95-A7C6A62E0FBB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B587AC9C-4FC0-4B95-9767-555D98299007"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C8B968AD-078C-46EE-9D51-FC3C8F3A0B1E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9AAE4E63-4740-4D0A-9EA3-A3BB8E2E76BA"/>
    <pav:lineageUri>urn:domeoserver:annotation:8FDE737F-B251-4A67-B8F4-4821812263E3</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:52A266C8-BD6D-4417-AF6A-7213F832C8FC"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E823DCB5-68E6-44D4-90AF-E073AC268320</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:75910971-3EC6-488D-A422-B82608D18CDA">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-05-30 22:03:44 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:23D022D1-EA80-4401-9CAD-1D389D3CBFA6</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:70F1624B-4DDC-4293-845D-479AD773F5C3"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AB8114CE-610C-4124-9C3E-2295E1567A55</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:57FE5F64-C6AF-4C05-94AD-5F22CB4DB0D3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EAA16FB0-6E50-445E-BF34-DA761109B6BE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:34458739-6469-4197-83EC-E6C8EB6BC493"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:8ABCE2FE-42A6-45A3-98E5-6C33D3D4A19C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BBC10EFA-53E6-4C34-9B2E-34B215CFD530"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:6E4A8813-711F-430E-9983-79C3342D4206"/>
    <pav:createdOn>2014-05-30 22:03:19 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:798ECA6D-0410-4929-B302-F7127F7F2D66"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F591859B-62B9-40FA-91C8-7179A91A5161"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">26</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:96DD0695-5250-4676-A6D2-ADA9A5665EDC"/>
    <pav:previousVersion>urn:domeoserver:annotationset:492B7290-FA1D-4695-971A-D05DF24768C3</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:E6E4FD4B-754C-4F8E-9620-BE757F2BBC8A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:992566F3-FFA4-42DC-9DB4-595F92F623C2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E551EA94-1404-489C-BDD5-14D13FDCB84A">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:33CDA666-671E-4706-87B3-05E0EB5FC02E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E80A3C7-0DA2-4C83-8CC0-459B27FF2B77">
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00540</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Nortriptyline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:99C67B9D-A54C-4AE5-9FDD-DE412A8370A9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Amitriptyline</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00321</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3B159BCE-6B30-4AF9-95B2-C0A773F4AE82">
    <ao:body rdf:resource="urn:linkedspls:uuid:6AA59FBE-7293-46F0-BAD8-E6280C2AE5D6"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:6A994F2A-24CA-4057-A3BC-F10575E6BDA3"/>
    <pav:createdOn>2014-06-11 22:48:52 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:59590A65-90C8-4E95-A16E-96DB23D9D119</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:7AFF7907-9685-4787-9538-5C33837A6047"/>
    <pav:previousVersion>urn:domeoserver:annotationset:1F7D5BB1-2314-460E-BDF3-441604623507</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:4412DE53-2BC3-40E0-8DE9-3BAF5FCBB0C5"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:36A273A7-0C6B-4241-9DFB-4A45A45BB439"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:1EBD0F9B-983B-4C76-B987-841AC071F695"/>
    <pav:lastSavedOn>2014-06-11 22:54:16 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:E04994D7-F40E-4B21-BC65-82A17CD1BC3C"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:61A9C8B3-9E23-454A-8577-8ED786B424DA"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E823DCB5-68E6-44D4-90AF-E073AC268320</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:A19ACEB0-9504-44A2-902F-84ABC713DFA8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4B2E1FC3-159A-4698-8135-D2BC9ACCB5D7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9213920D-E92B-45F2-AB7C-A3F916F928B1"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:773B0020-6A5F-455B-AD23-885224987B5C">
    <ao:body rdf:resource="urn:linkedspls:uuid:138DA980-62F5-4DEC-BC05-1CD6931C6B83"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4C24D90F-5EB2-4628-8C61-BE8894CD184E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AF4D1134-F274-4751-A992-420E45473EB2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E22C099B-457C-4C62-B7AF-193DBA3ECBEF"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:78CDF494-5B5B-483B-B925-5C6DD3CE2A2D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:1494987D-ABE7-434B-8339-6728C3E9BC4E"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8CBB02C2-085F-4ADA-9BD7-FA840705DD6D</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-08-11 09:44:19 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:FC2157EC-3251-4065-9413-4ECFCF3F0EDF"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:7E5072D5-F0C5-4084-B8B2-E7F3EC81E688</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:72EEDE82-E0C5-449E-9CF9-550CDAB0D789"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:56D9EE71-12E6-452F-A362-FE03A6850CF6"/>
    <pav:createdOn>2014-08-11 09:35:17 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:948A2D7B-7BBD-49EA-8DEC-776BB3B00B8F">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12530</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>UGT1A1</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D1BA6F9D-59F1-41CB-8B32-2EE0B5E0C8DC">
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F3404877-ED90-4B73-80AC-39D302D28B84">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>breast cancer</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ED5E969D-E897-4E6E-A5BC-5DCBEA735062">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:23663</dailymed:HGNCGeneSymbol>
    <rdfs:label>VKORC1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4176C587-0C84-43AE-A494-C8F9A9A7236F">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:34298BE6-B74D-406D-9384-591173BD0A47">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D7A83E36-F4FB-45BB-B52E-6131237A4E04">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D2BA7E62-55F9-4F03-AE45-4A038C6303D9">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CFTR</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:1884</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E340B5EF-6C23-48E8-B6FC-2BC88A334DDD">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Do not start</rdfs:label>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-start</poc:DrugSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is not associated with any drug selection recommendation.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5FD85CCC-B925-4A8A-8E81-107133289231">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A839E5B1-73AB-48CF-9F1A-6A743BEE8446">
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to clinical trial</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F5CA6799-DCEC-466B-9EB1-D53E0F3A71BE">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#excretion-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Excretion Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in excretion of the drug</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:51803E64-2743-47F4-922F-8182279DDD24">
    <dct:description>A required monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#required</poc:MonitoringRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <rdfs:label>Required</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8ABCE2FE-42A6-45A3-98E5-6C33D3D4A19C">
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <rdfs:label>Prodrug</rdfs:label>
    <dct:description>Referred to Prodrug</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:932B560B-6084-4C46-9D8A-3F1C39C7C095">
    <ao:body rdf:resource="urn:linkedspls:uuid:E83BA42D-B9C5-478C-93C4-8B6245CC41FD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FCA55DDA-2E9A-4E93-ACEA-2A442C05986F"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:C8531EAF-6F1D-474A-B122-9915A99F4714"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:948A2D7B-7BBD-49EA-8DEC-776BB3B00B8F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DD6818B5-BF5E-4BB3-89C3-ACC2249D6D83"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7AAD6350-4A6B-4073-9A84-168BF468DB0A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:60E0B5A8-24C2-497C-88EC-11B3AC94EA74"/>
    <pav:lineageUri>urn:domeoserver:annotation:C92A3026-8EA6-4C9B-A144-ECB56776E37E</pav:lineageUri>
    <pav:lastSavedOn>2014-08-11 10:44:08 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:BB70B9F9-F9D1-4B52-9E5E-765B3B969ED3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5202BAC1-A366-40F2-B6A6-29F1283FB203"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-08-11 10:42:07 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:23D232D6-9A25-47F3-8DA1-D7CE366FB4BF</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:0C71A1DE-B3BE-4E3F-940A-55107C9E2FD1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:236F5979-1FBA-4772-8B92-B6FE2A4EA75C">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>(34078-6) NURSING MOTHERS</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34078-6) NURSING MOTHERS</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0EAFF42F-A32F-40BB-8BE2-3F3CA61DA578">
    <rdfs:label>Codeine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2D4017E4-9310-4CC2-B770-976481F72DDB">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6D031617-4D4C-4D4C-97B2-939AABE44E45">
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:8917A0C6-4EB0-4018-922E-B216A9A1DB0C">
    <domeo:deleted>false</domeo:deleted>
    <pav:lineageUri>urn:domeoserver:annotationset:5EBB77FD-51B8-46AE-8874-51C32A57C8E9</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:E5417C1F-0AC1-440C-9AF7-3EA4CBBE6A0D"/>
    <pav:createdOn>2014-08-11 08:57:12 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:56C4A1D8-6C50-47B7-A739-52ED0271119D"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304628d4c0014629cdc71a0000"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4F172E35-1434-4C38-B1C1-518434AE5B59"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9BE604B7-EBBE-4B0E-9A59-AC3F7715C1A0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F53530C7-F9B4-45F0-BA66-9CF8BBD31A54"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/RASBURICASE-0ae10bc4-6b65-402f-9db5-2d7753054922.html</ao:annotatesResource>
    <pav:previousVersion>urn:domeoserver:annotationset:A1974692-7810-4286-9D14-6C52DFDE7AAE</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:0177F263-51E4-4295-AD8B-8E97BBE69DF4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:277FA52F-9C73-4A40-A577-6882502C7DD9"/>
    <pav:lastSavedOn>2014-08-11 09:19:30 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <permissions:permissions rdf:nodeID="N096276d2d13748e3bfe965877548869e"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7EFD077D-9A39-4A6F-90B1-98DCD2CCF7AD">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>no gene symbol mentioned but it is a required choice.</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4573ADD2-C87F-40CE-AB64-6B4B2DC21EE2">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B9DE29DE-E668-47F0-B3C2-782D4D182420">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7bed07458efb4267935763d51762fccd">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2C5BD56A-E020-4675-BB40-DD0A1B5891F7">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C4B9C2C0-AC5D-4314-8B3F-C425ACE48FAA">
    <ao:body rdf:resource="urn:linkedspls:uuid:FAB952A2-2E8B-49FB-8695-7F8FDB63E8F6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:71672A41-892A-412D-9AA0-2AC13DF3B672"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:194C1AD8-F938-41C0-B828-AFE9B220A6DE"/>
    <pav:lastSavedOn>2014-05-31 14:38:56 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:C8F4F061-F6FA-4170-858F-BEE2F63A1408"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-05-31 14:38:56 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:EC69B0D6-2F53-4A79-BD91-D7F5122B3C9F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AB21E55C-91DD-4C2C-A009-AFAC3BB63DAF"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:F8ED2DAE-140B-4650-996D-94A8F60A716D"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:FA00EA59-A1F3-4077-9ADE-15EBC5C257E2</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:DECC9F11-B952-4822-B8CD-4014DFC45407</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E7184517-8C8B-4EA8-AA3A-A8A3B35FC722">
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0AF3E985-4E57-42CD-892A-EF3C03D77886">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#66106-6 PHARMACOGENOMICS SECTION</poc:productLabelSection>
    <sio:SIO_000111>66106-6 PHARMACOGENOMICS SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F6CB4F62-52CD-469C-8D72-319533AF7BEC">
    <pav:createdOn>2014-08-11 09:29:05 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:5D5F94E7-E1EB-4689-807D-127E37023AF4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5D7DF8DA-6179-4793-B756-6FF4ED109390"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EB7F1BA4-B05F-4434-9BB2-FB4E73BCDBD9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B98A97A3-27F6-4BE3-8E93-CC3FA17B06E2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DCC4DAB2-E748-40A7-859F-01971CEBD4FB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8CBB02C2-085F-4ADA-9BD7-FA840705DD6D</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:92D11857-AC3C-4F10-830F-4DC679E72BB6</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:DD843C34-8F5A-4461-916F-2018FFF2A5E4"/>
    <pav:lastSavedOn>2014-08-11 09:31:01 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:BF5AEF00-CA74-4A33-8C6F-F0EA6580784D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:FF0D52EA-0500-4EF7-9038-580F2BB6C8C2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5ED2E6DD-06DC-413E-950F-77AAB8EE792A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5BE86617-EF9E-48F2-9D21-149A3734C784">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>breast cancer</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:10D511DE-9049-477C-804F-816B19E1AC32">
    <ao:suffix>. Inherited resistance to activated protein C has been described in many patients with venous thromboembolic disorders but has not yet been evaluated as a risk factor for tissue necrosis. The risk associated with these conditions, both for recurrent thro</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-06-11 23:08:52 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:10D511DE-9049-477C-804F-816B19E1AC32"/>
    <ao:exact>Hereditary or acquired deficiencies of protein C or its cofactor, protein S, have been associated with tissue necrosis following warfarin administration. Not all patients with these conditions develop necrosis, and tissue necrosis occurs in patients without these deficiencies</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:277FA52F-9C73-4A40-A577-6882502C7DD9">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:85431EC6-4630-4FB1-8FB3-BAB6286B75B6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:B915F3E2-6E0F-4CA8-B101-75DE5AB7A51A"/>
    <pav:previousVersion>urn:domeoserver:annotationset:F7C58D05-6A18-4BC2-A3FF-57CF5791EFF0</pav:previousVersion>
    <pav:lastSavedOn>2014-08-11 09:12:14 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:0F5B0035-B040-4413-89A7-0D6C98096DDF"/>
    <pav:createdOn>2014-08-11 09:09:18 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:1C93816A-0721-43F3-8EF6-40E27BDC3CF6"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:00597C44-88CF-425B-9A33-957EEAA04758"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8917A0C6-4EB0-4018-922E-B216A9A1DB0C</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:A1E72881-9857-48B6-BADF-BFCA7D7E7D11"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CC2B9C2A-ADA5-4784-8879-4D6AB8610F0C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:5EBB77FD-51B8-46AE-8874-51C32A57C8E9</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D217AC15-238E-462D-B127-1282765E996E">
    <pav:createdOn>2014-06-11 23:17:30 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:FF8A7FEA-E9F0-4C9A-A109-D74453FB9F56"/>
    <pav:lineageUri>urn:domeoserver:annotation:F91B158C-C5F8-4F7A-A1CA-D61F0E505DC7</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E823DCB5-68E6-44D4-90AF-E073AC268320</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:938B4787-1810-40A2-BFDC-F1723DB98EC5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A933DC7D-F83D-48EC-B298-8AF97F821400"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:4F64A062-757D-4E3E-8E6D-EB71697EB890"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E0117D95-059E-48FC-A208-FDBF96D17A48"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:8CBDE889-AD70-4B21-8DE7-B26CC5CFB0E3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1D9D1E08-3ED3-4125-832F-C0FAF81694C7"/>
    <pav:lastSavedOn>2014-06-11 23:20:00 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:7D0F8841-3170-4EB6-9AD8-EA2EFF394FB9"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:6B94756B-C223-4510-AB02-5A668E291766"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A3DEE863-519E-41C0-BA1A-9D4FB10CDF68">
    <ao:body rdf:resource="urn:linkedspls:uuid:1172F052-303D-4627-B3B4-2565FC586F39"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:6D1DF150-027F-4D8F-A91B-7E9ACD7B4153"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:22CDA9BA-0C0D-4030-9B4C-4D21B294BDC4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7EFD077D-9A39-4A6F-90B1-98DCD2CCF7AD"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:5AC117A6-17C1-40E5-8034-B56BAC1F9C82</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:549613B2-0DF9-46A6-92C0-2F41F029B40F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6413F7E7-7EE1-411C-9E9B-0255AD5CECD2"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:B94B4D30-9482-4AE7-A3DB-756CB93EF0AE"/>
    <pav:createdOn>2014-05-30 20:51:19 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AB8114CE-610C-4124-9C3E-2295E1567A55</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:3D5E2CE3-0C4D-4C43-AFE7-C5441DAFFF1A"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:7A8CA5B7-DBD1-4651-AE34-3CAE5A10D2D0"/>
    <pav:lineageUri>urn:domeoserver:annotationset:23D022D1-EA80-4401-9CAD-1D389D3CBFA6</pav:lineageUri>
    <pav:lastSavedOn>2014-05-30 20:55:37 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:F6C4C1F5-9C1B-4A9C-B277-4E6A3665D42D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7F06CD0F-DDEF-4AD7-ACBB-01312A3A36F0">
    <ao:body rdf:resource="urn:linkedspls:uuid:BD4D401E-13BC-40DA-9282-9035FFFDBC36"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:656565A4-9FEE-416A-9A4E-FBC1A3179D87"/>
    <pav:lineageUri>urn:domeoserver:annotation:E6B51EF9-C8A4-47AB-996E-08FDB2D53722</pav:lineageUri>
    <pav:lastSavedOn>2014-08-11 10:06:24 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B50A464E-FBA5-4A39-92EE-AE6B0AEFA6B4"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:65A3E5C7-33A3-442B-A6F5-07D168A16AD0"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:E464726E-DEBC-48DC-8C6D-12E7E85B1734"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:82D57F69-146C-49DE-8423-547A6134FCBF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F0ED4F46-5FEA-4FCC-BB1B-8D77CD2A1715"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:81310DBB-B705-40ED-B397-0EE4A46B8875</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:631081EE-4991-433C-B87F-E1AFB7E076F0"/>
    <pav:createdOn>2014-08-11 10:06:24 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D9F3A073-976F-4B84-B1B8-21AC11CA8C6C">
    <rdfs:label>Variant Frequency</rdfs:label>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0100375E-6C66-4D5A-BA68-DA8813CEE98F">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:658947BF-6474-4863-9B00-AF08AC87C241">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34081-0) PEDIATRIC USE</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>(34081-0) PEDIATRIC USE</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DD43C8BC-2C95-438D-B8EE-7A8590B1ADDE">
    <domeo:uuid>DD43C8BC-2C95-438D-B8EE-7A8590B1ADDE</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Node-Negative\n\nIndividual Studies\n\nNSABP B-14, a prospective, double-blind, randomized study, compared tamoxifen to placebo in women with axillary node-negative, estrogen receptor positive (≥ 10 fmol/mg cytosol protein) breast cancer (as adjuvant therapy, following total mastectomy and axillary dissection, or segmental resection, axillary dissection, and breast radiation). After 5 years of treatment, there was a significant improvement in disease-free survival in women receiving tamoxifen. This benefit was apparent both in women under age 50 and in women at or beyond age 50.</ao:exact>
    <pav:createdOn>2014-06-01 20:46:42 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DD43C8BC-2C95-438D-B8EE-7A8590B1ADDE"/>
    <ao:suffix>One additional randomized stud</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3B6B17D2-B6A8-442E-9E28-66ADC7447594">
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>7/7, 6/6, *28</ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E6E4FD4B-754C-4F8E-9620-BE757F2BBC8A">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Metabolism Increase</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:242AF40D-528F-47DB-8914-17FBC7DCDFC4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C2E7571D-EE81-4466-A0FC-4F946020B57C">
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:663A99AE-FE41-416A-A8AA-3D6A51A36D23">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1B5D6A9A-E3B1-40BB-A570-F2A637C887EE">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>death, respiratory depression</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:05CE04BA-9DB6-41CA-BC81-3E4FDB6EC2C0">
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:05CE04BA-9DB6-41CA-BC81-3E4FDB6EC2C0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:prefix>In the Hubay study, patients with a positive (more than 3 fmol) estrogen receptor were more likely to benefit.</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-06-01 20:17:22 -0400</pav:createdOn>
    <ao:exact> In the NSABP B-09 study in women age 50 to 59 years, only women with both estrogen- and progesterone-receptor levels 10 fmol or greater clearly benefited, while there was a nonstatistically significant trend toward adverse effect in women with both estrogen- and progesterone-receptor levels less than 10 fmol. In women aged 60 to 70 years, there was a trend toward a beneficial effect of tamoxifen without any clear relationship to estrogen- or progesterone-receptor status.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:071EF91C-F1B0-4F3B-92DE-4CF6E10605F6">
    <pav:lineageUri>urn:domeoserver:annotation:A937EFAC-4424-425E-8A2B-FA011CB7A891</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:4202AA4C-3DA1-44DB-8C9E-E3AE273CCA5A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4B3630AE-2F0E-405C-AB3A-305B64A525B4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:56DFDEAC-0AE0-40BB-AB8F-4C3342777B18"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:694BD2B0-9D20-4826-9AF8-D3635CF44A15"/>
    <pav:createdOn>2014-06-01 20:37:53 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:lastSavedOn>2014-06-01 20:38:19 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:64DDD100-240D-4C42-92AF-E6FBF90BA0CE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:ACA08787-ABED-45D0-BC60-0BF267096A11"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1A9267A8-5284-4711-BCFA-4B1FC22D6C5C</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DED546EB-06CB-4DCA-981F-C1C5EB8061F4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeo:software:id:Domeo-2.1alpha-050">
    <rdfs:label>Domeo Annotation Toolkit</rdfs:label>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Software"/>
    <foafx:version>2.1alpha</foafx:version>
    <foafx:build>050</foafx:build>
    <foafx:homepage></foafx:homepage>
    <foafx:name>Domeo Annotation Toolkit</foafx:name>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1A81D59A-F609-4BA8-92A5-E3D5B44090C1">
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EFC96F15-EB0C-4B97-9204-E6395785E4B1">
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2124832A-A4E1-40D2-B6C7-E760197CFD52">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>bleeding</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:027BD55A-C997-4342-B547-9E7D756378AF">
    <pav:lineageUri>urn:domeoserver:annotationset:23D022D1-EA80-4401-9CAD-1D389D3CBFA6</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:FF92FA2D-BCB8-4392-8DE6-252A42F2E10E</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:F9A074AA-C7A1-4CD6-BFB4-FA6CEC5AD64C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FCAC9960-3E31-4519-9F6C-01E2D662FE3B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6FDE851D-2841-43BE-AF4E-9ABB2DDED526"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A83D3BE1-F713-4A8A-AF83-80E88F3E09D5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:7C4A727C-A3BD-40B6-967F-D4F4F5CCC6AC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:095D7662-94DC-44E2-9C5A-C6A6C54B4C47"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">16</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:63809DA6-C69A-4815-974D-4F4881BBFC98"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:422FF05E-3360-43EB-A942-F9397CA2BDA6"/>
    <pav:createdOn>2014-05-30 21:04:28 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AB8114CE-610C-4124-9C3E-2295E1567A55</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:274DCB2B-EBB4-46D5-B0B5-3832AA1ECBAD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:89896431-9916-44B8-A58B-E0C1ECE666F3"/>
    <pav:lastSavedOn>2014-05-30 21:26:22 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:434D95B3-1543-4A9E-AFA3-65A24E8E401D">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:899D476C-F5E4-4D2D-9CB4-0E92FDBF03BE">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00022</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Peginterferon_alfa-2b</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DABC8FCA-B994-4FD3-AB27-F579A0AA91C4">
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:80CFC228-C5AD-4697-B4BC-A0BEB597B99B"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-08-11 09:31:01 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:C0B00E6F-1720-4577-8DEF-593495B789C6"/>
    <pav:lastSavedOn>2014-08-11 09:31:01 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:D1BA6F9D-59F1-41CB-8B32-2EE0B5E0C8DC"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AF34AEA4-B827-4D72-90A3-5CFA8902A66C"/>
    <pav:lineageUri>urn:domeoserver:annotationset:92D11857-AC3C-4F10-830F-4DC679E72BB6</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8CBB02C2-085F-4ADA-9BD7-FA840705DD6D</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:C9C86070-F79C-409E-AA7F-F83FE99AE665"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:8F7A6302-ACFE-4CD2-8A11-0D3BEFF6B89F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0DE492CC-375E-4575-AEA5-007BE44AAF67"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D63AE510-EDFF-4DB6-A705-268BBE758ADA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A2DFC83C-6A39-4071-900F-8235B89FCAD2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:92B5AF9E-5429-4D66-9291-831F8D2829CB">
    <rdfs:label>Prodrug</rdfs:label>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <dct:description>Referred to Prodrug</dct:description>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:8CBB02C2-085F-4ADA-9BD7-FA840705DD6D">
    <pav:previousVersion>urn:domeoserver:annotationset:C589CBA9-73FD-47EF-8B39-52E71A3A2662</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <permissions:permissions rdf:nodeID="N9d7ad3eacfff4b9d939eeee919283cf5"/>
    <pav:lastSavedOn>2014-08-11 09:44:18 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:92D11857-AC3C-4F10-830F-4DC679E72BB6</pav:lineageUri>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304628d4c0014629cdc71a0000"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DABC8FCA-B994-4FD3-AB27-F579A0AA91C4"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IVACAFTOR-0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:E6E1AE8F-CC0E-47FC-915A-0080616833AD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5FB54727-E732-44AA-AF8C-16375388C122"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FAA5D452-A6B4-4DA0-AF68-2DFB1DB9CF37"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E2E802A3-D5AF-4770-B15B-809809AD101B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F6CB4F62-52CD-469C-8D72-319533AF7BEC"/>
    <pav:createdOn>2014-08-11 09:22:55 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
    <rdfs:label>Default Set</rdfs:label>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:A09FB5EC-B7A0-4198-8AB7-A4A4CB06C3A8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:858873E0-5564-4039-9659-DFE0191571E0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:773B0020-6A5F-455B-AD23-885224987B5C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:274DCB2B-EBB4-46D5-B0B5-3832AA1ECBAD">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer-positive</poc:TestResult>
    <rdfs:label>ultra-metabolizer-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5A4DB16C-955E-4D38-A654-F402477D523E">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>(34078-6) NURSING MOTHERS</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34078-6) NURSING MOTHERS</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3A1A2DB1-B595-412A-A19B-1DD1EC83B05C">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DD843C34-8F5A-4461-916F-2018FFF2A5E4">
    <pav:createdOn>2014-08-11 09:29:05 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DD843C34-8F5A-4461-916F-2018FFF2A5E4"/>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IVACAFTOR-0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene.</ao:exact>
    <domeo:uuid>DD843C34-8F5A-4461-916F-2018FFF2A5E4</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6B94756B-C223-4510-AB02-5A668E291766">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <rdfs:label>Recommend</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:83A1D844-AA66-4DC4-AB44-0B22E63D2464">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>In a prospective study (n=250) to investigate the role of UGT1A1*28 polymorphism in the development of toxicity in patients treated with CAMPTOSAR (180 mg/m2) in combination with infusional 5-FU/LV, the incidence of grade 4 neutropenia in patients homozygous for the UGT1A1*28 allele was 4.5%, and in patients heterozygous for this allele the incidence was 5.3%. Grade 4 neutropenia was observed in 1.8% of patients homozygous for the wild-type allele.\n\nIn another study in which 109 patients were treated with CAMPTOSAR (100–125 mg/m2) in combination with bolus 5-FU/LV, the incidence of grade 4 neutropenia in patients homozygous for the UGT1A1*28 allele was 18.2%, and in patients heterozygous for this allele the incidence was 11.1%. Grade 4 neutropenia was observed in 6.8% of patients homozygous for the wild-type allele.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IRINOTECAN-e518dfc6-7e93-4fee-a66c-51e1ab71c056.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:83A1D844-AA66-4DC4-AB44-0B22E63D2464"/>
    <ao:prefix>once-every-3-weeks), the incidence of grade 4 neutropenia in patients homozygous for the UGT1A1*28 allele was 50%, and in patients heterozygous for this allele (UGT1A1 6/7 genotype) the incidence was 12.5%.  No grade 4 neutropenia was observed in patients homozygous for the wild-type allele (UGT1A1 6/6 genotype). </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-08-11 10:43:25 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D544FA4B-2E59-4E71-8C09-112D2ADAE5ED">
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdfs:label>Variant Frequency</rdfs:label>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:81310DBB-B705-40ED-B397-0EE4A46B8875">
    <pav:lastSavedOn>2014-08-11 10:06:24 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7F06CD0F-DDEF-4AD7-ACBB-01312A3A36F0"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-08-11 10:03:55 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:A80EF5E9-B3C7-488C-953D-86523C030390"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOMPIRAMINE-4074b555-7635-41a9-809d-fae3b3610059.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:5E326BAF-7779-462A-B318-744A387244E6</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304628d4c0014629cdc71a0000"/>
    <permissions:permissions rdf:nodeID="N6edb9fd47b6e4004a266011b2b14139c"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E7DD7830-B387-493A-A27D-3EE25F45CCC2">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>overdose, sleepiness, confusion, shallow breathing, nursing, breastfeeding</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:82AD605C-D9BE-4FD4-82FA-8D791B59A15D">
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A13C2109-BF6C-421F-9281-7F7FF9A5D781">
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Clinical Trial</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A9E8823F-1264-471E-92FE-9A5C76144578">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>. SN-38 glucuronide had 1/50 to 1/100 the activity of SN-38 in cytotoxicity assays using two cell lines</ao:suffix>
    <pav:createdOn>2014-08-11 11:34:07 -0400</pav:createdOn>
    <ao:prefix>njugated predominantly by the enzyme UDP-glucuronosyl transferase 1A1 (UGT1A1) to form a glucuronide metabolite. UGT1A1 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity such as the UGT1A1*28 polymorphism.</ao:prefix>
    <domeo:uuid>A9E8823F-1264-471E-92FE-9A5C76144578</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IRINOTECAN-e518dfc6-7e93-4fee-a66c-51e1ab71c056.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact> Approximately 10% of the North American population is homozygous for the UGT1A1*28 allele (also referred to as UGT1A1 7/7 genotype). In a prospective study, in which irinotecan was administered as a single-agent (350 mg/m2) on a once-every-3-week schedule, patients with the UGT1A1 7/7 genotype had a higher exposure to SN-38 than patients with the wild-type UGT1A1 allele (UGT1A1 6/6 genotype) [see Warnings and Precautions (5.3) and Dosage and Administration (2)]</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A9E8823F-1264-471E-92FE-9A5C76144578"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:38598C50-CA0B-4C3A-A78B-C34411635E7D">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(43679-0) MECHANISM OF ACTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>(43679-0) MECHANISM OF ACTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9D7DA31C-DADD-4663-AD3E-246C6FFB0855">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:29451F08-7CF7-4042-9F81-C3DF0DB3B24D">
    <rdfs:label>Influences Drug Response</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A879EB99-7631-4723-8190-DF455675E5A6">
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E5B7EBB1-3D85-485C-87BB-07013C8460EB">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F93A42FB-85AB-454A-876A-5F61EDEB190B">
    <ao:body rdf:resource="urn:linkedspls:uuid:E2FA19D2-1FF2-4A14-B128-50B2AD4E11D0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BDFD32B6-09B7-4805-970B-8F812A66A511"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E647A62C-71D5-414D-82D7-9B2980EB4814"/>
    <pav:createdOn>2014-08-11 10:40:11 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:E25A112E-A5DC-4365-ABF4-53C09C8FA58E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4893BECD-9F9C-4886-8C6E-6A8073B27ABA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:34298BE6-B74D-406D-9384-591173BD0A47"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:A7EAC193-CF12-4590-978A-E230000C50AA"/>
    <pav:lineageUri>urn:domeoserver:annotationset:DA691DE3-F7C0-4EE6-A746-38D540E1AA19</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:B68C2C79-390F-47E6-9883-9801E445D22E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A697F9EC-3FE9-4390-AB13-C95B2FF610AB"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:EE2C5004-5777-466C-893F-6258A614287F</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:23D232D6-9A25-47F3-8DA1-D7CE366FB4BF</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-08-11 10:40:12 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F90ACC5B-6D0A-405E-B915-A14C66CD9386">
    <ao:suffix> Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting Elitek </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>F90ACC5B-6D0A-405E-B915-A14C66CD9386</domeo:uuid>
    <pav:createdOn>2014-08-11 09:10:44 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Hemolysis\n\nDo not administer Elitek to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Immediately and permanently discontinue Elitek in patients developing hemolysis.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F90ACC5B-6D0A-405E-B915-A14C66CD9386"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/RASBURICASE-0ae10bc4-6b65-402f-9db5-2d7753054922.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A7EFD62D-B87A-45FB-A018-C5588824815C">
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/NORTRITYLINE-e17dc299-f52d-414d-ab6e-e809bd6f8acb.html</ao:hasSource>
    <domeo:uuid>A7EFD62D-B87A-45FB-A018-C5588824815C</domeo:uuid>
    <ao:exact>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. </ao:exact>
    <pav:createdOn>2014-08-11 09:59:31 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A7EFD62D-B87A-45FB-A018-C5588824815C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2B0185C8-59AA-4FE3-B38D-775C36A6FCA6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ESR1</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1D9D1E08-3ED3-4125-832F-C0FAF81694C7">
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <rdfs:label>Recommended</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4D3FD3EB-8A3B-4840-BA6B-AC7762FB73EF">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3AC25B98-BE61-42EA-B711-7AF4AA730C0B">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A91EF184-DE3B-4CDE-995D-15015C878693">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(66106-6) PHARMACOGENOMICS</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(66106-6) PHARMACOGENOMICS</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:57FE5F64-C6AF-4C05-94AD-5F22CB4DB0D3">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Codeine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B50A464E-FBA5-4A39-92EE-AE6B0AEFA6B4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Clomipramine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01242</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B1F3EB09-6D39-4C92-8835-6F2C1B38EA5A">
    <domeo:uuid>B1F3EB09-6D39-4C92-8835-6F2C1B38EA5A</domeo:uuid>
    <ao:exact>Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting Elitek [see Boxed Warning, Contraindications (4)].</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B1F3EB09-6D39-4C92-8835-6F2C1B38EA5A"/>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/RASBURICASE-0ae10bc4-6b65-402f-9db5-2d7753054922.html</ao:hasSource>
    <pav:createdOn>2014-08-11 09:19:07 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6FDE851D-2841-43BE-AF4E-9ABB2DDED526">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4EB785E5-84D0-4C42-B964-D168B530CF68">
    <ao:body rdf:resource="urn:linkedspls:uuid:3338E6D3-C4DA-4CB9-9E36-7B052E30D34B"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AB8114CE-610C-4124-9C3E-2295E1567A55</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:49AE4751-F95D-4FD4-91E4-56608E2453F0"/>
    <pav:lastSavedOn>2014-05-30 21:58:40 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:23D022D1-EA80-4401-9CAD-1D389D3CBFA6</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:60BE726A-6CBA-4702-8177-1F8E90B3002B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EF9794C3-352E-4126-BD14-1B210084ED33"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B42A8BFF-C4FF-4631-B83D-EED27445586A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D59D2FAE-261B-49E9-B8EB-5D10F30D62E6"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:31AFD1A3-4F36-484A-8EEA-FF8CEEE245D7</pav:previousVersion>
    <pav:createdOn>2014-05-30 21:58:39 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:DBD796B5-63BA-4FD6-B6F1-99AFD62D62C4"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:BF79250C-CC52-4453-BEEA-C94910F9869A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:68B4BD22-611B-4BCF-A771-5D0A339C28D6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">24</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:0309BC2D-861F-4AA6-B8E8-26D426761989"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:97794AE4-CFBC-4CB6-A538-08F16796CE0B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9819ABA2-582F-4DAC-8C77-A1B2945346D2">
    <domeo:uuid>9819ABA2-582F-4DAC-8C77-A1B2945346D2</domeo:uuid>
    <pav:createdOn>2014-08-11 09:31:52 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>KALYDECO is not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9819ABA2-582F-4DAC-8C77-A1B2945346D2"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IVACAFTOR-0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CFA29740-CED7-4D5F-8A5F-BDE8F47DE421">
    <domeo:belongsToSet>urn:domeoserver:annotationset:E823DCB5-68E6-44D4-90AF-E073AC268320</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:1F7D5BB1-2314-460E-BDF3-441604623507</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:7E27E8DC-75C7-45E7-AC4A-A581364BEBD7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D6B64898-A075-4971-B3BF-C65AC2F44FF7"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:01E7E5A1-ECD6-421C-94B5-20870BA07DDA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9CC55933-9B06-428C-8A1D-660D7B7A8C67"/>
    <pav:lastSavedOn>2014-06-11 22:54:16 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:FA3C442E-8A92-4772-AF8D-270876833A4C"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:4CC3E100-162B-4FCA-95F1-AC53E3A61FE9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CA2E74B2-FACC-44F8-9BF9-0B3F442757AB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:535498E1-E966-463D-B73B-849E5E82BB91"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7A7AB1C5-69A8-4593-8161-523CF94B4184"/>
    <pav:createdOn>2014-06-11 22:53:32 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:59590A65-90C8-4E95-A16E-96DB23D9D119</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:38598C50-CA0B-4C3A-A78B-C34411635E7D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:4A49ABE7-4A74-4FA8-8CA3-C2605319A6BA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FF8A7FEA-E9F0-4C9A-A109-D74453FB9F56">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Warfarin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B4FB2FD7-E678-4286-BD4E-AD1AAE5CBC1E">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
    <rdfs:label>ER_receptor</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F1E77C2F-A625-4BF7-93F0-9ECDCBA34773">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Tamoxifen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:750B313C-5E26-4DEF-8171-E44FEF807165">
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6DED6328-BB8E-4963-99FF-9232EF2ECF37">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FC65E752-F436-43B1-AF5C-C4FE334DE22B"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1A9267A8-5284-4711-BCFA-4B1FC22D6C5C</domeo:belongsToSet>
    <pav:lastSavedOn>2014-06-01 20:35:15 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:91CCCC07-7184-40F8-A821-57E723DB4570"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:27E48CF2-9A8E-4F71-9E7D-1F3221859A96"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3A254987-20A8-4C90-9EFA-9C531CCE9F25"/>
    <pav:previousVersion>urn:domeoserver:annotationset:9EA314B7-223F-47ED-825F-91B271162E68</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:6957573C-BFB4-4755-B99E-89E932A7FB72"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AE969407-A095-4E14-8724-87542A9C2CE2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:42BAA89A-99B1-458E-8ED2-25A3BE50DAD4"/>
    <pav:lineageUri>urn:domeoserver:annotationset:FAE19553-957D-45CE-8E2F-EDE4651240ED</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:BA3D4FC3-D4A8-45EF-B295-6256DA05F50F"/>
    <pav:createdOn>2014-06-01 20:35:14 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D41DB05B-F6E2-44BF-BB52-A2A0A7AFB008">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8CBDE889-AD70-4B21-8DE7-B26CC5CFB0E3">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34068-7) DOSAGE AND ADMINISTRATION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>(34068-7) DOSAGE AND ADMINISTRATION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:AB8114CE-610C-4124-9C3E-2295E1567A55">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">31</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:5C1CC348-287D-4619-B06D-724AB619F25D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:4EB785E5-84D0-4C42-B964-D168B530CF68"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:454625FE-AA6E-403D-BDEF-45E4AAF0F9FE"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:5D8BED39-A132-4BB4-A712-DA7693E3199D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C26D08C1-000D-4C41-920A-0962FE68BD68"/>
    <pav:lineageUri>urn:domeoserver:annotationset:23D022D1-EA80-4401-9CAD-1D389D3CBFA6</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:75910971-3EC6-488D-A422-B82608D18CDA"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:314BCEF4-0FF7-4FF6-98A4-1870933D139B"/>
    <pav:previousVersion>urn:domeoserver:annotationset:F135BA39-6ECA-4681-9886-AA5D32AA93A9</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304628d4c0014629cdc71a0000"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:760EB474-EF58-4374-B2D9-EC1C2A117479"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AE7F9525-1179-43D7-B3E0-3F4D44CFF1F5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B1DC5CBA-947F-4ACA-AB8B-EF1CE2F7E6FA"/>
    <pav:createdOn>2014-05-30 20:06:09 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:A3DEE863-519E-41C0-BA1A-9D4FB10CDF68"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:765924DC-1F41-4886-95B6-2751263F960E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:027BD55A-C997-4342-B547-9E7D756378AF"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <permissions:permissions rdf:nodeID="N4d663486f1854d7590e4fa0f664182fc"/>
    <pav:lastSavedOn>2014-06-02 13:36:04 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BAF3BB27-DF50-4BA9-B74F-2C86F2DB2297">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to Prodrug</dct:description>
    <rdfs:label>Prodrug</rdfs:label>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0C058F94-94D1-4AEE-BF18-3B8E067C9F8A">
    <ao:body rdf:resource="urn:linkedspls:uuid:75E3BD22-0CB8-4476-9F00-863BECE17EDF"/>
    <pav:lineageUri>urn:domeoserver:annotation:98A52881-A4FD-49FF-8343-59761D0DCF0D</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4E0C4F09-6B85-4E68-9712-4B0E61E32B7E"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-06-11 23:20:00 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:0CA59420-1D9E-44F2-AE9F-252EA8FFE1B6"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E823DCB5-68E6-44D4-90AF-E073AC268320</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:A31FA154-7864-4B8B-9092-E596919033A8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3B6E1EDF-506E-424B-A6B2-10E770D966DD"/>
    <pav:createdOn>2014-06-11 23:20:00 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EDF04A7B-AD1A-4009-BC06-B0871EB93435">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:55D8D3AE-CB65-4FF2-98EE-324FBE75B67C">
    <rdfs:label>Ivacaftor</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB08820</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:34FFFD8F-0932-4522-9B73-7489CDB20686">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CEA0B6F6-7EA5-4130-AE8A-811D45687345">
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A8AD1C73-797E-4880-98AC-3E9A39F3A6ED">
    <rdfs:label>VKORC1</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0C8955C0-E620-4E69-BA2A-398A81C5E1D8">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F851EC8F-462C-4B22-BD30-4E182DF6A476">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8F633A1E-F893-4514-B632-12D8BAB8F1B2">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34078-6) NURSING MOTHERS</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>(34078-6) NURSING MOTHERS</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5AC1006F-C104-46C9-9EB8-77A43580FE51">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00049</dailymed:pharmgxDrug>
    <rdfs:label>Rasburicase</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0309BC2D-861F-4AA6-B8E8-26D426761989">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(68498-5) PATIENT MEDICATION INFORMATION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(68498-5) PATIENT MEDICATION INFORMATION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:618476AA-4D11-476A-8AEA-306370717435">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-level-low</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-level-low</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C653116F-7526-437C-8DF3-490943F87724">
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E64CBD14-4A0C-4364-BBE8-4E573E3E7B3A">
    <rdfs:label>ER_receptor</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FA09E146-1527-4DD9-A474-62CC009AA182">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:78CD071A-8A83-43E3-BFA8-20599AB468CD">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>respiratory depression, death, tonsillectomy, adenoidectomy</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:32B08FD0-4B17-4E4B-90ED-664575C528E9">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>breast cancer</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DCC4DAB2-E748-40A7-859F-01971CEBD4FB">
    <rdfs:label>Influences Drug Response</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5C1CC348-287D-4619-B06D-724AB619F25D">
    <ao:body rdf:resource="urn:linkedspls:uuid:D124E537-48D7-4B9B-8CE2-E6A1219B5DF8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AFEFEFDF-C463-4852-8F26-12A6AE942FC3"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:03CEFBFC-E1A2-448D-A350-9AC0CDCC4C9C"/>
    <pav:previousVersion>urn:domeoserver:annotationset:2D2D900F-1347-413F-9512-0B868FB594CB</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:84B2DCAD-2378-422F-9E85-1BEAE03D6C55"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9954D2BE-75FB-4269-9C7A-A685B5BE43A2"/>
    <pav:createdOn>2014-05-30 21:25:57 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:242AF40D-528F-47DB-8914-17FBC7DCDFC4"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:663A99AE-FE41-416A-A8AA-3D6A51A36D23"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5A4DB16C-955E-4D38-A654-F402477D523E"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:23D022D1-EA80-4401-9CAD-1D389D3CBFA6</pav:lineageUri>
    <pav:lastSavedOn>2014-05-30 22:05:26 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AB8114CE-610C-4124-9C3E-2295E1567A55</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CBD63B99-54EF-45C7-8E1C-44F15FB12DE4"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7B417F76-E2BF-4AE6-934A-BBCA251C5264">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Warfarin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1172F052-303D-4627-B3B4-2565FC586F39">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Codeine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:712D0B93-947C-4E60-94CD-CA048223D543">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:69D56571-D51E-4E60-B89E-8AC18205728D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F40691B5-66E4-45B5-9D51-AC8E41363978">
    <ao:exact>Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/NORTRITYLINE-e17dc299-f52d-414d-ab6e-e809bd6f8acb.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F40691B5-66E4-45B5-9D51-AC8E41363978"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-08-11 10:01:25 -0400</pav:createdOn>
    <domeo:uuid>F40691B5-66E4-45B5-9D51-AC8E41363978</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>educed in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D6B64898-A075-4971-B3BF-C65AC2F44FF7">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B9E417AB-68D7-405F-8085-8A3676799FB2">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>low-or-absent-activity</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:13801219-5A2A-4077-946C-7C8800233016">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:710AA502-4DC7-453E-835B-7C94AA6D6FC2">
    <ao:prefix>Some individuals may be ultra-rapid metabolizers because of a specific CYP2D6 genotype (gene duplications denoted as *1/*1xN or *1/*2xN). </ao:prefix>
    <pav:createdOn>2014-05-30 21:02:42 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:710AA502-4DC7-453E-835B-7C94AA6D6FC2"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups. These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. Even at labeled dosage regimens, individuals who are ultra-rapid metabolizers may have life-threatening or fatal respiratory depression or experience signs of overdose (such as extreme sleepiness, confusion, or shallow breathing) [see Overdosage (10.1)].</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1B92794A-5D16-44FF-9839-347A36320F8A">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:56DFDEAC-0AE0-40BB-AB8F-4C3342777B18">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>(34067-9) INDICATIONS AND USAGE</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34067-9) INDICATIONS AND USAGE</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:46C7ACCC-401F-4C49-AA5C-1FD2B825E099">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>VKORC1</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B106C82C-2445-4565-8B23-119EBE1AAFAB">
    <rdfs:label>G6PD</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4057</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AE969407-A095-4E14-8724-87542A9C2CE2">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6A134217-69F9-48C3-A4D9-F3B264FFB552">
    <rdfs:label>Codeine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5A4B6334-D8F8-47CB-A7EE-87EB926A3273">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:78CDF494-5B5B-483B-B925-5C6DD3CE2A2D">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>cystic fibrosis</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6FDFE80C-09DD-4F16-B16F-3F70B8370AAC">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ESR1</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F9A074AA-C7A1-4CD6-BFB4-FA6CEC5AD64C">
    <rdfs:label>Codeine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A96B7152-56EB-40F5-8549-B9B13CC0F722">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34066-1 BOXED WARNING SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34066-1 BOXED WARNING SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9213920D-E92B-45F2-AB7C-A3F916F928B1">
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Variant Frequency</rdfs:label>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E88ECE97-0020-499D-BA2C-3FB2A9F6B89A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer.</ao:exact>
    <domeo:uuid>E88ECE97-0020-499D-BA2C-3FB2A9F6B89A</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E88ECE97-0020-499D-BA2C-3FB2A9F6B89A"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-06-09 15:36:12 -0400</pav:createdOn>
    <ao:suffix> Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3D0CBB53-933A-4637-BA26-135978494D06">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6DFDAA16-44D3-43E0-8A12-F4471F995081">
    <poc:MedicalCondition>respiratory depression, obstructive sleep apnea, death, post-operative, tonsillectomy, adenoidectomy, pain</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1BC31CD3-4807-42D6-98DC-9E688603602F">
    <ao:body rdf:resource="urn:linkedspls:uuid:E329FA1D-EAA0-4508-9A60-233980C1CA0D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C19A3897-6FD8-453C-BFBB-A90D6DD2296F"/>
    <pav:createdOn>2014-06-11 23:01:59 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:A26D8703-BF5E-4BF1-B559-161D21C43D33"/>
    <pav:lastSavedOn>2014-06-11 23:03:21 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E823DCB5-68E6-44D4-90AF-E073AC268320</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:DD65E152-396A-4270-9B21-8A1A9F65C1E5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4717900B-348E-4C90-8453-B1BB8C17975A"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:934ED61B-00FD-4C4D-9FF7-73A4362EA997</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:899EFB8F-88EE-4077-B6C2-0A07E96AFC41"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:8807ADF7-6B92-467F-9259-A54B7471185B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:921DD4DE-1801-4A8F-88EC-01393ACEAEB4">
    <dct:description>A required test is related to the biomarker.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Required</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#required</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:110C086B-6C5F-467B-8F39-9E447CF281CA">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact> Nursing mothers who are ultra-rapid metabolizers may also experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing. Prescribers should closely monitor mother-infant pairs and notify treating pediatricians about the use of codeine during breastfeeding [see Warnings and Precautions (5.1)].</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:110C086B-6C5F-467B-8F39-9E447CF281CA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>The risk of infant exposure to codeine and morphine through breast milk should be weighed against the benefits of breastfeeding for both the mother and the baby. Caution should be exercised when codeine is administered to a nursing woman. If a codeine containing product is selected, the lowest dose should be prescribed for the shortest period of time to achieve the desired clinical effect. Mothers using codeine should be informed about when to seek immediate medical care and how to identify the signs and symptoms of neonatal toxicity, such as drowsiness or sedation, difficulty breastfeeding, breathing difficulties, and decreased tone, in their baby. </ao:prefix>
    <pav:createdOn>2014-05-30 22:03:45 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1AD7E9BF-E7B7-4AD9-93C2-348373810B26">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>highlights section. no gene symbol stated.</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:156006C3-2DEB-4094-8ADA-E3E97A326E9D">
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:13CDA93B-1A06-435B-8673-F230C0DAF54E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A879EB99-7631-4723-8190-DF455675E5A6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BD7F5133-18E0-4098-BED9-9E7889E22A18"/>
    <pav:previousVersion>urn:domeoserver:annotationset:EE2C5004-5777-466C-893F-6258A614287F</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:5656D780-B40C-440C-87D7-4E2DD1B998A2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:05A0BB96-0F88-42B7-8179-407EBE32C312"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:E5B7EBB1-3D85-485C-87BB-07013C8460EB"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:23D232D6-9A25-47F3-8DA1-D7CE366FB4BF</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:DA691DE3-F7C0-4EE6-A746-38D540E1AA19</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:1442B962-ACFC-4270-880D-17CA73493CAA"/>
    <pav:lastSavedOn>2014-08-11 10:40:12 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-08-11 10:35:51 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:33DA9304-0936-4205-868E-BCE2EA1347B2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F96AD79C-92FA-42B4-BCEE-4A007AEB615C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7C4A727C-A3BD-40B6-967F-D4F4F5CCC6AC">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7C4A727C-A3BD-40B6-967F-D4F4F5CCC6AC"/>
    <ao:suffix>The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are n</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Some individuals may be ultra-rapid metabolizers because of a specific CYP2D6 genotype (gene duplications denoted as *1/*1xN or *1/*2xN). </ao:exact>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-05-30 21:26:21 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:00912755-73D6-4B51-90B0-80DF9BE1274F">
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to clinical trial</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DC0167DB-2B51-461B-BBF2-53ECD0194ED5">
    <ao:exact>The dose of warfarin sodium tablets must be individualized by monitoring the PT/INR. Not all factors causing warfarin dose variability are known. The maintenance dose needed to achieve a target PT/INR is influenced by:\n\n●\n         Clinical factors including age, race, body weight, sex, concomitant medications, and comorbidities and \n\n●\n         Genetic factors (CYP2C9 and VKORC1 genotypes). </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>An INR of greater than 4.0 appears to provide no additional therapeutic benefit in most patients and is associated with a higher risk of bleeding. Initial Dosage </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DC0167DB-2B51-461B-BBF2-53ECD0194ED5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <pav:createdOn>2014-06-11 23:11:58 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FA6CF576-BA2B-4674-A310-C4159468BEED">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Codeine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9FC61583-D771-4783-B2EC-AF97FFC879A4">
    <poc:MedicalCondition>respiratory depression, overdose, extreme sleepiness, confusion, shallow breathing</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E59CEE6C-28A3-49F4-BFD4-B063AAB97FAD">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3B7230BE-C691-4047-80E8-10D1C90920CB">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-negative</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-haplotype-negative</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:631DABFD-76E2-40E6-AFB1-A8F8EF76BE0A">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/RASBURICASE-0ae10bc4-6b65-402f-9db5-2d7753054922.html</ao:hasSource>
    <pav:createdOn>2014-08-11 09:18:27 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:631DABFD-76E2-40E6-AFB1-A8F8EF76BE0A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>631DABFD-76E2-40E6-AFB1-A8F8EF76BE0A</domeo:uuid>
    <ao:exact>Elitek is contraindicated in patients with G6PD deficiency because hydrogen peroxide is one of the major by-products of the conversion of uric acid to allantoin. In clinical studies, hemolysis occurs in &lt;1% patients receiving Elitek; severe hemolytic reactions occurred within 2–4 days of the start of Elitek. Immediately and permanently discontinue Elitek administration in any patient developing hemolysis. Institute appropriate patient monitoring and support measures (e.g., transfusion support).</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting Elitek </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CD5198BF-D7AD-4002-8129-AAD38CE56DBE">
    <rdfs:label>Increased Efficacy</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4F64A062-757D-4E3E-8E6D-EB71697EB890">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <rdfs:label>VKORC1</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:107C00DB-57D0-4D17-9EA4-E6FF35655A39">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(68498-5) PATIENT MEDICATION INFORMATION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(68498-5) PATIENT MEDICATION INFORMATION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:28D78CA7-B125-4E41-ADD8-84C01BDC8716">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8A8D925D-835B-4D44-B7A7-B8F6C7960539">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>G6PD</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4057</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4A49ABE7-4A74-4FA8-8CA3-C2605319A6BA">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>not sure how to annotate this one. </poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D59D2FAE-261B-49E9-B8EB-5D10F30D62E6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>tonsillectomy, adenoidectomy, obstructive sleep apnea, death, respiratory depression.</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:91CCCC07-7184-40F8-A821-57E723DB4570">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:227BB51A-6B6A-4920-9192-A2D446742C97">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A31FA154-7864-4B8B-9092-E596919033A8">
    <poc:Comment>cannot annotate the full sentance</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E6E1AE8F-CC0E-47FC-915A-0080616833AD">
    <pav:lastSavedOn>2014-08-11 09:44:19 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:313ECEEA-22BE-4331-9624-D871C19A1554"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C2ACC792-8961-4157-AF5E-F5AECCEBB1AE"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:0708A2BE-9195-4301-983E-5CE7D201D648</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:17D16801-EE7B-467B-AF52-6C574F902E98"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8CBB02C2-085F-4ADA-9BD7-FA840705DD6D</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:A4B4A60E-8253-4589-9454-E87129986ECE"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:F052B5F8-F483-4354-9E49-6BB05A8B88E8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A99E2562-6BF1-434D-ACFE-F30BE454E920"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:CAD7C478-F98C-453E-9312-2116927C50C1"/>
    <pav:createdOn>2014-08-11 09:39:38 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:244AF803-63BF-4AD6-B0EB-82FB70703A6F"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E3609C9E-AE63-4C95-A952-DC3DA4BDA90B">
    <rdfs:label>biomarker-level-low</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-level-low</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4D4CC677-4FC9-4792-A19B-EC78BD2A66E6">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12530</dailymed:HGNCGeneSymbol>
    <rdfs:label>UGT1A1</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F591859B-62B9-40FA-91C8-7179A91A5161">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0C749FEB-4CF0-4A48-81AD-1EC629725AA2">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:549613B2-0DF9-46A6-92C0-2F41F029B40F">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4A881955-7882-48B0-82B3-290FABDED458">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-06-01 20:01:42 -0400</pav:createdOn>
    <ao:exact>Among 29,441 patients with ER positive or unknown breast cancer, 58% were entered into trials comparing tamoxifen to no adjuvant therapy and 42% were entered into trials comparing tamoxifen in combination with chemotherapy vs. the same chemotherapy alone. Among these patients, 54% had node-positive disease and 46% had node-negative disease.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4A881955-7882-48B0-82B3-290FABDED458"/>
    <ao:prefix>t of patients received one year or less of trial treatment, 52% received 2 years, and 23% received about 5 years. Forty-eight percent of tumors were estrogen receptor (ER) positive (&gt; 10 fmol/mg), 21% were ER poor (&lt; 10 fmol/l), and 31% were ER unknown. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:194C1AD8-F938-41C0-B828-AFE9B220A6DE">
    <poc:Comment>should be highlight section. had to chose a gene symbol</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7256C964-CB91-4D53-857B-541FF202FEFE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0D365496-AE4A-487E-BBD5-1A444096DB46">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CFTR</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:1884</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2ABD4105-D202-43EA-B659-FF4F8F9CEB16">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:72EEDE82-E0C5-449E-9CF9-550CDAB0D789">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>72EEDE82-E0C5-449E-9CF9-550CDAB0D789</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>The most common adverse reactions in the 221 patients treated with KALYDECO were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%). </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:72EEDE82-E0C5-449E-9CF9-550CDAB0D789"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The incidence of adverse reactions below is based upon two double-blind, placebo-controlled, 48-week clinical trials (Trials 1 and 2) in a total of 213 patients with CF ages 6 to 53 who have a G551D mutation in the CFTR gene and who were treated with KALYDECO 150 mg orally or placebo twice daily. Table 1 shows adverse reactions occurring in ≥8% of KALYDECO-treated patients with CF who have a G551D mutation in the CFTR gene that also occurred at a higher rate than in the placebo-treated patients in the two double-blind, placebo-controlled trials.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IVACAFTOR-0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25.html</ao:hasSource>
    <pav:createdOn>2014-08-11 09:35:17 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D70F7EB6-3197-4B39-9ECE-D27D645B1AD2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#discontinue-do-not-restart</poc:DrugSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Discontinue/Do not restart</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E49A8CE3-66CF-4BE6-A6FC-6D706B0D31F5">
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:701FFC73-E68A-488A-95DE-F31620897352"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <permissions:permissions rdf:nodeID="Ndd8637b21fa341618e29c3a9e1d2ffb0"/>
    <pav:lastSavedOn>2014-08-11 10:01:50 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304628d4c0014629cdc71a0000"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:lineageUri>urn:domeoserver:annotationset:27AFA552-8040-4C66-BAAE-2C710C3DA5F4</pav:lineageUri>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/NORTRITYLINE-e17dc299-f52d-414d-ab6e-e809bd6f8acb.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:B696B2DA-E0B0-4D18-A749-FA9A6C9B2853"/>
    <pav:createdOn>2014-08-11 09:58:21 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A84EA4DD-61D0-433D-98C0-AEDF2E9BD642">
    <sio:SIO_000111>(43679-0) MECHANISM OF ACTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(43679-0) MECHANISM OF ACTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4893BECD-9F9C-4886-8C6E-6A8073B27ABA">
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:313EEDAB-77F3-4A80-A1A0-4BC7AB232A13">
    <poc:MedicalCondition>node negative, breast cancer, total mastectomy, axillary dissection, postmenopausal </poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5E6952F5-F167-424A-A398-06547BB8D349">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IVACAFTOR-0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25.html</ao:hasSource>
    <ao:exact>Efficacy results from a double-blind, placebo-controlled trial in patients with CF who are homozygous for the F508del mutation in the CFTR gene showed no statistically significant difference in forced expiratory volume exhaled in one second (FEV1) over 16 weeks of KALYDECO treatment compared to placebo [see Clinical Studies (14.3)]. Therefore, KALYDECO should not be used in patients homozygous for the F508del mutation in the CFTR gene</ao:exact>
    <domeo:uuid>5E6952F5-F167-424A-A398-06547BB8D349</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-08-11 09:37:50 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5E6952F5-F167-424A-A398-06547BB8D349"/>
    <ao:prefix>F508del Mutation in the CFTR Gene </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:81770CFC-5B23-4D34-B89B-EA666A357006">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-level-low</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-level-low</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4FE2FB6E-6B8E-49B8-A407-14D1A81AF659">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>breastfeeding</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:89F7CFDB-3891-4DCB-A87B-BD3C0387A574">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B797A8A1-B8D8-422B-B700-779551BD8B7B">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BFF14F39-B888-4590-94C7-29C8F2DEFDAC">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34067-9) INDICATIONS AND USAGE</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>(34067-9) INDICATIONS AND USAGE</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:01E7E5A1-ECD6-421C-94B5-20870BA07DDA">
    <ao:prefix>Table 1 Relationship between S-Warfarin Clearance and CYP2C9 Genotype in Caucasian Patients </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:exact>CYP2C9 GenotypeNS-Warfarin Clearance/Lean Body Weight(mL/min/kg)Mean (SD)**SD=standard deviation.p&lt;0.001. Pairwise comparisons indicated significant differences among all 3 genotypes.*1/*11180.065 (0.025)*1/*2 or*1/*3590.041 (0.021)*2/*2, *2/*3or *3/*3110.020 (0.011)Total188Other CYP2C9 alleles associated with reduced enzymatic activity occur at lower frequencies, including *5, *6, and *11 alleles in populations of African ancestry and *5, *9 and *11 alleles in Caucasians</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:01E7E5A1-ECD6-421C-94B5-20870BA07DDA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-06-11 22:54:15 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7CFC1D14-598A-4CC4-BD02-4E9E347AE3EB">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E582725A-F7B5-4491-97DA-2FC0690054E9">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43684-0 USE IN SPECIFIC POPULATIONS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>43684-0 USE IN SPECIFIC POPULATIONS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:01E6A884-4CF2-46AE-9EF0-6FAD18DB4E77">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43682-4 PHARMACOKINETICS SECTION</poc:productLabelSection>
    <sio:SIO_000111>43682-4 PHARMACOKINETICS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1618a8982cc042c993d462ab8b021d9a">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BA0A2CCB-A66A-4E3E-B2CD-C0585FD48A08">
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdfs:label>Clinical Trial</rdfs:label>
    <dct:description>Referred to clinical trial</dct:description>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8F1A0E06-9096-4D0A-8CC0-41A7835D1F9A">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C626ECB3-EE49-492C-8C12-0F8DD52C22EB">
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dct:description>Referred to clinical trial</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdfs:label>Clinical Trial</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9954D2BE-75FB-4269-9C7A-A685B5BE43A2">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:213F21FB-4220-480F-B77B-34166DE42650">
    <dct:description>Referred to Prodrug</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <rdfs:label>Prodrug</rdfs:label>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:125D4098-DFEB-4C27-878C-BA3274477BB7">
    <ao:suffix>Therapeutic doses of warfarin decrease the total amount of the active form of each vitamin K dependent clotting factor made by the liver by approximately 30% to 50%.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:125D4098-DFEB-4C27-878C-BA3274477BB7"/>
    <pav:createdOn>2014-06-11 22:53:55 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Warfarin is thought to interfere with clotting factor synthesis by inhibition of the C1 subunit of the vitamin K epoxide reductase (VKORC1) enzyme complex, thereby reducing the regeneration of vitamin K1 epoxide. The degree of depression is dependent upon the dosage administered and, in part, by the patient's VKORC1 genotype. </ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3EE1F896-7F97-4ACD-83FA-900C07C5EB3B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ESR1</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CAD7C478-F98C-453E-9312-2116927C50C1">
    <ao:prefix>Ivacaftor is a potentiator of the CFTR protein. The CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. Ivacaftor facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein. </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-08-11 09:39:38 -0400</pav:createdOn>
    <domeo:uuid>CAD7C478-F98C-453E-9312-2116927C50C1</domeo:uuid>
    <ao:exact>In vitro, ivacaftor increased CFTR-mediated transepithelial current (IT) in rodent cells expressing the G551D-CFTR protein following addition of a cyclic adenosine monophosphate (cAMP) agonist with an EC50 of 100 ± 47 nM; however, ivacaftor did not increase IT in the absence of cAMP agonist. Ivacaftor also increased IT in human bronchial epithelial cells expressing G551D-CFTR protein following addition of a cAMP agonist by 10-fold with an EC50 of 236 ± 200 nM. Ivacaftor increased the open probability of G551D-CFTR protein in single channel patch clamp experiments using membrane patches from rodent cells expressing G551D-CFTR protein by 6-fold versus untreated cells after addition of PKA and ATP. In addition to G551D-CFTR, ivacaftor increased the channel-open probability of other mutant CFTR forms expressed in rodent cells, resulting in enhanced CFTR-mediated IT. These mutant CFTR forms included G178R-, S549N-, S549R-, G551S-, G970R-, G1244E-, S1251N-, S1255P-, and G1349D-CFTR. In vitro responses do not necessarily correspond to in vivo pharmacodynamic response or clinical benefit.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CAD7C478-F98C-453E-9312-2116927C50C1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IVACAFTOR-0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BF79250C-CC52-4453-BEEA-C94910F9869A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to Prodrug</dct:description>
    <rdfs:label>Prodrug</rdfs:label>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A217F02D-01C1-4AA2-AABD-B86B9BCD15B4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E8417695-A485-406D-9874-2FCD4E30F0C5">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2621</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2C19</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C2ACC792-8961-4157-AF5E-F5AECCEBB1AE">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4CAED7E0-8FF2-4BA9-9B67-950D17E07D7C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12530</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>UGT1A1</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:633B5B68-6257-4DC5-BE7F-E205BAC802C2">
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E647A62C-71D5-414D-82D7-9B2980EB4814">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>neutropenia</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AEEF2B8A-832D-4932-B3BD-F237AB38B922">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A933DC7D-F83D-48EC-B298-8AF97F821400">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:50AC0747-86DA-40B2-8A81-E912BEA6B2E8">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <rdfs:label>Recommend</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:938B4787-1810-40A2-BFDC-F1723DB98EC5">
    <pav:createdOn>2014-06-11 23:17:30 -0400</pav:createdOn>
    <ao:prefix>CLINICAL PHARMACOLOGY and PRECAUTIONS ). </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:938B4787-1810-40A2-BFDC-F1723DB98EC5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>938B4787-1810-40A2-BFDC-F1723DB98EC5</domeo:uuid>
    <ao:exact>The patient's CYP2C9 and VKORC1 genotype information, when available, can assist in selection of the starting dose</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7AAD6350-4A6B-4073-9A84-168BF468DB0A">
    <rdfs:label>Irinotecan</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00762</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F6127F6B-C3CB-4328-AE9D-64A04E8BDEEC">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>breast cancer, ovarectomy, adrenalectomy, hypophysectomy</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:33DA9304-0936-4205-868E-BCE2EA1347B2">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:600CF376-91F6-49B3-AACF-A44E7BA0F614">
    <poc:MedicalCondition>tumor</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:00655BEA-9C8D-4E9D-9918-EA549CDA1000">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>An anastrozole adjuvant trial was conducted in 9,366 postmenopausal women with operable breast cancer who were randomized to receive adjuvant treatment with either anastrozole 1 mg daily, tamoxifen 20 mg daily, or a combination of these two treatments for 5 years or until recurrence of the disease. At a median follow-up of 33 months, the combination of anastrozole and tamoxifen did not demonstrate any efficacy benefit when compared with tamoxifen therapy alone in all patients as well as in the hormone receptor positive subpopulation.</ao:exact>
    <ao:suffix> This treatment arm was discontinued from the trial. Please refer to </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:00655BEA-9C8D-4E9D-9918-EA549CDA1000"/>
    <pav:createdOn>2014-06-01 20:11:28 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F052B5F8-F483-4354-9E49-6BB05A8B88E8">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:70FD5292-2B34-4C99-BB2E-B0E7E40EE8CD">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is not associated with clinically relevant pharmacodynamic effect</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Not Important</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-important</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E9F7EB74-4FBD-43C4-BF4C-75366355E766">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:B797A8A1-B8D8-422B-B700-779551BD8B7B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4D4CC677-4FC9-4792-A19B-EC78BD2A66E6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A6673259-863F-41A8-A4D5-A0403A166F9F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1A81D59A-F609-4BA8-92A5-E3D5B44090C1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D2EC88EE-D435-456E-8AF0-AD701EB4555A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F7215BEA-75B5-430F-A678-EE60062C02FF"/>
    <pav:lineageUri>urn:domeoserver:annotation:F1C758C1-23BC-491A-8401-A189635521D1</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:83A1D844-AA66-4DC4-AB44-0B22E63D2464"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:020F88C5-E7D6-49C0-926B-E5660B9490CE"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:2893C185-0D79-4866-AC5C-B8B939DF14AE"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:23D232D6-9A25-47F3-8DA1-D7CE366FB4BF</domeo:belongsToSet>
    <pav:lastSavedOn>2014-08-11 10:44:08 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:4B26F869-3038-468D-A3C3-B1DAFC208969"/>
    <pav:createdOn>2014-08-11 10:43:25 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3D5E2CE3-0C4D-4C43-AFE7-C5441DAFFF1A">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(43685-7) WARNINGS AND PRECAUTIONS</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>(43685-7) WARNINGS AND PRECAUTIONS</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A450E726-0EB5-4B8F-99D6-3DC0A90EC6C7">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IVACAFTOR-0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25.html</ao:hasSource>
    <ao:exact>Changes in sweat chloride response to KALYDECO were evaluated in four clinical trials. In two randomized, double-blind, placebo-controlled clinical trials in patients with a G551D mutation in the CFTR gene, one in patients 12 and older (Trial 1) and the other in patients 6-11 years of age (Trial 2), the treatment difference (between KALYDECO and placebo) in mean change in sweat chloride from baseline through Week 24 was -48 mmol/L (95% CI -51, -45) and -54 mmol/L (95% CI -62, -47), respectively. These changes persisted through 48 weeks. In a 16-week randomized, double-blind, placebo-controlled, parallel-group clinical trial in patients with CF age 12-years and older who were homozygous for the F508del mutation in the CFTR gene (Trial 3), the treatment difference in mean change in sweat chloride from baseline through 8 weeks of treatment was -3 mmol/L (95% CI -6, -0.2). In a two-part, randomized, double-blind, placebo-controlled, crossover clinical trial in patients with CF who had a G1244E, G1349D, G178R, G551S, G970R, S1251N, S1255P, S549N, or S549R mutation in the CFTR gene (Trial 4), the treatment difference in mean change in sweat chloride from baseline through 8 weeks of treatment was -49 mmol/L (95% CI -57, -41). In Trial 4, mean changes in sweat chloride for the mutations for which KALYDECO is indicated ranged from -51 to -78, whereas the range for individual subjects with the G970R mutations was -1 to -11 mmol/L.</ao:exact>
    <pav:createdOn>2014-08-11 09:41:13 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A450E726-0EB5-4B8F-99D6-3DC0A90EC6C7"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>There was no direct correlatio</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>A450E726-0EB5-4B8F-99D6-3DC0A90EC6C7</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DA8E62CA-7575-4B2B-831C-6AED2AEB4954">
    <rdfs:label>Influences Drug Response</rdfs:label>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:72477FCD-9596-4DC3-AC10-288164FE5812">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2B3B1B0F-EB68-49FD-A395-B1EE8DE84DB0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CBD63B99-54EF-45C7-8E1C-44F15FB12DE4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9A72C8FC-2539-4E0A-907E-33D2FB07D903">
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdfs:label>Variant Frequency</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:63809DA6-C69A-4815-974D-4F4881BBFC98">
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D124E537-48D7-4B9B-8CE2-E6A1219B5DF8">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to Prodrug</dct:description>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdfs:label>Prodrug</rdfs:label>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:182DFCE4-0DF9-4262-8B5D-5549152326E5">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-level-high</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-level-high</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2572BDB2-3424-437E-A3AF-AFB6B2EF494B">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2572BDB2-3424-437E-A3AF-AFB6B2EF494B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Patients with Reduced UGT1A1 Activity: Individuals who are homozygous for the UGT1A1*28 allele are at increased risk for neutropenia following initiation of CAMPTOSAR treatment. (5.3)</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IRINOTECAN-e518dfc6-7e93-4fee-a66c-51e1ab71c056.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-08-11 10:30:46 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>:  Manage promptly with antibiotic support.  Interrupt CAMPTOSAR and reduce subsequent doses if necessary. ( 5.2 ) </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:437C6B85-1383-49D7-997E-1836FFFF051C">
    <ao:exact>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so-called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available.</ao:exact>
    <ao:suffix> Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:437C6B85-1383-49D7-997E-1836FFFF051C"/>
    <ao:prefix>– </ao:prefix>
    <domeo:uuid>437C6B85-1383-49D7-997E-1836FFFF051C</domeo:uuid>
    <pav:createdOn>2014-08-11 10:05:17 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOMPIRAMINE-4074b555-7635-41a9-809d-fae3b3610059.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:089E1BAF-C3A9-4ECC-A064-E87C51504FAA">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:089E1BAF-C3A9-4ECC-A064-E87C51504FAA"/>
    <ao:suffix>. Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting Elitek therapy (</ao:suffix>
    <domeo:uuid>089E1BAF-C3A9-4ECC-A064-E87C51504FAA</domeo:uuid>
    <ao:exact>Hemolysis: Do not administer Elitek to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Immediately and permanently discontinue Elitek if hemolysis occurs</ao:exact>
    <pav:createdOn>2014-08-11 09:07:48 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/RASBURICASE-0ae10bc4-6b65-402f-9db5-2d7753054922.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C248DA70-0F7D-45F9-8DFE-C3873FCB6963">
    <rdfs:label>IL2RA</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:6008</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9AE33C26-FA00-40A8-A8A6-F8E0A93D6460">
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:83EA85D0-5404-4AFF-99EF-671BD16F1942">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Irinotecan</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00762</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:34BCFD81-E525-4D87-801E-8BF68CF4067E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dct:description>Referred to clinical trial</dct:description>
    <rdfs:label>Clinical Trial</rdfs:label>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2893C185-0D79-4866-AC5C-B8B939DF14AE">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:00597C44-88CF-425B-9A33-957EEAA04758">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Recommend</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6311CEA1-933E-4F82-9A78-141447F539CE">
    <poc:MedicalCondition>hemolysis</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E04994D7-F40E-4B21-BC65-82A17CD1BC3C">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F6C4C1F5-9C1B-4A9C-B277-4E6A3665D42D">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:648DC081-1A41-4B91-A341-82121D34ED7B">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9DDECF86-419A-42F5-901E-662CA3B37338">
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4E0ADC3B-B8FA-435D-AD38-A81840D33A5A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdfs:label>Decrease from baseline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B915F3E2-6E0F-4CA8-B101-75DE5AB7A51A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4057</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>G6PD</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8884A95A-78BA-4744-9667-E8D7174B552F">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8884A95A-78BA-4744-9667-E8D7174B552F"/>
    <ao:exact>Respiratory depression and death have occurred in children who received codeine following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine due to a CYP2D6 polymorphism.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-06-02 13:36:05 -0400</pav:createdOn>
    <domeo:uuid>8884A95A-78BA-4744-9667-E8D7174B552F</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D5E03124-9770-4F4A-B0F6-8BC0B95821D0">
    <ao:body rdf:resource="urn:linkedspls:uuid:B9DE29DE-E668-47F0-B3C2-782D4D182420"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:E7184517-8C8B-4EA8-AA3A-A8A3B35FC722"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:C29B3793-D502-4501-9EFD-32F312A451FD"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:99C67B9D-A54C-4AE5-9FDD-DE412A8370A9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D9F3A073-976F-4B84-B1B8-21AC11CA8C6C"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:C5743B39-3807-4708-AAD0-38ED73FF71F3"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:D41DB05B-F6E2-44BF-BB52-A2A0A7AFB008"/>
    <pav:lineageUri>urn:domeoserver:annotation:15710F39-571E-4DE7-98D1-5D1B1F9E44F2</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:253B53A7-DCE5-4C46-A701-839D86872338</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:221F7C86-009D-4635-88A4-D4D29EE3F743"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-08-11 08:27:35 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:CA5F2011-211B-4BB3-A00A-864828B8FB28"/>
    <pav:lastSavedOn>2014-08-11 08:28:52 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9F6D48E0-E480-41A0-8123-BD1B114C23B0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:38BDCE31-FFC7-4D65-B0A0-A8173E83A9E7">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DE8F307F-8E67-439D-95BF-FA8E4BA2DC86">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>UGT1A1</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12530</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AD336335-5550-4CE1-A924-F414BCBBD4CE">
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#discontinue-do-not-restart</poc:DrugSelectionRecommendation>
    <rdfs:label>Discontinue/Do not restart</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A4B4A60E-8253-4589-9454-E87129986ECE">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:1884</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CFTR</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:656565A4-9FEE-416A-9A4E-FBC1A3179D87">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FCA55DDA-2E9A-4E93-ACEA-2A442C05986F">
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F1557B24-E3F8-43AB-BBFF-CAFBF8278531">
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2BF08D4D-676B-4B26-B46B-1E72556B734F">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B91E7C5C-388E-4BC6-B871-0E3637976FE5">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6A994F2A-24CA-4057-A3BC-F10575E6BDA3">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(43679-0) MECHANISM OF ACTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(43679-0) MECHANISM OF ACTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A4889A7B-C631-4691-8F08-9B1598CB39F3">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>breast cancer</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FA3C442E-8A92-4772-AF8D-270876833A4C">
    <rdfs:label>poor-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5D5F94E7-E1EB-4689-807D-127E37023AF4">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB08820</dailymed:pharmgxDrug>
    <rdfs:label>Ivacaftor</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:535498E1-E966-463D-B73B-849E5E82BB91">
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A7EAC193-CF12-4590-978A-E230000C50AA">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IRINOTECAN-e518dfc6-7e93-4fee-a66c-51e1ab71c056.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A7EAC193-CF12-4590-978A-E230000C50AA"/>
    <pav:createdOn>2014-08-11 10:40:11 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Individuals who are homozygous for the UGT1A1*28 allele (UGT1A1 7/7 genotype) are at increased risk for neutropenia following initiation of CAMPTOSAR treatment.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>In a study of 66 patients who </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:77C74F0C-9D35-436F-BDE7-215BA8B93567">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A9AD9EFC-A746-47AD-BC2D-A953146DE48D">
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Variant Frequency</rdfs:label>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7fa45c1e6381458eafa1dac3a353bceb">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EB2A64A0-F97F-4CBA-BA78-FBB8C09A8EAA">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>postmenopausal, locally advanced breast cancer, metastatic breast cancer</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6F649B39-A8EA-43CF-8743-84185775E0F2">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1553C2FB-88A9-4ADB-B08E-C0E3C9F74918">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles> G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7FA245FC-343C-46A5-A8B0-66AA73754F3C">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E22C099B-457C-4C62-B7AF-193DBA3ECBEF">
    <rdfs:label>CFTR</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:1884</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B21EC6B5-C2EE-4874-A4F2-AF1A3F4EFEC2">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2FA2182A-FCE8-44BD-B87E-E4EC718D2246">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles> G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:91E09E80-9836-4378-8EB6-A4753C404BED">
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B696B2DA-E0B0-4D18-A749-FA9A6C9B2853">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:DED546EB-06CB-4DCA-981F-C1C5EB8061F4"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:1A6A0D8F-56BA-46EA-BF5F-5FA921F4B3D9</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-08-11 10:01:51 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:D970767A-45AD-49F4-BE28-26ED292A3E62"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:E49A8CE3-66CF-4BE6-A6FC-6D706B0D31F5</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:6D031617-4D4C-4D4C-97B2-939AABE44E45"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:F68E58D5-4F58-4034-87A5-AC58FAFB7E78"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:67AF96D5-3D05-4A47-AD38-21EA5E53A18E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3D0CBB53-933A-4637-BA26-135978494D06"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3E80A3C7-0DA2-4C83-8CC0-459B27FF2B77"/>
    <pav:createdOn>2014-08-11 10:01:25 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:F40691B5-66E4-45B5-9D51-AC8E41363978"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A26D8703-BF5E-4BF1-B559-161D21C43D33">
    <pav:createdOn>2014-06-11 23:01:59 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A26D8703-BF5E-4BF1-B559-161D21C43D33"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:exact>In 201 Caucasian patients treated with stable warfarin doses, genetic variations in the VKORC1 gene were associated with lower warfarin doses. In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gene alone; about 40% of the variance in warfarin dose could be attributed to variations in VKORC1 and CYP2C9 genes combined.5 About 55% of the variability in warfarin dose could be explained by the combination of VKORC1 and CYP2C9 genotypes, age, height, body weight, interacting drugs, and indication for warfarin therapy in Caucasian patients.5 Similar observations have been reported in Asian patients</ao:exact>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B81A2078-50C0-4910-A12C-3046FE1A92AB">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:23663</dailymed:HGNCGeneSymbol>
    <rdfs:label>VKORC1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E835F65E-751D-40B2-B2FC-B4ED11EAD9BF">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>F508</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D2DBCEA4-A79C-418A-8450-AED0D1F3D2E8">
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#required</poc:MonitoringRecommendation>
    <rdfs:label>Required</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <dct:description>A required monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EC69B0D6-2F53-4A79-BD91-D7F5122B3C9F">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4CC3E100-162B-4FCA-95F1-AC53E3A61FE9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Warfarin</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:67DE162A-DA85-4146-836D-0F1035653732">
    <rdfs:label>F5</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3542</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FCAC9960-3E31-4519-9F6C-01E2D662FE3B">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:39FEA412-819C-4C0D-86FA-8CC5A530161E">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-negative</poc:TestResult>
    <rdfs:label>biomarker-negative</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C29B3793-D502-4501-9EFD-32F312A451FD">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BD3CA01F-BBC4-4CBC-9AEE-72C34636957E">
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7B28BBA4-58C5-4DE8-A6D0-57CA21C3BB71">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34067-9 INDICATIONS AND USAGE SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>34067-9 INDICATIONS AND USAGE SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5ED2E6DD-06DC-413E-950F-77AAB8EE792A">
    <sio:SIO_000111>42229-5 SPL UNCLASSIFIED SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42229-5 SPL UNCLASSIFIED SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1537B5B1-327F-4D78-B32A-7D38E4760E41">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The effect of the scheduled duration of tamoxifen may be described as follows. In women with ER positive or unknown breast cancer receiving 1 year or less, 2 years or about 5 years of tamoxifen, the proportional reductions in mortality were 12%, 17% and 26%, respectively (trend significant at 2p &lt; 0.003). The corresponding reductions in breast cancer recurrence were 21%, 29% and 47% (trend significant at 2p &lt; 0.00001).</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>1537B5B1-327F-4D78-B32A-7D38E4760E41</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1537B5B1-327F-4D78-B32A-7D38E4760E41"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> nodes who received about 5 years of treatment, overall survival at 10 years was 78.9% for tamoxifen vs. 73.3% for control (logrank 2p &lt; 0.00001). The recurrence-free rate at 10 years was 79.2% for tamoxifen vs. 64.3% for control (logrank 2p &lt; 0.00001). </ao:prefix>
    <pav:createdOn>2014-06-01 20:45:15 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F958F428-C8AC-4342-BA1F-00448919C596">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-level-high</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-level-high</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:70F1624B-4DDC-4293-845D-479AD773F5C3">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B37CEB82-FBDE-4810-AAB7-410EE82AB578">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7E27E8DC-75C7-45E7-AC4A-A581364BEBD7">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2C9</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CFCAFF12-40D6-475A-8EB8-DEBB506AFD60">
    <sio:SIO_000111>42229-5 SPL UNCLASSIFIED SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42229-5 SPL UNCLASSIFIED SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9F39B172-380F-45DA-9FEB-5F209CDD16E0">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Tamoxifen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:007C39EF-F7FF-4A41-B4B6-98F069755344">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Metabolism Increase</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8D480615-10DE-4B2F-8A84-433E5FFF50CE">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-08-11 09:55:18 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8D480615-10DE-4B2F-8A84-433E5FFF50CE"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IMIPRAMINE-1827a5aa-733a-49d9-89d9-48ea0367b230.html</ao:hasSource>
    <domeo:uuid>8D480615-10DE-4B2F-8A84-433E5FFF50CE</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E1F634FA-0B50-4678-B039-7AC9BD9E20B3">
    <rdfs:label>Increased Efficacy</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F252085F-2ADD-4E6C-BEE1-E41BC65F23F3">
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D1DCE20B-C7F3-462D-A0A2-8BD9EB0F1A58">
    <dct:description>The pharmacogenomic biomarker is not associated with any drug selection recommendation.</dct:description>
    <rdfs:label>Do not start</rdfs:label>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-start</poc:DrugSelectionRecommendation>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5D7DF8DA-6179-4793-B756-6FF4ED109390">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Do not start</rdfs:label>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-start</poc:DrugSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is not associated with any drug selection recommendation.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3FD2EA01-F336-4A53-A416-9D778C301842">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Codeine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7F85C5F2-AB6F-4E72-9822-94E1F4700750">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2902BD91-BA54-41F1-AD03-1637EE6A183C">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CB47B861-6AFD-49F1-A341-3200E25FD70F">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F8ED2DAE-140B-4650-996D-94A8F60A716D">
    <pav:createdOn>2014-05-31 14:38:56 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F8ED2DAE-140B-4650-996D-94A8F60A716D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:exact>Letrozole tablet is an aromatase inhibitor indicated for: \n\n    Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer (1.1)</ao:exact>
    <ao:suffix>Extended adjuvant treatment of</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:612C854A-ABD0-498F-B420-5EEBFCBC78B0">
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:207BCCE4-7FBE-4EE8-841D-A4A6ABDFABDC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Codeine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:567489D0-D90D-4084-81AD-F4F95290D857">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(43679-0) MECHANISM OF ACTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>(43679-0) MECHANISM OF ACTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4998874B-1A5E-4B67-B6C7-648AD7C1D990">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <rdfs:label>ESR1</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:14C29279-2575-4E13-9D89-1CA9E8B51410">
    <poc:Comment>indicated for</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3B6E1EDF-506E-424B-A6B2-10E770D966DD">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34068-7) DOSAGE AND ADMINISTRATION</poc:productLabelSection>
    <sio:SIO_000111>(34068-7) DOSAGE AND ADMINISTRATION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F1552F75-D639-4451-9E82-568A07E36CA9">
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <rdfs:label>Recommended</rdfs:label>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D36812F9-ED9C-48FF-B48A-E7431CB631BD">
    <pav:createdOn>2014-08-11 09:44:18 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D36812F9-ED9C-48FF-B48A-E7431CB631BD"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>. </ao:prefix>
    <ao:exact>Treatment with KALYDECO resulted in no improvement in FEV1 relative to placebo in patients with CF homozygous for the F508del mutation in the CFTR gene [mean absolute change from baseline through Week 16 in percent predicted FEV1 was 1.5% and -0.2% for patients in the KALYDECO and placebo-treated groups, respectively (P = 0.15)]. </ao:exact>
    <ao:suffix>There were no meaningful differences between patients treated with KALYDECO compared to placebo for secondary endpoints (change in CF symptoms, change in weight, or change in sweat chloride concentration)</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IVACAFTOR-0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>D36812F9-ED9C-48FF-B48A-E7431CB631BD</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5577F2EC-D99F-4443-9541-C267391FCB4F">
    <rdfs:label>gene-haplotype-negative</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-negative</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B8AFC44F-5BF6-49A7-B333-80B112548B34">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:56D9EE71-12E6-452F-A362-FE03A6850CF6">
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdfs:label>Clinical Trial</rdfs:label>
    <dct:description>Referred to clinical trial</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:41B4380D-E9E8-448C-815D-2175DFF7E34D">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:suffix>•Respiratory depression: Incre</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:41B4380D-E9E8-448C-815D-2175DFF7E34D"/>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-05-30 20:27:59 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:exact>Risk of death in ultra-rapid metabolizers: Conversion of codeine into its active metabolite, morphine, may occur more rapidly and completely resulting in higher than expected morphine levels and respiratory depression or death. (5.1)</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9E39FCEE-4DFF-4CF1-9F19-486CDBD27E32">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>Warfarin reduces the regeneration of vitamin K from vitamin K epoxide in the vitamin K cycle, through inhibition of vitamin K epoxide reductase (VKOR), a multiprotein enzyme complex. </ao:prefix>
    <ao:suffix>. In 201 Caucasian patients treated with stable warfarin doses, genetic variations in the VKORC1 gene were associated with lower warfarin doses. In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gen</ao:suffix>
    <pav:createdOn>2014-06-11 22:59:56 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9E39FCEE-4DFF-4CF1-9F19-486CDBD27E32"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:exact>Certain single nucleotide polymorphisms in the VKORC1 gene (especially the -1639G&gt;A allele) have been associated with lower dose requirements for warfarin</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:000CBFF7-A536-481F-B29E-C34569C8BFFA">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>43685-7 WARNINGS AND PRECAUTIONS SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#43685-7 WARNINGS AND PRECAUTIONS SECTION</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:700515BA-CB28-4B9B-A2DF-EAB6732AF85D">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>cystic fibrosis</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A848E299-3D2C-4584-96EC-6D1F0EDC0E2D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Rasburicase</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00049</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A697F9EC-3FE9-4390-AB13-C95B2FF610AB">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12530</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>UGT1A1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:448BDC25-26B6-4F32-B3A5-CB0A9AB8BCEC">
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3A254987-20A8-4C90-9EFA-9C531CCE9F25">
    <rdfs:label>ER_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:345C8298-3DC9-43D5-A7FD-B4A816C710F9">
    <rdfs:label>biomarker-level-low</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-level-low</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FF0D52EA-0500-4EF7-9038-580F2BB6C8C2">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>F508</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4A877B68-D6A4-4B4E-A6DC-6D9FFC98F744">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00049</dailymed:pharmgxDrug>
    <rdfs:label>Rasburicase</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:17D16801-EE7B-467B-AF52-6C574F902E98">
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB08820</dailymed:pharmgxDrug>
    <rdfs:label>Ivacaftor</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3525E0B9-9E13-4D14-A0C0-6E86A5C5A4B0">
    <ao:body rdf:resource="urn:linkedspls:uuid:227BB51A-6B6A-4920-9192-A2D446742C97"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E823DCB5-68E6-44D4-90AF-E073AC268320</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:153E8775-DF56-4BAA-A262-782EDA682A90</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:66A6AA04-893C-4689-8EFB-7BB71414A92D"/>
    <pav:createdOn>2014-06-11 23:11:58 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:DC0167DB-2B51-461B-BBF2-53ECD0194ED5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DBF911A3-DA19-4C9A-9E86-9CD741EC7C67"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:13C196BC-7A07-4D57-AB1D-25C7D330FF77"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:CEA0B6F6-7EA5-4130-AE8A-811D45687345"/>
    <pav:createdBy>urn:person:uuid:080e14304628d4c0014629cdc71a0000</pav:createdBy>
    <pav:lastSavedOn>2014-06-11 23:12:35 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:EA9669D6-C5D3-4B2A-A48C-049FF66DC450"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E5335936-B45E-45FB-88B1-5412D6A59C96"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D63AE510-EDFF-4DB6-A705-268BBE758ADA">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34067-9 INDICATIONS AND USAGE SECTION</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34067-9 INDICATIONS AND USAGE SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C8B76DF6-F630-4603-9A11-340E0CE5AADC">
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0809D41C-DDCF-4224-8C9A-99FAC41A6E5D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdfs:label>Variant Frequency</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C55D8F3D-2A90-46A8-BD71-FBBA80DB6590">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <rdfs:label>Recommend</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BA476DCB-2C26-4971-9305-A432013E7B4A">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:71672A41-892A-412D-9AA0-2AC13DF3B672">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <rdfs:label>Letrozole</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0EB0E245-2D2C-4498-ACF7-D0506797B006">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C836722F-7BEC-415A-8929-4F586A537BCB">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:27E48CF2-9A8E-4F71-9E7D-1F3221859A96">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-06-01 20:35:14 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:27E48CF2-9A8E-4F71-9E7D-1F3221859A96"/>
    <ao:exact>Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen citrate tablet therapy.</ao:exact>
    <ao:prefix>Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen citrate tablets are an alternative to oophorectomy or ovarian irradiation. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:60E0B5A8-24C2-497C-88EC-11B3AC94EA74">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>neutropenia</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:33A0F277-AAA6-489D-BE2B-6AA41F5A91CB">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F7D23FAD-3D78-4F2B-B321-7C84D21CD2AB">
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to clinical trial</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8F4E203D-604E-43E0-B731-E7F3F4924417">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER_receptor</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:095D7662-94DC-44E2-9C5A-C6A6C54B4C47">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(43685-7) WARNINGS AND PRECAUTIONS</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(43685-7) WARNINGS AND PRECAUTIONS</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C202EFD3-1731-4A08-BDA1-687FB9F032DC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7A7AB1C5-69A8-4593-8161-523CF94B4184">
    <rdfs:label>Influences Drug Response</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FAB952A2-2E8B-49FB-8695-7F8FDB63E8F6">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ESR1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4A1B0DE6-1E89-48B2-AD14-460A3AAE91B4">
    <rdfs:label>Imipramine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00458</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:858DBF32-AD18-4CD9-A58A-3F4F5D647BE1">
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3745D0DE-8525-456F-A7A7-27B9A58FB224">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:1884</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CFTR</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B27FFF87-B3D3-4C30-A4A5-BDB56AC4984D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7C5595A3-7B04-4765-B27C-AF9D94170E06">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B42A8BFF-C4FF-4631-B83D-EED27445586A">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1CEDDA85-963C-4A54-8397-2E6850BA4EA8">
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#discontinue-do-not-restart</poc:DrugSelectionRecommendation>
    <rdfs:label>Discontinue/Do not restart</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FC2157EC-3251-4065-9413-4ECFCF3F0EDF">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34092-7 CLINICAL STUDIES SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34092-7 CLINICAL STUDIES SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A84F12D8-CFCB-4C2E-93F3-B9E05CF8B7B2">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D2A2444C-4BA9-4190-BF52-CEBFB9BBA949">
    <rdfs:label>Ivacaftor</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB08820</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F0B1660B-2C74-47B7-A5C7-9C2449E35886">
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EA18C77F-C132-4E66-A85C-2936D0CE2688">
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EFDE0DDE-C4EB-4672-9316-AAD90F075F4F">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C8B968AD-078C-46EE-9D51-FC3C8F3A0B1E">
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E205ECA7-1611-4418-9C6E-D07A3C966002">
    <rdfs:label>ESR1</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:95035BEF-49E8-456F-BF8C-6D80EE2D0277">
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A required monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <rdfs:label>Required</rdfs:label>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#required</poc:MonitoringRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6413F7E7-7EE1-411C-9E9B-0255AD5CECD2">
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <rdfs:label>Prodrug</rdfs:label>
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to Prodrug</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:020F88C5-E7D6-49C0-926B-E5660B9490CE">
    <rdfs:label>Clinical Trial</rdfs:label>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dct:description>Referred to clinical trial</dct:description>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6C29BC4E-4436-4E07-B8CA-79B0959178F9">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:36A273A7-0C6B-4241-9DFB-4A45A45BB439">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FC65E752-F436-43B1-AF5C-C4FE334DE22B">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
    <rdfs:label>ESR1</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:89896431-9916-44B8-A58B-E0C1ECE666F3">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>CYP2D6*1/*1xN, CYP2D6*1/*2xN</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BF5AEF00-CA74-4A33-8C6F-F0EA6580784D">
    <rdfs:label>CFTR</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:1884</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A135C925-B8C7-4840-A1E5-2B3F5D238CA8">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A135C925-B8C7-4840-A1E5-2B3F5D238CA8"/>
    <ao:suffix>. The effects of about 5 years of tamoxifen on recurrence and mortality were similar regardless of age and concurrent chemotherapy. There was no indication that doses greater than 20 mg per day were more effective.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-06-01 20:45:25 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>A135C925-B8C7-4840-A1E5-2B3F5D238CA8</domeo:uuid>
    <ao:exact>Benefit is less clear for women with ER poor breast cancer in whom the proportional reduction in recurrence was 10% (2p = 0.007) for all durations taken together, or 9% (2p = 0.02) if contralateral breast cancers are excluded. The corresponding reduction in mortality was 6% (NS)</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AE643F72-0639-490A-AC1E-ED2480A9FBFB">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dct:description>Referred to clinical trial</dct:description>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdfs:label>Clinical Trial</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4202AA4C-3DA1-44DB-8C9E-E3AE273CCA5A">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9E0CF3F8-5667-40B1-ADC1-1789D3231C8E">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EDACF861-0712-42A8-A67C-62DEBC7398B0">
    <pav:createdOn>2014-06-11 22:57:11 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EDACF861-0712-42A8-A67C-62DEBC7398B0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>.</ao:suffix>
    <ao:exact>A meta-analysis of 9 qualified studies including 2775 patients (99% Caucasian) was performed to examine the clinical outcomes associated with CYP2C9 gene variants in warfarin-treated patients.3 In this meta-analysis, 3 studies assessed bleeding risks and 8 studies assessed daily dose requirements. The analysis suggested an increased bleeding risk for patients carrying either the CYP2C9*2 or CYP2C9*3 alleles. Patients carrying at least one copy of the CYP2C9*2 allele required a mean daily warfarin dose that was 17% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele. For patients carrying at least one copy of the CYP2C9*3 allele, the mean daily warfarin dose was 37% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0CCFAF6C-8269-4F99-B1E1-9F12C9D356CD">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Codeine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0AC0314D-9D17-4DFF-BCA9-CB04D6F3F88C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
    <rdfs:label>ESR1, PGR</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B587AC9C-4FC0-4B95-9767-555D98299007">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(66106-6) PHARMACOGENOMICS</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(66106-6) PHARMACOGENOMICS</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndd8637b21fa341618e29c3a9e1d2ffb0">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:85431EC6-4630-4FB1-8FB3-BAB6286B75B6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-level-low</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>biomarker-level-low</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1AD73171-F5E6-4C0B-A456-2F41B101FB2E">
    <dct:description>The pharmacogenomic biomarker is not associated with any drug selection recommendation.</dct:description>
    <rdfs:label>Do not start</rdfs:label>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-start</poc:DrugSelectionRecommendation>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1643699C-B62C-4A36-8D7A-4D109304FDD6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E444892B-98F2-4385-99DE-D83E88BAEF9B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Among women with ER positive or unknown breast cancer and positive nodes who received about 5 years of treatment, overall survival at 10 years was 61.4% for tamoxifen vs. 50.5% for control (logrank 2p &lt; 0.00001). The recurrence-free rate at 10 years was 59.7% for tamoxifen vs. 44.5% for control (logrank 2p &lt; 0.00001). Among women with ER positive or unknown breast cancer and negative nodes who received about 5 years of treatment, overall survival at 10 years was 78.9% for tamoxifen vs. 73.3% for control (logrank 2p &lt; 0.00001). The recurrence-free rate at 10 years was 79.2% for tamoxifen vs. 64.3% for control (logrank 2p &lt; 0.00001).</ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>Among 29,441 patients with ER positive or unknown breast cancer, 58% were entered into trials comparing tamoxifen to no adjuvant therapy and 42% were entered into trials comparing tamoxifen in combination with chemotherapy vs. the same chemotherapy alone. Among these patients, 54% had node-positive disease and 46% had node-negative disease. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E444892B-98F2-4385-99DE-D83E88BAEF9B"/>
    <pav:createdOn>2014-06-01 20:06:05 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B899C256-E92F-4A91-8422-32334B954484">
    <domeo:uuid>B899C256-E92F-4A91-8422-32334B954484</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Table 4 describes the characteristics of the breast cancers in the NSABP P-1 trial and includes tumor size, nodal status, ER status. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B899C256-E92F-4A91-8422-32334B954484"/>
    <ao:exact>Tamoxifen decreased the incidence of small estrogen receptor positive tumors, but did not alter the incidence of estrogen receptor negative tumors or larger tumors.</ao:exact>
    <pav:createdOn>2014-06-01 20:47:01 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:575FF64B-A150-4E5F-BFC4-C07E27E45946">
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:232C456A-AD10-4715-A3DA-32F723E5BEFE">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6575B7DA-A97D-4781-81EC-941DBAFAE3DA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/RASBURICASE-0ae10bc4-6b65-402f-9db5-2d7753054922.html</ao:hasSource>
    <pav:createdOn>2014-08-11 09:14:11 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6575B7DA-A97D-4781-81EC-941DBAFAE3DA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>6575B7DA-A97D-4781-81EC-941DBAFAE3DA</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Elitek is contraindicated in individuals deficient in glucose-6-phosphate dehydrogenase (G6PD) [see Boxed Warning, Warnings and Precautions (5.2)].</ao:exact>
    <ao:prefix>Warnings and Precautions (5) ]. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4B2E1FC3-159A-4698-8135-D2BC9ACCB5D7">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9B8317DC-DBC5-4662-8517-859AC64AF1BB">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Rasburicase</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00049</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:899EFB8F-88EE-4077-B6C2-0A07E96AFC41">
    <rdfs:label>Influences Drug Response</rdfs:label>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D83DA952-EF7A-4B56-8361-8ACDF5A03A79">
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdfs:label>Variant Frequency</rdfs:label>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C329A109-0A50-4C94-88A2-996BEB7A06F5">
    <rdfs:label>Variant Frequency</rdfs:label>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DD65E152-396A-4270-9B21-8A1A9F65C1E5">
    <rdfs:label>VKORC1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C9C86070-F79C-409E-AA7F-F83FE99AE665">
    <ao:suffix>Limitations of UseKALYDECO is </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>C9C86070-F79C-409E-AA7F-F83FE99AE665</domeo:uuid>
    <pav:createdOn>2014-08-11 09:31:01 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C9C86070-F79C-409E-AA7F-F83FE99AE665"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/IVACAFTOR-0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25.html</ao:hasSource>
    <ao:exact>KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:68B4BD22-611B-4BCF-A771-5D0A339C28D6">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6A30D2D0-C7F2-4DCF-9E4F-3B73BBEE44D3">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34068-7) DOSAGE AND ADMINISTRATION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>(34068-7) DOSAGE AND ADMINISTRATION</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:631081EE-4991-433C-B87F-E1AFB7E076F0">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CC513CF2-EB46-4314-B584-C5E6E349887C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A0BE39E4-856F-4C5F-A4B6-14F1AFB1A118">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-SNP-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-SNP-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E25A112E-A5DC-4365-ABF4-53C09C8FA58E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>*28, 7/7</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B2E9D831-40A3-42D2-B855-D69568385012">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>breast cancer, positive node, negative node</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FC3C56C7-F768-4370-B469-75408C898599">
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <rdfs:label>Recommended</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B5AA1B9C-4219-4D7B-A32D-27A3B23EB958">
    <poc:Comment>no gene symbol provide but is required. is patient medication info the same as patient counseling info? </poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4717900B-348E-4C90-8453-B1BB8C17975A">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Warfarin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:75E3BD22-0CB8-4476-9F00-863BECE17EDF">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2C9</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5B4975CD-8602-4FBA-8F3A-481CF5348CE2">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D30F34EA-099B-466C-96D3-277E2BC3D633">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER_receptor</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:67327FCB-D35F-4028-87F7-FCAA70114D05">
    <rdfs:label>gene-haplotype-negative</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-negative</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9AAE4E63-4740-4D0A-9EA3-A3BB8E2E76BA">
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <rdfs:label>Recommended</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4412DE53-2BC3-40E0-8DE9-3BAF5FCBB0C5">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BF5138D5-018B-4DE6-8FEB-2BFBE2837B77">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>hemolysis</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E3EAE727-22B5-409D-8F3D-BEB2E7D4613B">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00049</dailymed:pharmgxDrug>
    <rdfs:label>Rasburicase</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D327E6E7-D871-4646-8BBA-E3BD6539060E">
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4504339D-9515-45C4-BBEC-A51E70B6B08C">
    <rdfs:label>CFTR</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:1884</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:86D504AD-BBC8-443A-A553-79235C02F793">
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:143816BE-4598-4182-B7E2-841B4BD1D3C0">
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <dct:description>Referred to clinical trial</dct:description>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BDFD32B6-09B7-4805-970B-8F812A66A511">
    <rdfs:label>Irinotecan</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00762</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AE800E3E-F603-40B7-8D9F-760C016723B2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3F877F22-06C0-46C2-81DA-9539EF470EA2">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7D46C748-6F55-4EF9-AF2C-7C911242A72F">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DA46D445-577C-4454-BEAA-8EE2C7D79FCE">
    <rdfs:label>Clinical Trial</rdfs:label>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dct:description>Referred to clinical trial</dct:description>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4A346667-A2AD-4844-A4D0-1DB34D3C364F">
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1EBD0F9B-983B-4C76-B987-841AC071F695">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>*2, *3</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CF36AEF0-A63A-46BA-822E-60118413C424">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>no gene symbol</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7769A299-9EDC-46D5-9A8E-2DC99C2B622F">
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <rdfs:label>Clinical Trial</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Referred to clinical trial</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D28BD509-7995-462B-B1D6-7EF14705EEEF">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Letrozole</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BD4D401E-13BC-40DA-9282-9035FFFDBC36">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>34073-7 DRUG INTERACTIONS SECTION</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34073-7 DRUG INTERACTIONS SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C7710F78-E171-4D17-BA7B-BA89034BE79F">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>had to put gene symbol</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F753B571-DFFF-4AF6-A8BB-5435EA5A9721">
    <sio:SIO_000111>42229-5 SPL UNCLASSIFIED SECTION</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#42229-5 SPL UNCLASSIFIED SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:05A0BB96-0F88-42B7-8179-407EBE32C312">
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Decrease from baseline</rdfs:label>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7D0F8841-3170-4EB6-9AD8-EA2EFF394FB9">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-SNP-positive</poc:TestResult>
    <rdfs:label>gene-SNP-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AFEFEFDF-C463-4852-8F26-12A6AE942FC3">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>breastfeeding, nursing, death</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C39646A7-8258-45CA-82AB-826462109036">
    <rdfs:label>biomarker-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:75C67174-1C9D-4BFB-BDD8-D1A117FBDE7C">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A6673259-863F-41A8-A4D5-A0403A166F9F">
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A99E2562-6BF1-434D-ACFE-F30BE454E920">
    <rdfs:label>Clinical Trial</rdfs:label>
    <dct:description>Referred to clinical trial</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ClinicalTrial>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/clinical-trial</dailymed:ClinicalTrial>
    <sio:SIO_000628>dailymed:ClinicalTrial</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ABC3D8F9-AAFA-47F2-8209-24344F8D1099">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:1884</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>CFTR</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2A09FE24-D61B-4A4E-9C17-D82FE20B4AF1">
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <rdfs:label>Prodrug</rdfs:label>
    <dct:description>Referred to Prodrug</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:91B1C664-2F5D-4DA9-9910-31F8CC497DCA">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ultra-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4B26F869-3038-468D-A3C3-B1DAFC208969">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:66A6AA04-893C-4689-8EFB-7BB71414A92D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:84B2DCAD-2378-422F-9E85-1BEAE03D6C55">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-05-30 22:04:12 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:84B2DCAD-2378-422F-9E85-1BEAE03D6C55"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact> However, some women are ultra-rapid metabolizers of codeine. These women achieve higher-than-expected serum levels of codeine’s active metabolite, morphine, leading to higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breastfed infants. Therefore, maternal use of codeine can potentially lead to serious adverse reactions, including death, in nursing infants. </ao:exact>
    <ao:prefix>In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:22CAE21C-241A-45AF-B24A-F734D3ADD3D3">
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdfs:label>Variant Frequency</rdfs:label>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3A1C64BF-E219-4A28-8082-120EA42928B1">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34092-7 CLINICAL STUDIES SECTION</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34092-7 CLINICAL STUDIES SECTION</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B157947C-E68B-493C-9CCA-A69FFAAE539A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ESR1</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AE322383-4638-47D3-A12E-DCB5BDAFE0EB">
    <rdfs:label>ESR1</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4A0EC5B8-4233-41D6-9282-20CC0F57567E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(66106-6) PHARMACOGENOMICS</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>(66106-6) PHARMACOGENOMICS</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4574D005-AAB3-4DDC-AD6D-94FCA9CB49A8">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N096276d2d13748e3bfe965877548869e">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C97D3E3E-0F53-4385-830E-230D80B7C71B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Not Important</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-important</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is not associated with clinically relevant pharmacodynamic effect</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9F8455FE-40B6-499D-8AA6-6FCE4F1ED600">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34071-1) WARNINGS</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(34071-1) WARNINGS</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:50FA1816-5081-4E2F-A153-69B3F1DCA5AC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Warfarin</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A6338818-C41B-4AD9-A254-4C19EC45EC7B">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D8726ED9-ECDB-4232-81F1-F3FA746E767C">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A466DCB0-3CE4-4C4E-BA7B-AC46DC8AFAAF">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Codeine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B4BC87FA-A814-4D8D-9825-F2076A3E2DD6">
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:13C196BC-7A07-4D57-AB1D-25C7D330FF77">
    <dct:description>A required test is related to the biomarker.</dct:description>
    <rdfs:label>Required</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#required</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F68E58D5-4F58-4034-87A5-AC58FAFB7E78">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6EA21C8B-CAA9-44A6-A96E-785D93994656">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00540</dailymed:pharmgxDrug>
    <rdfs:label>Nortriptyline</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A19ACEB0-9504-44A2-902F-84ABC713DFA8">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DA0BBCD9-AE30-4547-8826-864EB07FD2F5">
    <poc:MedicalCondition>respiratory depression, overdose, sleepiness, confusion, shallow breathing</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:313ECEEA-22BE-4331-9624-D871C19A1554">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles> G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5656D780-B40C-440C-87D7-4E2DD1B998A2">
    <rdfs:label>Irinotecan</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00762</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ED718500-30EB-4DC5-93BE-1577F3828D52">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00762</dailymed:pharmgxDrug>
    <rdfs:label>Irinotecan</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C8F4F061-F6FA-4170-858F-BEE2F63A1408">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34066-1) BOXED WARNING</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>(34066-1) BOXED WARNING</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2E934232-9AF8-479B-884A-AC8CDD2390BA">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8F7A6302-ACFE-4CD2-8A11-0D3BEFF6B89F">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:255C0BC6-A709-4BB6-8DB0-EAD522DDB51A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EA9669D6-C5D3-4B2A-A48C-049FF66DC450">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DDDCA2AB-140F-4AC8-8A93-9A491387DA6C">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Irinotecan</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00762</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8BDD7B0F-3154-4442-959F-025AEC13F806">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DBD796B5-63BA-4FD6-B6F1-99AFD62D62C4">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6113881B-0446-46DB-8402-89CDC3C770E1">
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A3F48D31-5539-4F30-A2B9-C37E55FB8811">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#34070-3 CONTRAINDICATIONS SECTION</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>34070-3 CONTRAINDICATIONS SECTION</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:65E214AD-E447-487C-805C-46E6304AA30D">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#low-or-absent-activity</poc:Variant>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:97794AE4-CFBC-4CB6-A538-08F16796CE0B">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>no gene symbol provide but is required. is patient medication info the same as patient counseling? </poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CC627C3D-857E-4804-9D92-84F409E58486">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-level-low</poc:TestResult>
    <rdfs:label>biomarker-level-low</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:67AF96D5-3D05-4A47-AD38-21EA5E53A18E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:52A266C8-BD6D-4417-AF6A-7213F832C8FC">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2623</dailymed:HGNCGeneSymbol>
    <rdfs:label>CYP2C9</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:891377B7-86F4-4748-8B29-F52B454F56F8">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:694BD2B0-9D20-4826-9AF8-D3635CF44A15">
    <poc:MedicalCondition>node negative, breast cancer, total mastectomy, segmental mastectomy, axillary dissection, breast irradiation.</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:875E64F8-05B0-4653-B39F-3C01D331DE3F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CC2B9C2A-ADA5-4784-8879-4D6AB8610F0C">
    <rdfs:label>Rasburicase</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00049</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6D1DF150-027F-4D8F-A91B-7E9ACD7B4153">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F458BC55-5BDC-4147-B188-2A7D48CDE9E7">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:2625</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DB79FC8E-9B12-4E9B-89F4-23F28BFC72A0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>F508</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E2FA19D2-1FF2-4A14-B128-50B2AD4E11D0">
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6957573C-BFB4-4755-B99E-89E932A7FB72">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34067-9) INDICATIONS AND USAGE</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>(34067-9) INDICATIONS AND USAGE</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9CDFD245-0D94-4BAB-8C5B-DA64F5B60CA8">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Tamoxifen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C2ABDA4C-3DC7-4244-8EBE-DA6794F48AB3">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:88A0E7E7-706E-4FD4-9B9F-B8EB161DF234">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:60F900F0-AEC5-4C65-9922-275EC5D3B65A">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdfs:label>Codeine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:25F3EB1C-22D6-48CC-9715-E3CD0818E8FA">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E78C1263-515D-48F8-92BF-994FF6A4961D">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D2EC88EE-D435-456E-8AF0-AD701EB4555A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>*28</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D4DE924D-6DB5-40ED-A5EF-5DD5E8735F07">
    <poc:Comment>table issues</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:798ECA6D-0410-4929-B302-F7127F7F2D66">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>difficulty breastfeeding, nursing, sleepiness, limpness, breathing difficulties,</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DE455B1F-320B-4EC5-A467-62E687447CCF">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>*28</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B68C2C79-390F-47E6-9883-9801E445D22E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:138DA980-62F5-4DEC-BC05-1CD6931C6B83">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:476ACFAB-3FD0-4A82-885F-482B97DF26D1">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:8910</dailymed:HGNCGeneSymbol>
    <rdfs:label>ESR1, PGR</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C0B00E6F-1720-4577-8DEF-593495B789C6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles> G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E4B7AEB5-3AC4-4B5D-9402-12D9A17FD11E">
    <rdfs:label>Warfarin</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:22CDA9BA-0C0D-4030-9B4C-4D21B294BDC4">
    <poc:MedicalCondition>breast feeding, nursing</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B323F5BD-8FB7-47F3-AC95-A7C6A62E0FBB">
    <ncit:Alleles>*1,*3,*2</ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9ABDBB8F-5A5E-44F8-91C2-5F5FC91A7445">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9CC55933-9B06-428C-8A1D-660D7B7A8C67">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:758344AB-8D2C-4F3C-9A8E-EA2B0EE3E323">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:101B85D6-7313-4E3E-BEC7-5A2A07DC97E1">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CA2E74B2-FACC-44F8-9BF9-0B3F442757AB">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>*1/*11180.065(0.025),*1/*2, *1/*3590.041 (0.021, *2/*2, *3/*3110.020 (0.011), *5,*6, *11, *9</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3C31A0A4-BC10-4EE2-B299-34551320C59C">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1494987D-ABE7-434B-8339-6728C3E9BC4E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>G551D</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1f86d1fdb27a4fc289037390a651da41">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CD417AEB-F1C9-4975-B082-898B774DDB0C">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>extensive-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#extensive-metabolizer</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:334439E9-9AF3-48C7-A414-21D98ECD9456">
    <poc:MedicalCondition>breast cancer</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:485C9112-4FEE-4EAA-8973-98D0688DAE42">
    <dailymed:Prodrug>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/pro-drug</dailymed:Prodrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:Prodrug</sio:SIO_000628>
    <rdfs:label>Prodrug</rdfs:label>
    <dct:description>Referred to Prodrug</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BD7F5133-18E0-4098-BED9-9E7889E22A18">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>UGT1A1</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:12530</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9327D741-315C-4EA1-8C35-BC475642722A">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer</poc:Variant>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ACA08787-ABED-45D0-BC60-0BF267096A11">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>ESR1</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:3467</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D7EBE39C-C926-4CF7-94D0-5D5134BD7E4F">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>never gave gene symbol but it is required.</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:69FCED5B-802D-492B-881C-3F9235BAA2F5">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Ivacaftor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB08820</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:51F340EB-0793-4DE5-A16D-3D879F5D710B">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>highlights section
</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F96AD79C-92FA-42B4-BCEE-4A007AEB615C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>*28</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb21997a420a34d389c270510273769ab">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4CB55AB2-FFA0-484C-BEDF-42E3A8579A59">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34066-1) BOXED WARNING</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>(34066-1) BOXED WARNING</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:235C0D89-15E5-49F6-B714-A7A25AFA9D41">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DA214073-2362-48DC-9D34-A21E64C023DD">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>(34092-7) CLINICAL STUDIES</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#(34092-7) CLINICAL STUDIES</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:39014587-DC25-4E0A-88C6-1533483C98E7">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>neutropenia</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4d663486f1854d7590e4fa0f664182fc">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F0ED4F46-5FEA-4FCC-BB1B-8D77CD2A1715">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Naef51cb4210c458588c5b872e1a0636f">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D781577C-73DF-48C4-9F44-9C43DC0474F1">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>cystic fibrosis</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AB21E55C-91DD-4C2C-A009-AFAC3BB63DAF">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>breast cancer, postmenopausal</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6edb9fd47b6e4004a266011b2b14139c">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9d7ad3eacfff4b9d939eeee919283cf5">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
</rdf:RDF>
